[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2013158508A1 - Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking - Google Patents

Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking Download PDF

Info

Publication number
WO2013158508A1
WO2013158508A1 PCT/US2013/036479 US2013036479W WO2013158508A1 WO 2013158508 A1 WO2013158508 A1 WO 2013158508A1 US 2013036479 W US2013036479 W US 2013036479W WO 2013158508 A1 WO2013158508 A1 WO 2013158508A1
Authority
WO
WIPO (PCT)
Prior art keywords
cartridge
bio
cells
bioprinter
ink
Prior art date
Application number
PCT/US2013/036479
Other languages
French (fr)
Inventor
Keith Murphy
Scott Dorfman
Richard Jin Law
Vivian Anne LE
Original Assignee
Organovo, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organovo, Inc. filed Critical Organovo, Inc.
Priority to CA2868530A priority Critical patent/CA2868530A1/en
Priority to EP13778583.8A priority patent/EP2838985B1/en
Priority to AU2013249569A priority patent/AU2013249569B2/en
Publication of WO2013158508A1 publication Critical patent/WO2013158508A1/en
Priority to HK15108255.6A priority patent/HK1207660A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00Bioreactors or fermenters specially adapted for specific uses
    • C12M21/08Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10Processes of additive manufacturing
    • B29C64/106Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
    • B29C64/112Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00Processes of additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y30/00Apparatus for additive manufacturing; Details thereof or accessories therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B33ADDITIVE MANUFACTURING TECHNOLOGY
    • B33YADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00Products made by additive manufacturing
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B41PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41JTYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J3/00Typewriters or selective printing or marking mechanisms characterised by the purpose for which they are constructed
    • B41J3/407Typewriters or selective printing or marking mechanisms characterised by the purpose for which they are constructed for marking on special material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00Means for introduction, extraction or recirculation of materials, e.g. pumps
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M33/00Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062General methods for three-dimensional culture

Definitions

  • Drug discovery is the process by which drugs are discovered and/or designed. The process of drug discovery generally involves at least the steps of: identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, expensive, and inefficient process with low rate of new therapeutic discovery.
  • bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio-ink and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; and a means for dispensing the contents of at least one cartridge.
  • the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, hydraulics, or a combination thereof.
  • the bio-ink or support material comprises one or more UV cross-linkable materials.
  • the UV light module exposes the contents of at least one cartridge to UV light prior to dispensing.
  • the UV light module is tunable with respect to wavelength, intensity, exposure time, or any combination thereof.
  • the UV light module comprises one or more optionally engaged attenuation filters, wherein the attenuation filters lower UV intensity when engaged.
  • the bioprinter further comprises a means for applying a wetting agent to one or more of: a printer stage; a receiving surface; a deposition orifice; the bio-ink; the support material; and a printed construct; wherein the wetting agent is applied at one or more time points selected from: before the bio -ink or support material is dispensed by the bioprinter, substantially concurrently with dispensing, and after the bio -ink or support material is dispensed by the bioprinter.
  • a tissue construct comprising the steps of: depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has been exposed to UV light to partially or completely cross-link the UV cross- linkable material to form a semi-solid or solid body; and incubating the bio-ink to allow it to cohere and to form a tissue, wherein said incubation has a duration of about 1 hour to about 10 days.
  • the method further comprises the step of preparing a liquid bio-ink solution comprising a UV cross-linkable material and cells.
  • the method further comprises the step of exposing a liquid bio-ink solution comprising a UV cross-linkable material and cells to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body.
  • the method further comprises the step of depositing bio-ink onto a support, wherein the bio -ink comprises a UV cross-linkable material and has not been exposed to UV light.
  • the UV cross-linkable material is a hydrogel.
  • the bio-ink comprises mammalian cells.
  • the bio-ink comprises differentiated, mammalian cells.
  • the bio -ink comprises non-differentiated, mammalian cells.
  • the bio -ink is deposited by extrusion from a bioprinter.
  • bioprinter cartridges wherein the contents of the cartridge comprises a UV cross-linkable material and optionally cells.
  • the UV cross-linkable material is partially or completely cross-linked.
  • the UV cross-linkable material is a hydrogel.
  • the cartridge comprises a glass-walled reservoir. In some embodiments, the cartridge is permeable to UV light.
  • UV light modules for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light.
  • the UV light module is reversibly attachable to a bioprinter.
  • the UV light module is tunable with respect to wavelength, intensity, exposure time, or any combination thereof.
  • the UV light module further comprises one or more optionally engaged attenuation filters, wherein the attenuation filters lower UV intensity when engaged.
  • tissue constructs comprising a multicellular body on a support substrate, wherein the multicellular body comprises a UV cross -linkable material and cells, wherein the multicellular body was deposited by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body.
  • the construct comprises a plurality of multicellular bodies.
  • the UV cross-linkable material is a hydrogel.
  • the multicellular body comprises differentiated, mammalian cells.
  • the multicellular body comprises non-differentiated, mammalian cells.
  • Fig. 1 illustrates a non-limiting example of calibration of a cartridge using a horizontal laser.
  • Fig. 2 illustrates a non- limiting example of calibration of a cartridge using a vertical laser.
  • Fig. 3 illustrates a non-limiting example of a capillary priming process.
  • Fig. 4 illustrates a non-limiting example of a two-dimensional representation of a bio- printed tissue construct.
  • FIG. 5 illustrates a non-limiting example of a three-dimensional construct generated by continuous deposition of PF-127 using a NovoGen MMXTM bioprinter connected to a syringe with a 510 ⁇ needle; in this case, a pyramid-shaped construct.
  • FIG. 6 illustrates a non-limiting example of a three-dimensional construct generated by continuous deposition of PF-127 using a NovoGen MMXTM bioprinter connected to a syringe with a 510 ⁇ needle; in this case, cube-shaped (left) and hollow cube-shaped (right) constructs.
  • Fig. 7 illustrates a non-limiting schematic diagram depicting exemplary parameters for exposing a UV cross-linkable material to a UV light source in the context of a bioprinter.
  • Fig. 8 illustrates a non-limiting example of a NovoGen MMXTM bioprinter including a UV module; in this case, a printer head is positioned such that a capillary tube is partially introduced to a UV module.
  • Fig. 9 illustrates a non-limiting example of a NovoGen MMXTM bioprinter including a UV module; in this case, a printer head is positioned such that a capillary tube is entirely introduced to a UV module.
  • the invention relates to the fields of regenerative medicine, tissue/organ engineering, biologic and medical research, and drug discovery. More particularly, the invention relates to devices for fabricating tissues and organs, systems and methods for calibrating and using such devices, and tissues and organs fabricated by the devices, systems, and methods disclosed herein.
  • bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; and a means for dispensing the contents of at least one cartridge.
  • a tissue construct comprising the steps of: depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has been exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body; and incubating the bio-ink to allow it to cohere and to form a tissue, wherein said incubation has a duration of about 1 hour to about 10 days.
  • bioprinter cartridges wherein the contents of the cartridge comprises a UV cross-linkable material and optionally cells.
  • UV light modules for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light.
  • tissue constructs comprising a multicellular body on a support substrate, wherein the multicellular body comprises a UV cross- linkable material and cells, wherein the multicellular body was deposited by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body.
  • references to “a nucleic acid” includes one or more nucleic acids, and/or compositions of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth. Any reference to “or” herein is intended to encompass “and/or” unless otherwise stated.
  • raft means an organ or tissue derived from a genetically non- identical member of the same species as the recipient.
  • bio-ink means a liquid, semi-solid, or solid composition comprising a plurality of cells.
  • bio-ink comprises cell solutions, cell aggregates, cell- comprising gels, multicellular bodies, or tissues.
  • the bio -ink additionally comprises support material.
  • the bio -ink additionally comprises non-cellular materials that provide specific biomechanical properties that enable bioprinting.
  • bioprinting means utilizing three-dimensional, precise deposition of cells (e.g., cell solutions, cell-containing gels, cell suspensions, cell concentrations, multicellular aggregates, multicellular bodies, etc.) via methodology that is compatible with an automated, computer-aided, three-dimensional prototyping device (e.g., a bioprinter).
  • cells e.g., cell solutions, cell-containing gels, cell suspensions, cell concentrations, multicellular aggregates, multicellular bodies, etc.
  • an automated, computer-aided, three-dimensional prototyping device e.g., a bioprinter
  • carrier means any object that is capable of receiving (and holding) a bio-ink or a support material.
  • a "computer module” means a software component (including a section of code) that interacts with a larger computer system.
  • a software module (or program module) comes in the form of a file and typically handles a specific task within a larger software system.
  • a module may be included in one or more software systems.
  • a module may be seamlessly integrated with one or more other modules into one or more software systems.
  • a computer module is optionally a stand-alone section of code or, optionally, code that is not separately identifiable.
  • a key feature of a computer module is that it allows an end user to use a computer to perform the identified functions.
  • implantable means biocompatible and capable of being inserted or grafted into or affixed onto a living organism either temporarily or substantially permanently.
  • organ means a collection of tissues joined into structural unit to serve a common function.
  • organs include, but are not limited to, skin, sweat glands, sebaceous glands, mammary glands, bone, brain, hypothalamus, pituitary gland, pineal body, heart, blood vessels, larynx, trachea, bronchus, lung, lymphatic vessel, salivary glands, mucous glands, esophagus, stomach, gallbladder, liver, pancreas, small intestine, large intestine, colon, urethra, kidney, adrenal gland, conduit, ureter, bladder, fallopian tube, uterus, ovaries, testes, prostate, thyroid, parathyroid, meibomian gland, parotid gland, tonsil, adenoid, thymus, and spleen.
  • patient means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • subject means any individual.
  • recipient means any individual.
  • donor means any individual.
  • None of the terms should be construed as requiring the supervision (constant or otherwise) of a medical professional (e.g., physician, nurse, nurse practitioner, physician's assistant, orderly, hospice worker, social worker, clinical research associate, etc.) or a scientific researcher.
  • a medical professional e.g., physician, nurse, nurse practitioner, physician's assistant, orderly, hospice worker, social worker, clinical research associate, etc.
  • stem cell means a cell that exhibits potency and self-renewal.
  • Stem cells include, but are not limited to, totipotent cells, pluripotent cells, multipotent cells, oligopotent cells, unipotent cells, and progenitor cells.
  • Stem cells may be embryonic stem cells, peri-natal stem cells, adult stem cells, amniotic stem cells, and induced pluripotent stem cells.
  • tissue means an aggregate of cells.
  • tissues include, but are not limited to, connective tissue (e.g., areolar connective tissue, dense connective tissue, elastic tissue, reticular connective tissue, and adipose tissue), muscle tissue (e.g., skeletal muscle, smooth muscle and cardiac muscle), genitourinary tissue, gastrointestinal tissue, pulmonary tissue, bone tissue, nervous tissue, and epithelial tissue (e.g., simple epithelium and stratified epithelium), endoderm-derived tissue, mesoderm-derived tissue, and ectoderm-derived tissue.
  • connective tissue e.g., areolar connective tissue, dense connective tissue, elastic tissue, reticular connective tissue, and adipose tissue
  • muscle tissue e.g., skeletal muscle, smooth muscle and cardiac muscle
  • genitourinary tissue e.g., skeletal muscle, smooth muscle and cardiac muscle
  • genitourinary tissue e.g., skeletal muscle, smooth muscle and cardiac
  • xenograft means an organ or tissue derived from a different species as the recipient.
  • Organs are only derived from living donors (e.g., for kidney and liver donations), deceased donors (e.g., for lung and heart donations) and, in a few cases, animals (e.g., porcine heart valves).
  • living donors e.g., for kidney and liver donations
  • deceased donors e.g., for lung and heart donations
  • animals e.g., porcine heart valves
  • transplant rejection e.g., transplant rejections
  • hyperacute rejection means a complement -mediated immune response resulting from the recipient's having pre-existing antibodies to the donor organ. Hyperacute rejection occurs within minutes and is characterized by blood agglutination. If the transplanted organ is not immediately removed, the patient may become septic. Xenografts will produce hyperacute rejection unless the recipient is first administered immunosuppressants. In some embodiments, a tissue or organ fabricated de novo will not comprise any antigens and thus cannot be recognized by any antibodies of the recipient.
  • a patient receiving an organ transplant experiences acute rejection.
  • acute rejection means an immune response that begins about one week after transplantation to about one year after transplantation. Acute rejection results from the presence of foreign HLA molecules on the donor organ.
  • APCs recognize the foreign HLAs and activate helper T cells.
  • helper T cells activate cytotoxic T cells and macrophages.
  • the presence of cytotoxic T cells and macrophages results in the death of cells with the foreign HLAs and thus damage (or death) of the transplanted organ.
  • Acute rejection occurs in about 60-75% of kidney transplants, and 50-60% of liver transplants.
  • a tissue or organ fabricated de novo will not comprise any HLAs and thus will not result in the activation of helper T cells.
  • a patient receiving an organ transplant experiences chronic rejection.
  • chronic rejection means transplant rejection resulting from chronic inflammatory and immune responses against the transplanted tissue.
  • a tissue or organ fabricated de novo will not comprise any antigens or foreign HLAs and thus will not induce inflammatory or immune responses.
  • CAV chronic allograft vasculopathy
  • chronic allograft vasculopathy means loss of function in transplanted organs resulting from fibrosis of the internal blood vessels of the transplanted organ.
  • CAV is the result of long-term immune responses to a transplanted organ.
  • a tissue or organ fabricated de novo will not comprise any antigens or foreign HLAs and thus will not result in an immune response.
  • Immunosuppressants include, but are not limited to, corticosteroids (e.g., prednisone and hydrocortisone), calcineurin inhibitors (e.g., cyclosporine and tacrolimus), anti-proliferative agents (e.g., azathioprine and mycophenolic acid), antibodies against specific components of the immune system (e.g., basiliximab, dacluzimab, anti-thymocyte globulin (ATG) and anti-lymphocyte globulin (ALG) and mTOR inhibitors (e.g., sirolimus and everolimus)).
  • corticosteroids e.g., prednisone and hydrocortisone
  • calcineurin inhibitors e.g., cyclosporine and tacrolimus
  • anti-proliferative agents e.g., azathioprine and mycophenolic acid
  • antibodies against specific components of the immune system e.
  • immunosuppressants have several negative side-effects including, but not limited to, susceptibility to infection (e.g., infection by Pneumocystis carinii pneumonia (PCP), cytomegalovirus pneumonia (CMV), herpes simplex virus, and herpes zoster virus) and the spread of malignant cells, hypertension, dyslipidaemia, hyperglycemia, peptic ulcers, liver and kidney injury, and interactions with other medicines.
  • PCP Pneumocystis carinii pneumonia
  • CMV cytomegalovirus pneumonia
  • herpes simplex virus herpes simplex virus
  • herpes zoster virus herpes simplex virus
  • a tissue or organ fabricated de novo will not result in an immune response and thus will not require the administration of an immunosuppressant.
  • a donor organ may be infected with an infectious agent.
  • the infectious agent is able to spread throughout the donor (due in part to the use of immunosuppressant drugs).
  • recipients have contracted HIV, West Nile Virus, rabies, hepatitis C, lymphocytic choriomeningitis virus (LCMV), tuberculosis, Chagas disease, and Creutzfeldt-Jakob disease from transplanted organs.
  • LCMV lymphocytic choriomeningitis virus
  • a tissue or organ fabricated de novo will not comprise any infectious agents.
  • a living donor may also experience complications as a result of donating an organ. These complications include nosocomial infections, allergic reactions to the anesthesia, and surgical errors. Further, an organ donor may one day find themselves in need of the organ they donated. For example, the remaining kidney of a kidney donor or the remaining lobe of a liver donor may become damaged. In some embodiments, a tissue or organ fabricated de novo obviates the need for donor organs and thus will avoid negative side-effects to the donor.
  • Tissue engineering is an interdisciplinary field that applies and combines the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function through augmentation, repair, or replacement of an organ or tissue.
  • the basic approach to classical tissue engineering is to seed living cells into a biocompatible and eventually biodegradable environment (e.g., a scaffold), and then culture this construct in a bioreactor so that the initial cell population can expand further and mature to generate the target tissue upon implantation.
  • a scaffold that mimics the biological extracellular matrix (ECM)
  • ECM biological extracellular matrix
  • the viability of the tissues may be compromised by confinement material that limits
  • devices, systems, and methods that generate a three-dimensional tissue construct.
  • the devices, systems, and methods disclosed herein utilize a three-phase process: (i) pre-processing, or bio-ink preparation, (ii) processing, i.e. the actual automated delivery/printing of the bio-ink particles into the bio-paper by the bioprinter, and (iii) post-processing, i.e., the maturation/incubation of the printed construct in the bioreactor. Final structure formation takes place during post-processing via the fusion of the bio-ink particles.
  • the devices, systems, and methods disclosed herein have the following advantages:
  • Bioprinting enables improved methods of generating cell-comprising implantable tissues that are useful in tissue repair, tissue augmentation, tissue replacement, and organ replacement. Additionally, bioprinting enables improved methods of generating micro -scale tissue analogs including those useful for in vitro assays.
  • the devices are bioprinters.
  • the methods comprise the use bioprinting techniques.
  • the tissues and organs fabricated by use of the devices, systems, and methods described herein are bioprinted.
  • bioprinted cellular constructs, tissues, and organs are made with a method that utilizes a rapid prototyping technology based on three-dimensional, automated, computer-aided deposition of cells, including cell solutions, cell suspensions, cell-comprising gels or pastes, cell concentrations, multicellular bodies (e.g., cylinders, spheroids, ribbons, etc.), and support material onto a biocompatible surface (e.g., composed of hydrogel and/or a porous membrane) by a three-dimensional delivery device (e.g., a bioprinter).
  • a biocompatible surface e.g., composed of hydrogel and/or a porous membrane
  • the term "engineered,” when used to refer to tissues and/or organs means that cells, cell solutions, cell suspensions, cell-comprising gels or pastes, cell concentrates, multicellular aggregates, and layers thereof are positioned to form three-dimensional structures by a computer- aided device (e.g., a bioprinter) according to computer code.
  • the computer script is, for example, one or more computer programs, computer applications, or computer modules.
  • three-dimensional tissue structures form through the post- printing fusion of cells or multicellular bodies similar to self-assembly phenomena in early morphogenesis.
  • methods of bioprinting are continuous and/or substantially continuous.
  • a non- limiting example of a continuous bioprinting method is to dispense bio -ink from a bioprinter via a dispense tip (e.g., a syringe, capillary tube, etc.) connected to a reservoir of bio- ink.
  • a continuous bioprinting method is to dispense bio -ink in a repeating pattern of functional units.
  • a repeating functional unit has any suitable geometry, including, for example, circles, squares, rectangles, triangles, polygons, and irregular geometries.
  • a repeating pattern of bioprinted function units comprises a layer and a plurality of layers are bioprinted adjacently (e.g., stacked) to form an engineered tissue or organ.
  • 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more layers are bioprinted adjacently (e.g., stacked) to form an engineered tissue or organ.
  • a bioprinted functional unit repeats in a tessellated pattern.
  • tessellated pattern is a plane of figures that fills the plane with no overlaps and no gaps.
  • An advantage of continuous and/or tessellated bioprinting can include an increased production of bioprinted tissue. Increased production can include achieving increased scale, increased
  • Another non- limiting potential advantage can be reducing the number of calibration events that are required to complete the bioprinting of a three- dimensional construct. Continuous bioprinting may also facilitate printing larger tissues from a large reservoir of bio-ink, optionally using a syringe mechanism.
  • Methods in continuous bioprinting may involve optimizing and/or balancing parameters such as print height, pump speed, robot speed, or combinations thereof independently or relative to each other.
  • the bioprinter head speed for deposition was 3 mm/s, with a dispense height of 0.5 mm for the first layer and dispense height was increased 0.4 mm for each subsequent layer.
  • the dispense height is approximately equal to the diameter of the bioprinter dispense tip.
  • a suitable and/or optimal dispense distance does not result in material flattening or adhering to the dispensing needle.
  • the bioprinter dispense tip has an inner diameter of about, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 ⁇ , or more, including increments therein.
  • the bio-ink reservoir of the bioprinter has a volume of about .5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 cubic centimeters, or more, including increments therein.
  • the pump speed may be suitable and/or optimal when the residual pressure build-up in the system is low.
  • a suitable and/or optimal print speed enables the deposition of a uniform line without affecting the mechanical integrity of the material.
  • the inventions disclosed herein include business methods.
  • the speed and scalability of the devices and methods disclosed herein are utilized to design, build, and operate industrial and/or commercial facilities for production of engineered tissues and/or organs.
  • the engineered tissues and/or organs are produced, stored, distributed, marketed, advertised, and sold as, for example, materials, tools, and kits for medical treatment of tissue damage, tissue disease, and/or organ failure or materials, tools, and kits to conduct biological assays and/or drug screening as a service.
  • a bioprinter for fabricating tissues and organs.
  • a bioprinter is any instrument that automates a bioprinting process.
  • a bioprinter disclosed herein comprises: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material; a means for calibrating the position of at least one cartridge; and a means for dispensing the contents of at least one cartridge.
  • a bioprinter dispenses bio-ink and/or support material in predetermined geometries (e.g., positions, patterns, etc.) in two or three dimensions.
  • a bioprinter achieves a particular geometry by moving a printer head relative to a printer stage or receiving surface adapted to receive bioprinted materials.
  • a bioprinter achieves a particular geometry by moving a printer stage or receiving surface relative to a printer head.
  • the bioprinter is maintained in a sterile environment.
  • a bioprinter disclosed herein comprises one or more printer heads.
  • a printer head comprises a means for receiving and holding at least one cartridge.
  • a printer head comprises a means for receiving and holding more than one cartridge.
  • the means for receiving and holding at least one cartridge is selected from: magnetic attraction, a collet chuck grip, a ferrule, a nut, a barrel adapter, or a combination thereof.
  • the means for receiving and holding at least one cartridge is a collet chuck grip.
  • a bioprinter disclosed herein comprises a means for calibrating the position of at least one cartridge.
  • the means for calibrating the position of at least one cartridge of is selected from: laser alignment, optical alignment, mechanical alignment, piezoelectric alignment, magnetic alignment, electrical field or capacitance alignment, ultrasound alignment, or a combination thereof.
  • the means for calibrating the position of at least one cartridge is laser alignment.
  • a bioprinter disclosed herein comprises a means for dispensing the contents of at least one cartridge.
  • the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, application of hydraulics, or application of a combination thereof.
  • the means for dispensing the contents of at least one cartridge is application of a piston.
  • the diameter of the piston is less than the diameter of a cartridge.
  • a bioprinter disclosed herein further comprises a receiving surface.
  • a receiving surface is a non-cytotoxic surface onto which a bioprinter dispenses bio-ink and/or support material.
  • a bioprinter disclosed herein further comprises a printer stage.
  • a receiving surface is a surface of a printer stage.
  • a receiving surface is component separate from a printer stage, but is affixed to or supported by a stage.
  • the receiving surface is flat or substantially flat.
  • the surface is smooth or substantially smooth.
  • the surface is both substantially flat and substantially smooth.
  • the receiving surface is designed specifically to accommodate the shape, size, texture, or geometry of the bioprinted structure.
  • the receiving surface controls or influences the size, shape, texture, or geometry of a bioprinted construct.
  • a bioprinter disclosed herein further comprises a means for adjusting temperature.
  • the means for adjusting temperature adjusts and/or maintains the ambient temperature.
  • the means for adjusting temperature adjusts and/or maintains the temperature of, by way of non-limiting example, the print head, cartridge, contents of the cartridge (e.g., bio-ink, support material, etc.), the printer stage, and the receiving surface.
  • the means for adjusting temperature is a heating element. In some embodiments, the means for adjusting temperature is a heater. In some embodiments, the means for adjusting temperature is a radiant heater, a convection heater, a conductive heater, a fan heater, a heat exchanger, or a combination thereof. In some embodiments, the means for adjusting temperature is a cooling element. In some embodiments, the means for adjusting temperature is a container of coolant, a chilled liquid, ice, or a combination thereof. In some embodiments, the means for adjusting temperature is a radiant cooler, convection cooler, a conductive cooler, a fan cooler, or a combination thereof.
  • the means for adjusting temperature adjusts a temperature to about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90°C including increments therein. In some embodiments, temperature is adjusted to between about 40°C and about 90°C. In other embodiments, temperature is adjusted to between about 0°C and about 10°C.
  • a bioprinter disclosed herein further comprises a means for applying a wetting agent to one or more of: the printer stage; the receiving surface, the deposition orifice, bio-ink, support material, or the printed construct.
  • the means for applying the wetting agent is any suitable method of applying a fluid (e.g., a sprayer, a pipette, an inkjet, etc.).
  • the wetting agent is water, tissue culture media, buffered salt solutions, serum, or a combination thereof.
  • a wetting agent is applied after the bio- ink or supporting material is dispensed by the bioprinter.
  • a wetting agent is applied simultaneously or substantially simultaneously with the bio -ink or supporting material being dispensed by the bioprinter. In some embodiments, a wetting agent is applied prior to the bio- ink or supporting material being dispensed by the bioprinter.
  • a bioprinter for fabricating tissues and organs.
  • a bioprinter disclosed herein comprises one or more printer heads.
  • a printer head comprises a means for receiving and holding at least one cartridge.
  • a printer head attaches at least one cartridge to a bioprinter.
  • Suitable means for receiving and holding at least one cartridge include those that reliably, precisely, and securely attach at least one cartridge to a bioprinter.
  • the means for receiving and holding at least one cartridge is, by way of non-limiting example, magnetic attraction, a collet chuck grip, a ferrule, a nut, a barrel adapter, or a combination thereof.
  • a printer head disclosed herein receives and holds one cartridge. In various other embodiments, a printer head disclosed herein receives and holds 2, 3, 4, 5, 6, 7, 8, 9, 10, or more cartridges simultaneously. In further embodiments, a printer head disclosed herein further comprises a means to select a cartridge to be employed in bioprinting from among a plurality of cartridges received and held.
  • a printer head disclosed herein further comprises (or is in fluid communication with) a reservoir to contain bio-ink and/or support materials beyond the capacity of the one or more cartridges.
  • a reservoir supplies bio -ink and/or support materials to one or more cartridges for dispensing via a dispensing orifice.
  • a reservoir has an internal volume of, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500 ml or more, including increments therein.
  • bioprinting involves using a computer to configure parameters such as print height, pump speed, robot speed, or combinations thereof independently or relative to each other.
  • computer code specifies the positioning of a printer head to configure printer head height above a receiving surface.
  • computer code specifies the direction and speed of the motion of a printer head to configure dispensing
  • bio-ink and/or support material characteristics for bio-ink and/or support material.
  • a cartridge attached to the bioprinter comprises bio -ink or support material.
  • the bioprinter dispenses bio -ink or support material in a specific pattern and at specific positions in order to form a specific cellular construct, tissue, or organ.
  • the bioprinter deposits the bio -ink or support material at precise speeds and in uniform amounts.
  • a cartridge with (a) a dispensing orifice that is smooth or substantially smooth, and (b) an internal surface that is smooth or substantially smooth.
  • “cartridge” means any object that is capable of receiving (and holding) a bio-ink and/or support material.
  • a cartridge disclosed herein comprises bio -ink.
  • a cartridge disclosed herein comprises support material. In some embodiments, a cartridge disclosed herein comprises a combination of bio -ink and support material.
  • a cartridge for use with a bioprinter disclosed herein, comprising at least one dispensing orifice.
  • a cartridge comprises one dispensing orifice.
  • a cartridge comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more dispensing orifices.
  • the edges of a dispensing orifice are smooth or substantially smooth.
  • suitable shapes for dispensing orifices include, by way of non-limiting examples, circular, ovoid, triangular, square, rectangular, polygonal, and irregular.
  • the orifice is circular.
  • the orifice is square.
  • the orifice is oval, oblong, or rectangular and dispenses solid or semi-solid bio-ink and/or support materials in a ribbon- like form.
  • the internal surface of the cartridge is smooth or substantially smooth.
  • the cartridge is comprised of a rigid structure to facilitate calibration.
  • the walls of the cartridge are comprised of a material that resists attachment of cells.
  • the cartridges are comprised of a material that is biocompatible.
  • Many types of cartridges are suitable for use with bioprinters disclosed herein and the methods of using the same.
  • a cartridge is compatible with bioprinting that involves extruding a semi-solid or solid bio-ink or a support material through one or more dispensing orifices.
  • a cartridge is compatible with bioprinting that involves dispensing a liquid or semi-solid cell solution, cell suspension, or cell concentration through one or more dispensing orifices.
  • a cartridge is compatible with non-continuous bioprinting.
  • a cartridge is compatible with continuous and/or substantially continuous bioprinting.
  • a cartridge is a capillary tube or a micropipette.
  • a cartridge is a syringe or a needle.
  • Many internal diameters are suitable for substantially round or cylindrical cartridges.
  • suitable internal diameters include, by way of non- limiting examples, 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more ⁇ , including increments therein.
  • suitable internal diameters include, by way of non-limiting examples, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more mm, including increments therein.
  • a cartridge has an internal diameter of about 1 ⁇ to about 1000 ⁇ . In a particular embodiment, a cartridge has an internal diameter of about 500 ⁇ .
  • a cartridge has an internal diameter of about 250 ⁇ .
  • suitable internal volumes include, by way of non- limiting examples, 1, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more ⁇ , including increments therein.
  • suitable internal volumes include, by way of non-limiting examples, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 or more ml, including increments therein.
  • a cartridge has a volume of about 1 ⁇ to about 50 ⁇ . In a particular embodiment, a cartridge has a volume of about 5 ⁇ .
  • a cartridge is compatible with ink -jet printing of bio-ink and/or support material onto a receiving surface such as that described in U.S. Patent Number 7,051,654.
  • a cartridge includes dispensing orifices in the form of voltage-gated nozzles or needles under the control of the computer code described herein.
  • the cartridge is primed.
  • priming the cartridge increases the accuracy of the dispensing, deposition, or extrusion process.
  • “primed” means the contents of the cartridge are made ready for dispensing, deposition, or extrusion by compacting and advancing the contents of the cartridge until the material to be dispensed (bio -ink or supporting material) is located in a position in contact with the dispensing orifice. See, e.g., Fig. 3.
  • the cartridge is primed when the contents are compact or substantially compact, and the contents are in physical contact with the orifice of the cartridge.
  • a cartridge is marked to indicate the composition of its contents. In further embodiments, a cartridge is marked to indicate the composition of a bio -ink and/or support material contained therein. In some embodiments, the surface of the cartridge is colored. In some embodiments, the outer surface of the cartridge is dyed, painted, marked with a pen, marked by a sticker, or a combination thereof.
  • the outer surface of a cartridge is marked to increase the opacity of the surface of the cartridge (e.g., to increase the amount of a laser beam that is reflected off the surface of the cartridge).
  • the surface of a cartridge is colored.
  • the outer surface of a cartridge is scored. As used herein, "scored" means marking the surface of a cartridge to reduce the smoothness of the surface. Any suitable method is used to score the surface of a cartridge (e.g., application of an acidic substance, application of a caustic substance, application of an abrasive substance, etc.).
  • the outer surface of a cartridge is painted, polished (e.g., fire polished), etched (e.g., laser etched), marked with a pen, marked by a sticker, or a combination thereof.
  • a cartridge attached to a bioprinter comprises bio -ink and/or support material.
  • the bioprinter dispenses the bio -ink and/or support material in a specific pattern and at specific positions in order to form a specific cellular construct, tissue, or organ.
  • a cartridge comprising bio -ink is disposable.
  • the cartridge is ejected from the bioprinter following extrusion of the contents.
  • a new cartridge is subsequently attached to the bioprinter.
  • bioprinters disclosed herein dispense bio -ink and/or support material from a cartridge with a suitable repeatable accuracy.
  • suitable repeatable accuracies include those of about ⁇ 5, 10, 20, 30, 40, or 50 ⁇ on any axis.
  • the bioprinters disclosed herein dispense bio -ink and/or support material from a cartridge with a repeatable accuracy of about ⁇ 20 ⁇ .
  • uncontrolled removal and insertion of cartridges can result in alterations of the position of the printer head (and thus the cartridges) with respect to the tissue construct, such that precision of the placement of the first bio-ink particle deposited from a new cartridge may vary relative to the last bio -ink particle deposited from the previous cartridge.
  • there is a need for a method of attaching and securing a cartridge to a printer head wherein said attaching and securing produce minimal alterations in the position of the printer head.
  • a cartridge to a bioprinter, comprising: (a) inserting the cartridge into a collet chuck, wherein the collet chuck is attached to a printer head of the bioprinter; and (b) adjusting the outer collar of the collet chuck; wherein the inserting and adjusting do not substantially alter the position of the printer head.
  • systems for attaching a cartridge to a bioprinter comprising: a means for receiving and securing a cartridge to a printer head of a bioprinter; wherein use of the means for receiving and securing the cartridge do not substantially alter the position of the printer head.
  • the means for receiving and securing the cartridge to a printer head is a chuck or ferrule.
  • chuck means a holding device consisting of adjustable jaws.
  • the means for receiving and securing the cartridge to a printer head is a collet.
  • colllet means a subtype of chuck— that forms a collar around the object to be held and exerts a strong clamping.
  • ferrule means a band (e.g., a metal band) used to secure one object to another.
  • the means for receiving and securing the cartridge to a printer head is a barrel adaptor.
  • barrel adaptor means a threaded tube used to secure one object to another.
  • a bioprinter comprises a ultraviolet (UV) light module.
  • a UV module enables a bioprinter disclosed herein to automatically cure and print UV cross-linkable materials.
  • a UV module comprises a light chamber for exposing the contents of a cartridge (e.g., a glass capillary tube) to UV light.
  • a UV module comprises a UV light line to expose the contents of a cartridge to UV light evenly along its length.
  • a UV module comprises a slot to accept an optional attenuation filter that reduces the intensity of UV light to which the contents of a cartridge is exposed.
  • a UV module is integrated with a bioprinter.
  • a UV module is permanently, semi-permanently, or reversibly attached to a bioprinter. In other embodiments, a UV module is not attached to a bioprinter.
  • a UV module described herein is used by first aspirating uncured material into a glass capillary tube.
  • the glass capillary then is lowered into the light chamber, where a high power fiber optic light line transmits UV light from a UV light source across the length of the capillary.
  • a high power fiber optic light line transmits UV light from a UV light source across the length of the capillary.
  • the material is ready to print (e.g., be extruded or deposited, etc.).
  • an optional attenuation filter is placed between the capillary and the light guide to achieve lower UV intensities.
  • UV light is electromagnetic radiation with a wavelength in the range 10 nm to 400 nm and energies from 3 eV to 124 eV. UV light, in some cases, alters chemical bonds in molecules and can cause chemical reactions. UV light from various sources is characterized by having many suitable wavelengths and many suitable associated energies. See Table 1, infra.
  • suitable sources of UV light include, by way of non-limiting examples, UV lamps, UV fluorescent lamps, UV LEDs, UV lasers, and the like.
  • a UV lamp e.g., black light, black light blue or BLB lamps, etc.
  • Fluorescent black lights are typically made using a UV-emitting phosphor.
  • the phosphor typically used for a near 368-371 nm emission peak is either europium-doped strontium fluoroborate (SrB 4 0yF:Eu 2+ ) or europium-doped strontium borate (SrB 4 0 7 :Eu 2+ ), whereas the phosphor used to produce a peak around 350-353 nm is lead-doped barium silicate (BaSi 2 05:Pb + ).
  • Fluorescent black lights are also typically made using Wood's glass, a nickel-oxide-doped glass, which blocks almost all visible light above 400 nm.
  • a black light may also be formed, very inefficiently, by simply using Wood's glass instead of clear glass as the envelope for a common incandescent bulb.
  • UV fluorescent lamps without a phosphorescent coating to convert UV to visible light, emit ultraviolet light with two peaks at 253.7 nm and 185 nm due to the peak emission of the mercury within the bulb. With the addition of a suitable phosphor (phosphorescent coating), they can be modified to produce UVA or UVB.
  • Light-emitting diodes LEDs
  • UV laser diodes and UV solid-state lasers can be manufactured to emit light in the UV range. Direct UV- emitting laser diodes are available at 375 nm.
  • UV diode lasers have been demonstrated using crystals of cerium doped with lithium strontium aluminum fluoride (Ce:LiSAF). Wavelengths shorter than 375 nm are generated from diodes in solid-state modules that use frequency doubling or tripling diode-pumped solid state (DPSS) technology. Wavelengths available include 262, 266, 349, 351, 355, and 375 nm.
  • DPSS diode-pumped solid state
  • a UV module comprises a UV light source that is a UV lamp.
  • a cartridge includes a glass capillary tube into which a UV cross-linkable material is aspirated.
  • the cartridge is positioned within the light chamber of the UV module such that it is about 3 inches from the UV lamp.
  • the UV lamp in this embodiment emits UV light with a wavelength of about 365 nm.
  • a bioprinter in a particular embodiment, includes a printer head 800, which holds a cartridge 810.
  • a cartridge 810 includes a glass capillary tube which is partially lowered into a UV light module 820 attached to the bioprinter.
  • the UV module 820 in this case, comprises a housing, a cover, and an opening to allow introduction of the cartridge 810.
  • a printer head 800 which holds a cartridge 810 is completely lowered into a UV light module 820.
  • a UV module enables a bioprinter disclosed herein to automatically cure and print UV cross-linkable materials by exposing them to UV light for a pre-determined period of time.
  • Many durations of exposure to a UV light source are suitable.
  • particular UV cross-linkable materials are suited to particular exposure times.
  • exposure time is selected to completely UV cross-link a material, resulting in a more solid structure.
  • exposure time is selected to partially UV cross-link a material, resulting in a more semi-solid structure.
  • suitable exposure times include, by way of non-limiting examples, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more seconds.
  • suitable exposure times include, by way of non- limiting examples, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more minutes.
  • exposure time is about 5 seconds to about 15 minutes.
  • exposure time is about 10 seconds to about 10 minutes.
  • exposure time is about 15 seconds to about 5 minutes.
  • exposure time is adjusted for the presence of cells in a UV cross-linkable material.
  • bioprinters for fabricating tissues and organs.
  • the bioprinter dispenses a plurality of elements, sections, and/or areas of bio-ink and/or support material onto a receiving surface.
  • dispensing occurs in a specific pattern and at specific positions.
  • the locations at which the bioprinter deposits bio-ink and/or support material onto a receiving surface are defined by user input and translated into computer code.
  • each of the elements, sections, and/or areas of bio -ink and/or support material has dimensions of less than 300 mm x 300 mm x 160 mm.
  • the dimensions of a section of bio-ink or support material may be 75 mm x 5.0 mm x 5.0 mm; 0.3 mm x 2.5 mm x 2.5 mm; 1 mm x 1 mm x 50 mm; or 150 mm x 150 mm x 80 mm. Due to the generally small size of each section, and in some cases, the high degree of precision required, minute imperfections in the receiving surface may result in imperfections (and possibly, failure) of a cellular construct, tissue, or organ. Thus, there is a need for a substantially smooth and substantially flat receiving surface, or a defined or substantially defined receiving surface, that is able to receive sections of bio-ink and/or support material.
  • receiving surfaces for receiving one or more structures generated by the bioprinter disclosed herein.
  • the receiving surface is flat or substantially flat.
  • the receiving surface is smooth or substantially smooth.
  • the receiving surface is flat or substantially flat.
  • the receiving surface is defined or substantially defined. In other embodiments the receiving surface is designed specifically to accommodate the shape, size, texture, or geometry of a specific bioprinted structure. In further embodiments, the receiving surface controls or influences the size, shape, texture, or geometry of a bioprinted construct.
  • the receiving surface comprises a solid material, a semi-solid material, or a combination thereof.
  • the receiving surface comprises glass, coated glass, plastic, coated plastic, metal, a metal alloy, or a combination thereof.
  • the receiving surface comprises a gel.
  • the receiving surface and any coatings thereon are biocompatible.
  • the receiving surface comprises any of the support materials and/or confinement materials disclosed herein.
  • the receiving surface comprises polymerized NovoGelTM or polymerized agarose, polymerized gelatin, extracellular matrix (or components thereof), collagen, or a combination thereof.
  • bioprinters for fabricating tissues and organs.
  • one or more cartridges attached to the bioprinter comprise bio -ink and/or support material.
  • the bioprinter dispenses bio-ink or support material in a specific pattern and at specific positions in order to form a specific cellular construct, tissue, or organ.
  • the bioprinter deposits the bio -ink or support material at precise locations (in two or three dimensions) on a receiving surface.
  • the locations at which the bioprinter deposits bio -ink and/or support material are defined by user input and translated into computer code.
  • the computer code includes a sequence of instructions, executable in the central processing unit (CPU) of a digital processing device, written to perform a specified task.
  • additional bioprinting parameters including, by way of non-limiting examples, print height, pump speed, robot speed, control of variable dispensing orifices, UV intensity, and UV exposure time are defined by user input and translated into computer code.
  • bioprinting parameters are not directly defined by user input, but are derived from other parameters and conditions by the computer code described herein.
  • a computer module receiving input of a visual representation of a desired tissue construct; a computer module generating a series of commands, wherein the commands are based on the visual representation and are readable by a bioprinter; a computer module providing the series of commands to a bioprinter; and the bioprinter depositing bio-ink and/or support material according to the commands to form a construct with a defined geometry.
  • the locations at which the bioprinter deposits the bio-ink and/or support material are defined by user input and translated into computer code.
  • the devices, systems, and methods disclosed herein further comprise non-transitory computer readable storage media or storage media encoded with computer readable program code.
  • a computer readable storage medium is a tangible component of a digital processing device such as a bioprinter (or a component thereof) or a computer connected to a bioprinter (or a component thereof).
  • a computer readable storage medium is optionally removable from a digital processing device.
  • a computer readable storage medium includes, by way of non-limiting examples, CD-ROMs, DVDs, flash memory devices, solid state memory, magnetic disk drives, magnetic tape drives, optical disk drives, cloud computing systems and services, and the like.
  • the program and instructions are permanently, substantially permanently, semi-permanently, or non-transitorily encoded on the storage media.
  • the devices, systems, and methods described herein comprise software, server, and database modules.
  • a "computer module” is a software component (including a section of code) that interacts with a larger computer system.
  • a software module (or program module) comes in the form of one or more files and typically handles a specific task within a larger software system.
  • a module is included in one or more software systems. In other embodiments, a module is integrated with one or more other modules into one or more software systems.
  • a computer module is optionally a stand-alone section of code or, optionally, code that is not separately identifiable.
  • the modules are in a single application. In other embodiments, the modules are in a plurality of applications.
  • the modules are hosted on one machine. In other embodiments, the modules are hosted on a plurality of machines. In some embodiments, the modules are hosted on a plurality of machines in one location. In other embodiments, the modules are hosted a plurality of machines in more than one location. Further described herein is the formatting of location and positioning data.
  • the data files described herein are formatted in any suitable data serialization format including, by way of non-limiting examples, tab-separated values, comma-separated values, character-separated values, delimiter-separated values, XML, JSON, BSON, and YAML.
  • a key feature of a computer module is that it allows an end user to use a computer to perform the identified functions.
  • a computer module comprises a graphic user interface (GUI).
  • GUI graphic user interface
  • a computer module comprises a display screen.
  • a computer module presents, via a display screen, a two- dimensional GUI.
  • a computer module presents, via a display screen, a three- dimensional GUI such as a virtual reality environment.
  • the display screen is a touchscreen or multitouchscreen and presents an interactive GUI.
  • the display screen presents a GUI that consists essentially of a grid comprising regularly spaced objects of substantially the same shape and substantially equal size.
  • the objects presented have any suitable shape.
  • suitable shapes for objects include, by way of non-limiting examples, circle, oval, square, rectangle, triangle, diamond, polygon, or a combination thereof.
  • a user defines the content of one or more objects to form a two-dimensional or three-dimensional visual representation of a desired tissue construct. See, e.g., Fig. 4.
  • the user-defined content of an object is, by way of non-limiting examples, a bio-ink with various compositions or support material with various compositions.
  • the user defines the content of an object by modifying the color of the cell or the shape of the object.
  • the devices comprise one or more printer heads for receiving and holding at least one cartridge that optionally contains bio-ink.
  • the methods comprise the use of bio -ink.
  • the tissues and organs fabricated by use of the devices, systems, and methods described herein comprise bio -ink at the time of fabrication or thereafter.
  • bio-ink includes liquid, semi-solid, or solid compositions comprising a plurality of cells.
  • bio-ink comprises liquid or semi-solid cell solutions, cell suspensions, or cell concentrations.
  • a cell solution, suspension, or concentration comprises a liquid or semi-solid (e.g., viscous) carrier and a plurality of cells.
  • the carrier is a suitable cell nutrient media, such as those described herein.
  • bio-ink comprises semi-solid or solid multicellular aggregates or multicellular bodies.
  • the bio -ink is produced by 1) mixing a plurality of cells or cell aggregates and a biocompatible liquid or gel in a pre -determined ratio to result in bio-ink, and 2) compacting the bio-ink to produce the bio-ink with a desired cell density and viscosity.
  • the compacting of the bio -ink is achieved by centrifugation, tangential flow filtration ("TFF"), or a combination thereof.
  • the compacting of the bio-ink results in a composition that is extrudable, allowing formation of multicellular aggregates or multicellular bodies.
  • "extrudable” means able to be shaped by forcing (e.g., under pressure) through a nozzle or orifice (e.g., one or more holes or tubes).
  • the compacting of the bio-ink results from growing the cells to a suitable density.
  • the cell density necessary for the bio -ink will vary with the cells being used and the tissue or organ being produced.
  • the cells of the bio -ink are cohered and/or adhered.
  • "cohere,” “cohered,” and “cohesion” refer to cell-cell adhesion properties that bind cells, multicellular aggregates, multicellular bodies, and/or layers thereof.
  • the terms are used interchangeably with “fuse,” “fused,” and “fusion.”
  • the bio-ink additionally comprises support material, cell culture medium, extracellular matrix (or components thereof), cell adhesion agents, cell death inhibitors, anti-apoptotic agents, antioxidants, extrusion compounds, and combinations thereof.
  • bio-inks that include liquid, semisolid, or solid compositions comprising a plurality of cells.
  • bio -ink comprises liquid or semi-solid cell solutions, cell suspensions, or cell concentrations.
  • any mammalian cell is suitable for use in bio-ink and in the fabrication of tissues and organs using the devices, systems, and methods described herein.
  • the cells are any suitable cell.
  • the cells are vertebrate cells, mammalian cells, human cells, or combinations thereof.
  • the type of cell used in a method disclosed herein depends on the type of cellular construct, tissue, or organ being produced.
  • the bio-ink comprises one type of cell (also referred to as a "homologous ink”). In some embodiments, the bio-ink comprises more than one type of cell (also referred to as a "heterologous ink”).
  • the cells are, by way of non-limiting examples, contractile or muscle cells (e.g., skeletal muscle cells, cardiomyocytes, smooth muscle cells, and myoblasts), connective tissue cells (e.g., bone cells, cartilage cells, fibroblasts, and cells differentiating into bone forming cells, chondrocytes, or lymph tissues), bone marrow cells, endothelial cells, skin cells, epithelial cells, breast cells, vascular cells, blood cells, lymph cells, neural cells, Schwann cells, gastrointestinal cells, liver cells, pancreatic cells, lung cells, tracheal cells, corneal cells, genitourinary cells, kidney cells, reproductive cells, adipose cells, parenchymal cells, pericytes, mesothelial cells, stromal cells, undifferentiated cells (e.g., embryonic cells, stem cells, and progenitor cells), endoderm-derived cells, mesoderm-derived cells, ectoderm
  • contractile or muscle cells
  • the cells are adult, differentiated cells.
  • differentiated cells are cells with a tissue-specific phenotype consistent with, for example, a smooth muscle cell, a fibroblast, or an endothelial cell at the time of isolation, wherein tissue-specific phenotype (or the potential to display the phenotype) is maintained from the time of isolation to the time of use.
  • the cells are adult, non-differentiated cells.
  • non-differentiated cells are cells that do not have, or have lost, the definitive tissue-specific traits of for example, smooth muscle cells, fibroblasts, or endothelial cells.
  • non-differentiated cells include stem cells.
  • stem cells are cells that exhibit potency and self-renewal.
  • Stem cells include, but are not limited to, totipotent cells, pluripotent cells, multipotent cells, oligopotent cells, unipotent cells, and progenitor cells.
  • Stem cells may be embryonic stem cells, adult stem cells, amniotic stem cells, and induced pluripotent stem cells.
  • the cells are a mixture of adult, differentiated cells and adult, non-differentiated cells.
  • the bio-ink comprises a cell culture medium.
  • the cell culture medium is any suitable medium.
  • suitable cell culture media include, by way of non-limiting examples, Dulbecco's Phosphate Buffered Saline, Earle's Balanced Salts, Hanks' Balanced Salts, Tyrode's Salts, Alsever's Solution, Gey's Balanced Salt Solution, Kreb's- Henseleit Buffer Modified, Kreb's-Ringer Bicarbonate Buffer, Puck's Saline, Dulbecco's Modified Eagle's Medium, Dulbecco's Modified Eagle's Medium/Nutrient F-12 Ham, Nutrient Mixture F-10 Ham (Ham's F-10), Medium 199, Minimum Essential Medium Eagle, RPMI-1640 Medium, Ames' Media, BGJb Medium (Fitton- Jackson Modification), Click's Medium, CMRL-1066 Medium, Fischer's Medium, Glascow Minimum Essential Medium (GMEM),
  • the cell culture medium is modified or supplemented.
  • the cell culture medium further comprises albumin, selenium, transferrins, fetuins, sugars, amino acids, vitamins, growth factors, cytokines, hormones, antibiotics, lipids, lipid carriers,
  • the bio-ink further comprises one or more components of an extracellular matrix or derivatives thereof.
  • extracellular matrix includes proteins that are produced by cells and transported out of the cells into the extracellular space, where they may serve as a support to hold tissues together, to provide tensile strength, and/or to facilitate cell signaling.
  • extracellular matrix components include, but are not limited to, collagen, fibronectin, laminin, hyaluronates, elastin, and proteoglycans.
  • multicellular aggregates may contain various ECM proteins (e.g., gelatin, fibrinogen, fibrin, collagen, fibronectin, laminin, elastin, and/or proteoglycans).
  • the ECM components or derivatives of ECM components can be added to the cell paste used to form the multicellular aggregate.
  • the ECM components or derivatives of ECM components added to the cell paste can be purified from a human or animal source, or produced by recombinant methods known in the art.
  • the ECM components or derivatives of ECM components can be naturally secreted by the cells in the elongate cellular body, or the cells used to make the elongate cellular body can be genetically manipulated by any suitable method known in the art to vary the expression level of one or more ECM components or derivatives of ECM components and/or one or more cell adhesion molecules or cell-substrate adhesion molecules (e.g., selectins, integrins, immunoglobulins, and adherins).
  • the ECM components or derivatives of ECM components may promote cohesion of the cells in the multicellular aggregates.
  • gelatin and/or fibrinogen can suitably be added to the cell paste, which is used to form multicellular aggregates. The fibrinogen can then be converted to fibrin by the addition of thrombin.
  • the bio-ink further comprises an agent that encourages cell adhesion.
  • the bio-ink further comprises an agent that inhibits cell death
  • the bio-ink further comprises an anti-apoptotic agent.
  • Agents that inhibit cell death include, but are not limited to, small molecules, antibodies, peptides, peptibodies, or combination thereof.
  • the agent that inhibits cell death is selected from: anti-TNF agents, agents that inhibit the activity of an interleukin, agents that inhibit the activity of an interferon, agents that inhibit the activity of an GCSF (granulocyte colony- stimulating factor), agents that inhibit the activity of a macrophage inflammatory protein, agents that inhibit the activity of TGF-B (transforming growth factor B), agents that inhibit the activity of an MMP (matrix metalloproteinase), agents that inhibit the activity of a caspase, agents that inhibit the activity of the MAPK/JNK signaling cascade, agents that inhibit the activity of a Src kinase, agents that inhibit the activity of a JAK (Janus kinase), or a
  • the bio -ink comprises an anti-oxidant.
  • the bio-ink further comprises an extrusion compound (i.e., a compound that modifies the extrusion properties of the bio-ink).
  • extrusion compounds include, but are not limited to gels, hydrogels (including UV cross-linkable and thermoreversible hydrogels described herein), surfactant polyols (e.g., Pluronic F-127 or PF-127), thermo -responsive polymers, hyaluronates, alginates, extracellular matrix components (and derivatives thereof), collagens, other biocompatible natural or synthetic polymers, nanofibers, and self-assembling nano fibers.
  • Gels sometimes referred to as jellies, have been defined in various ways.
  • the United States Pharmacopoeia defines gels as semisolid systems consisting of either suspensions made up of small inorganic particles or large organic molecules interpenetrated by a liquid.
  • Gels include a single-phase or a two-phase system.
  • a single -phase gel consists of organic macro molecules distributed uniformly throughout a liquid in such a manner that no apparent boundaries exist between the dispersed macromolecules and the liquid.
  • Some single -phase gels are prepared from synthetic macromolecules (e.g., carbomer) or from natural gums (e.g., tragacanth).
  • single-phase gels are generally aqueous, but will also be made using alcohols and oils.
  • Two-phase gels consist of a network of small discrete particles.
  • Gels can also be classified as being hydrophobic or hydrophilic.
  • the base of a hydrophobic gel consists of a liquid paraffin with polyethylene or fatty oils gelled with colloidal silica, or aluminum or zinc soaps.
  • the base of hydrophobic gels usually consists of water, glycerol, or propylene glycol gelled with a suitable gelling agent (e.g., tragacanth, starch, cellulose derivatives, carboxyvinylpolymers, and magnesium-aluminum silicates).
  • a suitable gelling agent e.g., tragacanth, starch, cellulose derivatives, carboxyvinylpolymers, and magnesium-aluminum silicates.
  • the rheology of the compositions or devices disclosed herein is pseudo plastic, plastic, thixotropic, or dilatant.
  • Suitable hydrogels include those derived from collagen, hyaluronate, fibrin, alginate, agarose, chitosan, and combinations thereof. In other embodiments, suitable hydrogels are synthetic polymers. In further embodiments, suitable hydrogels include those derived from poly(acrylic acid) and derivatives thereof, poly(ethylene oxide) and copolymers thereof, poly( vinyl alcohol), polyphosphazene, and combinations thereof.
  • the support material is selected from: hydrogel, NovoGelTM, agarose, alginate, gelatin, MatrigelTM, hyaluronan, poloxamer, peptide hydrogel, poly(isopropyl n-polyacrylamide), polyethylene glycol diacrylate (PEG-DA), hydroxyethyl methacrylate, polydimethylsiloxane, polyacrylamide, poly(lactic acid), silicon, silk, or combinations thereof.
  • Suitable hydrogels include methacrylated hydrogels, such as Polyethylene (glycol) diacrylate-based (PEG-DA) hydrogels, which are used in cell biology due to their ability to crosslink in presence of UV light and due to their inertness to cells.
  • PEG-DA Polyethylene (glycol) diacrylate-based hydrogels
  • PEG-DA is commonly used as scaffold in tissue engineering since polymerization occurs rapidly at room temperature and requires low energy input, has high water content, is elastic, and can be customized to include a variety of biological molecules.
  • an extrusion compound comprises a photoinitiator, which is a molecule that upon absorption of light at a specific wavelength produces reactive species capable of catalyzing polymerization or poly condensation reactions. These reactions area also called photopolymerization or radiation curing. Photoinitiators are typically ketones which contain both aromatic and carbonyl groups.
  • photoinitiators There are two types of photoinitiators: cationic and radical photoinitiators. Radical photoinitiators are water-compatible and act on molecules containing an acrylate or styrene group. The range of wavelengths used is typically near UV (300 nm-400 nm) but recent progress in initiator chemistry is expanding the ranges of wavelengths that can be used. Photoinitiators used in biology such as Irgacure 2959, 184, and 651 fall into this class.
  • a suitable photoinitiator for use with the bio-inks and/or support materials described herein is Irgacure 2959 (4-(2-hydroxyethoxy) phenyl-(2 -propyl) ketone (Glycosan BioSystems, Inc.; Salt Lake City, Utah) due to its high solubility in water and its minimal toxicity compared to other Irgacure species.
  • Rate of reaction during the first step is dependent on the nature of the photoinitiator (quantum yield, photoinitiator efficiency) and intensity of light while the later steps (propagation and termination) are a function of vinyl bond concentration and the rate constants for propagation and termination.
  • hydro gel-based extrusion compounds are thermoreversible gels (also known as thermo -responsive gels or thermogels).
  • a suitable thermoreversible hydrogel is not a liquid at room temperature.
  • the gelation temperature (Tgel) of a suitable hydrogel is about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, and about 40°C, including increments therein.
  • the Tgel of a suitable hydrogel is about 10°C to about 25°C.
  • the bio-ink (e.g., comprising hydrogel, one or more cell types, and other additives, etc.) described herein is not a liquid at room temperature.
  • the gelation temperature (Tgel) of a bio-ink described herein is about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, and about 40°C, including increments therein.
  • the Tgel of a bio-ink described herein is about 10°C to about 25°C.
  • thermoreversible gels when incorporated into aqueous solutions. These polymers have the ability to change from the liquid state to the gel state at temperatures that can be maintained in a bioprinter apparatus.
  • the liquid state-to-gel state phase transition is dependent on the polymer concentration and the ingredients in the solution.
  • Poloxamer 407 (Pluronic F-127 or PF-127) is a nonionic surfactant composed of polyoxyethylene-polyoxypropylene copolymers.
  • Other polo xamers include 188 (F-68 grade), 237 (F-87 grade), 338 (F-108 grade).
  • Aqueous solutions of poloxamers are stable in the presence of acids, alkalis, and metal ions.
  • PF-127 is a commercially available po lyo xy ethylene - polyoxypropylene triblock copolymer of general formula El 06 P70 E 106, with an average molar mass of 13,000.
  • the polymer can be further purified by suitable methods that will enhance gelation properties of the polymer.
  • PF-127 has good solubilizing capacity, low toxicity and is, therefore, considered a suitable extrusion compound.
  • the viscosity of the hydrogels and bio-inks presented herein is measured by any means described.
  • an LVDV-II+CP Cone Plate Viscometer and a Cone Spindle CPE-40 is used to calculate the viscosity of the hydrogels and bio-inks.
  • a Brookfield (spindle and cup) viscometer is used to calculate the viscosity of the hydrogels and bio-inks.
  • the viscosity ranges referred to herein are measured at room temperature. In other embodiments, the viscosity ranges referred to herein are measured at body temperature (e.g., at the average body temperature of a healthy human).
  • the hydrogels and/or bio-inks are characterized by having a viscosity of between about 500 and 1,000,000 centipoise, between about 750 and 1,000,000 centipoise; between about 1000 and 1,000,000 centipoise; between about 1000 and 400,000 centipoise; between about 2000 and 100,000 centipoise; between about 3000 and 50,000 centipoise; between about 4000 and 25,000 centipoise; between about 5000 and 20,000 centipoise; or between about 6000 and 15,000 centipoise.
  • the bio-ink comprises cells and extrusion compounds suitable for continuous bioprinting.
  • the bio-ink has a viscosity of about 1500 mPa » s.
  • a mixture of Pluronic F-127 and cellular material may be suitable for continuous bioprinting.
  • Such a bio-ink may be prepared by dissolving Pluronic F-127 powder by continuous mixing in cold (4 °C) phosphate buffered saline (PBS) over 48 hours to 30% (w/v). Pluronic F-127 may also be dissolved in water.
  • Cells may be cultivated and expanded using standard sterile cell culture techniques.
  • the cells may be pelleted at 200g for example, and re-suspended in the 30%> Pluronic F-127 and aspirated into a reservoir affixed to a bioprinter where it can be allowed to solidify at a gelation temperature from about 10 to about 25°C. Gelation of the bio -ink prior to bioprinting is optional.
  • the bio-ink, including bio-ink comprising Pluronic F-127 can be dispensed as a liquid.
  • the concentration of Pluronic F-127 can be any value with suitable viscosity and/or cytotoxicity properties.
  • a suitable concentration of Pluronic F-127 may also be able to support weight while retaining its shape when bioprinted.
  • the concentration of Pluronic F-127 is about 10%>, about 15%, about 20%, about 25%, about 30%, about 35%), about 40%>, about 45%, or about 50%>.
  • the concentration of Pluronic F-127 is between about 30%> and about 40%>, or between about 30%> and about 35%.
  • a three-dimensional, pyramid- shaped construct is generated by continuous deposition of PF-127 using a NovoGen MMXTM bioprinter connected to a syringe with a 510 ⁇ needle.
  • the non-cellular components of the bio-ink are removed prior to use.
  • the non-cellular components are, for example, hydrogels, surfactant polyols, thermo -responsive polymers, hyaluronates, alginates, collagens, or other biocompatible natural or synthetic polymers.
  • the non-cellular components are removed by physical, chemical, or enzymatic means. In some embodiments, a proportion of the non-cellular components remain associated with the cellular components at the time of use.
  • the cells are pre -treated to increase cellular interaction.
  • cells may be incubated inside a centrifuge tube after centrifugation in order to enhance cell-cell interactions prior to shaping the bio -ink.
  • the devices comprise one or more printer heads for receiving and holding at least one cartridge that optionally contains support material.
  • the methods comprise the use of support material.
  • the tissues and organs fabricated by use of the devices, systems, and methods described herein comprise support material at the time of fabrication or thereafter.
  • the support material is capable of excluding cells growing or migrating into or adhering to it. In some embodiments, the support material is permeable for nutrient media.
  • the viscosity of the support material is changeable. In some embodiments, the viscosity of the support material is changed by modifying the temperature of the support material. In some embodiments, the viscosity of the support material is changed by modifying the pressure of the support material. In some embodiments, the viscosity of the support material is changed by modifying the concentration of the support material. In some embodiments, the viscosity of the support material is changed by cross-linking (e.g., by use of a chemical cross- linker), or photo crossinking (e.g., using ultraviolet light exposure).
  • cross-linking e.g., by use of a chemical cross- linker
  • photo crossinking e.g., using ultraviolet light exposure
  • the permeability of the support material is changeable. In some embodiments, the permeability of the support material is modified by varying the temperature of the support material or the temperature surrounding the support material. In some embodiments, the permeability of the support material is modified by contacting the support material with an agent that modifies permeability.
  • the compliance (i.e., elasticity or hardness) of the support material is modified.
  • the compliance of the support material is modified by varying the temperature of the support material or the temperature surrounding the support material.
  • the compliance of the support material is modified by contacting the support material with an agent that modifies compliance.
  • hydrogels are exemplary support materials possessing one or more advantageous properties including: non-adherent, biocompatible, extrudable, bioprintable, non-cellular, and of suitable strength.
  • suitable hydrogels are natural polymers.
  • the confinement material is comprised of NovoGelTM.
  • suitable hydrogels include those derived from surfactant polyols (e.g., Pluronic F-127), collagen, hyaluronate, fibrin, alginate, agarose, chitosan, derivatives or combinations thereof.
  • suitable hydrogels are synthetic polymers.
  • suitable hydrogels include those derived from poly(acrylic acid) and derivatives thereof, poly(ethylene oxide) and copolymers thereof, poly( vinyl alcohol), polyphosphazene, and combinations thereof.
  • the confinement material is selected from: hydrogel, NovoGelTM, agarose, alginate, gelatin, MatrigelTM, hyaluronan, poloxamer, peptide hydrogel, poly(isopropyl n-polyacrylamide), polyethylene glycol diacrylate (PEG-DA), hydroxyethyl methacrylate, polydimethylsiloxane, polyacrylamide, poly(lactic acid), silicon, silk, or combinations thereof.
  • the support material contains cells prior to being present in the bioprinter.
  • the support material is a hydrogel containing a suspension of cells.
  • the support material is a hydrogel containing a mixture of more than one cell type.
  • the support material is used as building units for constructing a biological construct (e.g., cellular construct, tissue, organ, etc.).
  • the support material unit is used to define and maintain the domains void of cellular material (i.e., the intermediate cellular units) of a desired construct.
  • the support material is capable of assuming any shape or size.
  • NovoGelTM solution (originally in powder phase mixed with buffer and water) may be heated to reduce its viscosity and taken up in a micropipette with a desired dimension (or in a chamber of a desired shape by negative displacement of a piston).
  • the NovoGelTM solution in the pipette (or the chamber) may be cooled to room temperature, for example by forced air on the exterior of the pipette (or the chamber) or plunging the micropipette into a container with cold liquid, so that it can solidify into a gel with the desired shape, i.e., a support material.
  • the resulting support material may be dispensed from the pipette or chamber during the construction of a particular cellular construct, tissue, or organ. See e.g., Fig. 4.
  • the support material is used for increasing the viability of the engineered tissue or organ after bioprinting.
  • support material provides direct contact between the tissue or organ and a nutrient medium through a temporary or semipermanent lattice of confinement material (e.g., support material).
  • confinement material e.g., support material
  • the tissue is constrained in a porous or gapped material. Direct access of at least some of the cells of the tissue or organ to nutrients increases the viability of the tissue or organ.
  • the methods disclosed herein comprise additional and optional steps for increasing the viability of an engineered tissue or organ including: 1) optionally dispensing base layer of confinement material (e.g., support material) prior to placing cohered multicellular aggregates; 2) optionally dispensing a perimeter of confinement material; 3) bioprinting cells of the tissue within a defined geometry; and 4) dispensing elongate bodies (e.g., cylinders, ribbons, etc.) of confinement material overlaying the nascent tissue in a pattern that introduces gaps in the confinement material, such as a lattice, mesh, or grid.
  • confinement material e.g., support material
  • the gaps overlaying pattern are distributed uniformly or substantially uniformly around the surface of the tissue or organ.
  • the gaps are distributed non-uniformly, whereby the cells of the tissue or organ are exposed to nutrients non- uniformly.
  • the differential access to nutrients may be exploited to influence one or more properties of the tissue or organ. For instance, it may be desirable to have cells on one surface of a bioprinted, cellular construct, tissue, or organ proliferate faster than cells on another surface.
  • the exposure of various parts of the tissue or organ to nutrients can be changed at various times to influence the development of the tissue or organ toward a desired endpoint.
  • the confinement material is removed at any suitable time, including but not limited to, immediately after bioprinting (e.g., within 10 minutes), after bioprinting (e.g., after 10 minutes), before the cells are substantially cohered to each other, after the cells are substantially cohered to each other, before the cells produce an extracellular matrix, after the cells produce an extracellular matrix, just prior to use, and the like.
  • confinement material is removed by any suitable method. For example, in some embodiments, the confinement material is excised, pulled off the cells, digested, or dissolved.
  • a cartridge attached to the bioprinter comprises a bio -ink and/or a support material.
  • the bioprinter deposits the bio -ink or support material in a specific pattern and at specific positions in order to form a specific tissue construct.
  • a cartridge comprising bio-ink is disposable.
  • the cartridge is ejected from the bioprinter following extrusion, dispensing, or deposition of the contents.
  • a new cartridge is attached to the bioprinter.
  • the bioprinters disclosed herein dispense bio-ink and/or support material from a cartridge with a suitable repeatable accuracy.
  • suitable repeatable accuracies include those of about ⁇ 5, 10, 20, 30, 40, or 50 ⁇ on any axis.
  • the bioprinters disclosed herein dispense bio -ink and/or support material from a cartridge with a repeatable accuracy of about ⁇ 20 ⁇ .
  • the position of the printer head (and thus the cartridges) with respect to the tissue construct varies.
  • the method of calibrating the position of a printer head comprises use of at least one laser. In further embodiments, the method of calibrating the position of a printer head comprises use of a first and second laser.
  • the method of calibrating the position of a printer head comprises manual (e.g., visual) calibration.
  • the method of calibrating the position of a printer head comprises manual calibration and laser calibration.
  • the position of the printer head is calibrated along one axis, wherein the axis is selected from the x-axis, the y-axis, and the z-axis. In some embodiments, the position of the printer head is calibrated along two axes, wherein the axes are selected from the x- axis, the y-axis, and the z-axis. In some embodiments, the position of the printer head is calibrated along three axes, wherein the axes are selected from the x-axis, the y-axis, and the z-axis.
  • calibration is made by use of at least one laser. In further embodiments, calibration is made by use of a first and a second laser.
  • a method disclosed herein further comprises activating a laser and generating at least one substantially stable and/or substantially stationary laser beam, and where said laser beam is horizontal to the ground. See, e.g., Fig. 1.
  • the methods comprise, calibrating the position of a printer head along at least one axis, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of the printer head along at least two axes, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of the printer head along at least three axes, wherein the axis is selected from the x-axis, y-axis, and z-axis.
  • the methods comprise (a) calibrating the position of the printer head along the y-axis; (b) calibrating the position of the printer head along the x-axis; and/or (c) calibrating the position of the printer head along the z-axis; wherein each axis corresponds to the axis of the same name in the Cartesian coordinate system.
  • calibration is made by use of at least one laser. In some embodiments, calibration is made by use of a first and a second laser.
  • calibrating the position of a printer head along the y-axis comprises: (a) positioning the printer head so that the printer head is (i) located in a first y octant and (ii) the dispensing orifice is below the upper threshold of the laser beam; (b) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted by the printer head is the first y position; (c) re -positioning the printer head so that the printer head is located in the second y octant and the dispensing orifice is below the upper threshold of the laser beam; (d) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted is the second y position; (e) and calculating the mid-point between the first y position and the second y position.
  • calibrating the position of a printer head along the x-axis comprises: (a) positioning the printer head (i) at the mid-point between the first y position and the second y position, and (ii) outside the sensor threshold of the laser; and (b) moving the printer head towards the sensor threshold and stopping said movement as soon as the printer head contacts the sensor threshold; wherein the position at which the printer head contacts the sensor increased by half the printer head width is the x position.
  • calibrating the position of a printer head along the y-axis comprises: (a) positioning the printer head so that the laser beam can measure the precise location of one side of the printer head; (b) positioning the printer head so that the laser beam can measure the precise location of the opposing side of the printer head; (c) and calculating the midpoint location of the printer head to be relative to the laser location during each measurement and the measured distances.
  • calibrating the position of a printer head along the x-axis comprises: (a) positioning the printer head so that the laser beam can measure the precise location of one side of the printer head; (b) positioning the printer head so that the laser beam can measure the precise location of the opposing side of the printer head; (c) and calculating the midpoint location of the printer head to be relative to the laser location during each measurement and the measured distances.
  • calibrating the position of a printer head along the z-axis comprises: (a) positioning the printer head so that the dispensing orifice is located above the laser beam; and (b) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted is the z position.
  • a method disclosed herein further comprises activating the laser and generating at least one substantially stable and/or substantially stationary laser beam, and where said laser beam is vertical to the ground. See, e.g., Fig. 2.
  • the methods comprise, calibrating the position of a printer head along at least one axis, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of a printer head along at least two axes, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of a printer head along at least three axes, wherein the axis is selected from the x-axis, y-axis, and z-axis.
  • the methods comprise (a) calibrating the position of the printer head along the y-axis; (b) calibrating the position of the printer head along the x-axis; and (c) calibrating the position of the printer head along the z-axis; wherein each axis corresponds to the axis of the same name in the Cartesian coordinate system.
  • calibrating the position of a printer head along the y-axis comprises: (a) positioning the printer head so that the printer head is (i) located in a first y octant and (ii) the dispensing orifice is outside the sensor threshold of the laser; (b) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted by the printer head is the first y position; (c) re -positioning the printer head so that the printer head is located in the second y octant and the dispensing orifice is outside the sensor threshold of the laser; (d) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted is the second y position; (e) and calculating the mid-point between the first y position and the second y position.
  • calibrating the position of a printer head along the x-axis comprises: (a) positioning the printer head (i) at the mid-point between the first y position and the second y position, and (ii) outside the sensor threshold of the laser; and (b) moving the printer head towards the sensor threshold and stopping said movement as soon as the printer head contacts the sensor threshold; wherein the position at which the printer head contacts the sensor increased by half the printer head width is the x position.
  • calibrating the position of a printer head along the z-axis comprises: (a) positioning the printer head so that the dispensing orifice is located above the laser beam so that it is just outside of the laser sensor range threshold; and (b) lowering the printer head until the sensor threshold is reached, wherein the position at which the laser sensor threshold is reached is the z position.
  • steps (a) and (b) are repeated at multiple points of the printer head and measured heights are averaged to determine the z position.
  • calibrating the position of a printer head along the z-axis comprises: (a) positioning the printer head so that the laser beam can measure the precise location of one or more points on the bottom of the printer head; (b) calculating the absolute or average location of the printer head based on the laser position and known measured distance.
  • a printer head comprising a dispensing orifice, wherein the printer head is attached to a bioprinter, comprising calibrating the position of the printer head along at least one axis, wherein the axis is selected from the x-axis, y-axis, and z-axis.
  • the method comprises calibrating the position of a printer head along at least two axes, wherein the axis is selected from the x-axis, y-axis, and z-axis.
  • the method comprises calibrating the position of a printer head along at least three axes, wherein the axis is selected from the x-axis, y-axis, and z-axis.
  • the methods comprise (a) calibrating the position of the printer head along the y-axis; (b) calibrating the position of the printer head along the x-axis; and (c) calibrating the position of the printer head along the z-axis; wherein each axis corresponds to the axis of the same name in the Cartesian coordinate system.
  • calibration comprises use of a first laser and a second laser.
  • the first laser is a vertical laser and the second laser is a horizontal laser.
  • systems for calibrating the position of a cartridge comprising a deposition orifice, wherein the cartridge is attached to a bioprinter, said system comprising: a means for calibrating the position of the cartridge along at least one axis, wherein the axis is selected from the y-axis, x-axis, and z-axis.
  • systems for calibrating the position of a printer head comprising a dispensing orifice, wherein the printer head is attached to a bioprinter, said system comprising: a means for calibrating the position of the printer head along an x-axis; a means for calibrating the position of the printer head along a y-axis; and a means for calibrating the position of the printer head along a z-axis.
  • a system for calibrating the position of a printer head comprises a means for calibrating the printer head along the x-axis, y-axis, and z-axis.
  • the means for calibrating a printer head along the x-axis, y-axis, and z-axis is laser alignment, optical alignment, mechanical alignment, piezoelectric alignment, magnetic alignment, electrical field or capacitance alignment, ultrasound alignment, or a combination thereof.
  • a system for calibrating the position of a printer head comprises a means for calibrating the printer head along the x-axis, y-axis, and z-axis.
  • the means for calibrating a printer head along the x-axis, y-axis, and z-axis is laser alignment.
  • the laser alignment means comprises at least one laser.
  • the laser alignment means comprises a plurality of lasers.
  • the laser alignment means it has any suitable accuracy.
  • suitable accuracies include those of about ⁇ 5, 10, 20, 30, 40, or 50 ⁇ on any axis.
  • the laser alignment means is accurate to ⁇ 40 ⁇ on the vertical axis and ⁇ 20 ⁇ on the horizontal axis.
  • the laser path is uninterrupted between the laser source and the measurement point.
  • the laser path is altered by up to 179° by use of a reflective surface or optical lens.
  • the laser path is altered by 90°.
  • a horizontal laser beam is used to measure in a vertical path by deflection using a reflective surface.
  • a vertical laser beam is used to measure in a horizontal path by deflection using a reflective surface.
  • bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; a means for calibrating the position of at least one cartridge; and a means for dispensing the contents of at least one cartridge.
  • the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, hydraulics, or a combination thereof.
  • the bio -ink and/or support material comprise one or more UV cross-linkable materials.
  • the UV light module exposes the contents of at least one cartridge to UV light prior to dispensing. In some embodiments, the UV light module exposes the contents of at least one cartridge to UV light with a wavelength of about 300 nm to about 400 nm. In further embodiments, the UV light module exposes the contents of at least one cartridge to UV light with a wavelength of about 365 nm. In some embodiments, the UV light module is configurable to expose the contents of at least one cartridge to UV light for about 5 seconds to about 20 minutes. In some embodiments, the UV light module transmits UV light across the length of the at least one cartridge. In some embodiments, the UV light module is tunable with respect to intensity, exposure time, or both intensity and exposure time.
  • the UV light module comprises one or more optionally engaged attenuation filters, where the attenuation filters lower UV intensity when engaged.
  • the bioprinters further comprise a means for adjusting temperature.
  • the bioprinters comprising a means for adjusting the ambient temperature, the temperature of a cartridge, the temperature of the contents of the cartridge, the temperature of the receiving surface, or a combination thereof.
  • the means for adjusting temperature is a heating element.
  • the means for adjusting temperature is a radiant heater, a convection heater, a conductive heater, a fan heater, a heat exchanger, or a combination thereof.
  • the means for adjusting temperature is a cooling element.
  • the means for adjusting temperature is a container of coolant, a chilled liquid, ice, a radiant cooler, a convection cooler, a conductive cooler, a fan cooler, or a combination thereof.
  • the bioprinters further comprise a means for applying a wetting agent to one or more of: the printer stage; the receiving surface; the deposition orifice; bio- ink; support material; and a printed construct; wherein the wetting agent is applied at one or more time points selected from: before the bio-ink or support material is dispensed by the bioprinter, substantially concurrently with dispensing, and after the bio -ink or support material is dispensed by the bioprinter.
  • a tissue construct comprising the steps of: depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has been exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body; and incubating the bio-ink to allow it to cohere and to form a tissue, wherein said incubation has a duration of about 6 hours to about 10 days.
  • the method further comprises the step of preparing a liquid bio -ink solution comprising a UV cross-linkable material and mammalian cells.
  • the method further comprises the step of exposing a liquid bio-ink solution comprising a UV cross- linkable material and mammalian cells to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body.
  • the method further comprises the step of depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has not been exposed to UV light.
  • the UV cross- linkable material is a hydrogel.
  • the hydrogel is a methacrylated hydrogel.
  • the methacrylated hydrogel is PEG-DA.
  • the UV light is characterized by having a wavelength of about 300 nm to about 400 nm. In further embodiments, the UV light is characterized by having a wavelength of about 365 nm. In some embodiments, the exposure to UV light has a duration of about 5 seconds to about 20 minutes.
  • the bio-ink comprises mammalian cells. In further embodiments, the bio -ink comprises adult, differentiated, mammalian cells. In further embodiments, the bio -ink comprises adult, non-differentiated, mammalian cells. In some embodiments, the bio -ink comprises human smooth muscle cells. In some embodiments, the bio -ink comprises human endothelial cells. In some embodiments, the bio-ink comprises human fibroblasts.
  • the mammalian cells are selected from the group consisting of: liver cells, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiac cells, skin cells, smooth muscle cells, connective tissue cells, corneal cells, genitourinary cells, breast cells, reproductive cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipose cells, bone cells, bone marrow cells, cartilage cells, pericytes, mesothelial cells, stromal cells, stem cells, progenitor cells, lymph cells, blood cells, endoderm-derived cells, ectoderm-derived cells, and mesoderm-derived cells.
  • the bio-ink is deposited onto a support by extrusion from a bioprinter.
  • bioprinter cartridges wherein the contents of the cartridge comprise a UV cross-linkable material and optionally mammalian cells, wherein the UV cross-linkable material is partially or completely cross-linked.
  • the UV cross-linkable material is a hydrogel.
  • the hydrogel is a methacrylated hydrogel.
  • the methacrylated hydrogel is PEG-DA.
  • the cartridge comprises a glass-walled reservoir.
  • the cartridge comprises a glass capillary tube.
  • the cartridge comprises a glass syringe.
  • the cartridge is characterized by having an internal diameter of about 50 ⁇ ⁇ about 1000 ⁇ .
  • the cartridge is characterized by having an internal diameter of about 500 ⁇ .
  • the cartridge is characterized by having an internal diameter of about 250 ⁇ .
  • UV light modules for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light.
  • the UV light source optionally exposes the contents of at least one bioprinter cartridge to UV light along the length of the cartridge.
  • the UV light source is a fiber optic light line.
  • the UV light module is reversibly attachable to a bioprinter.
  • the UV light source exposes the contents of at least one cartridge to UV light with a wavelength of about 300 nm to about 400 nm.
  • the UV light module is tunable with respect to intensity, exposure time, or both intensity and exposure time.
  • the UV light module further comprises one or more optionally engaged attenuation filters, where the attenuation filters lower UV intensity when engaged.
  • tissue constructs comprising a multicellular body on a support substrate, wherein the multicellular body comprises a UV cross- linkable material and mammalian cells, wherein the multicellular body was generated by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body prior to deposition.
  • the tissue construct comprises about 2 to about 100 multicellular bodies.
  • the UV cross-linkable material is a hydrogel.
  • the hydrogel is a methacrylated hydrogel.
  • the methacrylated hydrogel is PEG-DA.
  • the UV light is characterized by having a wavelength of about 300 nm to about 400 nm. In further embodiments, the UV light is characterized by having a wavelength of about 365 nm. In some embodiments, the exposure to UV light has a duration of about 5 seconds to about 20 minutes.
  • the multicellular bodies comprise adult, differentiated, mammalian cells. In some embodiments, the multicellular bodies comprise adult, non-differentiated, mammalian cells. In some embodiments, at least one multicellular body comprises human smooth muscle cells. In some embodiments, at least one multicellular body comprises human endothelial cells. In some embodiments, at least one multicellular body comprises human fibroblasts.
  • the mammalian cells are selected from the group consisting of: liver cells, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiac cells, skin cells, smooth muscle cells, connective tissue cells, corneal cells, genitourinary cells, breast cells, reproductive cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipose cells, bone cells, bone marrow cells, cartilage cells, pericytes, mesothelial cells, stromal cells, stem cells, progenitor cells, lymph cells, blood cells, endoderm-derived cells, ectoderm-derived cells, mesoderm-derived cells, and combinations thereof.
  • liver cells gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiac cells, skin cells, smooth muscle cells, connective tissue cells, corneal cells, genitourinary cells, breast cells, reproductive
  • HASMC Primary human aortic smooth muscle cells
  • DMEM Dulbecco's modified eagle medium
  • FBS fetal bovine serum
  • Penicillin 100 U/ml Penicillin
  • streptomycin 100 U/ml
  • streptomycin 100 U/ml
  • streptomycin 100 U/ml
  • amphotericin B 0.25 ⁇ g/ml
  • HEPES 50 mg/L of proline
  • 50 mg/L of glycine 20 mg/L of alanine
  • 50 mg/L of ascorbic acid and 3 ⁇ g/L of CuS0 4 (all from Sigma, St. Louis, MO) at 37°C and 5% C0 2 .
  • Confluent cultures of HASMCs between passage 4 and 8 were used in all studies.
  • Endothelial cells Primary human aortic endothelial cells (HAEC) were maintained and expanded in Medium 200 supplemented with 2% FBS, 1 ⁇ / ml of hydrocortisone, 10 ng/ml of human epidermal growth factor, 3 ng/ml of basic fibroblast growth factor, 10 ⁇ i l of heparin, 100 U/ml Penicillin, 0.1 mg/ml streptomycin, and 0.25 ⁇ g/ml of amphotericin B (all from Invitrogen Corp., Carlsbad, CA). The cells were grown on gelatin (from porcine serum; Sigma, St. Louis, MO) coated tissue culture treated flasks at 37°C and 5% C0 2 . Confluent cultures of HAEC's between passage 4 and 8 were used in all studies.
  • the assembly was then placed horizontally at room temperature for 1 hour to allow complete gelation of the NovoGelTM. After gelation, the Teflon ® print was removed and the NovoGelTM mold was washed twice using DPBS. 17.5 ml of HASMC culture medium was then added to the NovoGelTM mold.
  • HASMC-HAEC mixed cellular cylinders To prepare mixed cellular cylinders HASMC and HAEC were individually collected and then mixed at pre-determined ratios. Briefly, the culture medium was removed from confluent culture flasks and the cells were washed with DPBS (1 ml/5 cm 2 of growth area). Cells were detached from the surface of the culture flasks by incubation in the presence of trypsin (1 ml/15 cm 2 of growth area) for 10 minutes. HASMC were detached using 0.15% trypsin while HAEC were detached using 0.1% trypsin. Following the incubation appropriate culture medium was added to the flasks (2X volume with respect to trypsin volume).
  • the cell suspension was centrifuged at 200g for 6 minutes followed by complete removal of supernatant solution. Cell pellets were resuspended in respective culture medium and counted using a hemacytometer. Appropriate volumes of HASMC and HAEC were combined to yield mixed cell suspensions containing 5, 7.5, 10, 12.5, and 15% HAEC (as a % of total cell
  • the mixed cell suspensions were centrifuged at 200g for 5 minutes followed by complete removal of supernatant solution.
  • Mixed cell pellets were resuspended in 6 ml of HASMC culture medium and transferred to 20 ml glass vials, followed by incubation on an orbital shaker at 150 rpm for 60 minutes, and at 37°C and 5% C0 2 . This allows the cells to aggregate with one another and initiate cell-cell adhesions. Post-incubation, the cell suspension was transferred to a 15 ml centrifuge tube and centrifuged at 200g for 5 minutes.
  • the cell pellet was resuspended in 400 ⁇ of HASMC culture medium and pipetted up and down several times to ensure all cell clusters were broken.
  • the cell suspension was transferred into a 0.5 ml micro fuge tube placed inside a 15 ml centrifuge tube followed by centrifugation at 2000g for 4 minutes to form a highly dense and compact cell pellet.
  • the supernatant medium was aspirated and the cells were transferred into capillary tubes (OD 1.0 mm, ID 0.5 mm, L 75 mm; Drummond Scientific Co., Broomall, PA) by aspiration so as to yield cell cylinders 50 mm in length.
  • the cell paste inside the capillaries was incubated in HASMC medium for 20 minutes at 37°C and 5% C0 2 .
  • the cellular cylinders were then deposited from the capillary tubes into the grooves of the
  • HASMC Primary human aortic smooth muscle cells
  • DMEM low glucose dulbecco's modified eagle medium
  • FBS fetal bovine serum
  • Penicillin 100 U/ml Penicillin
  • 0.1 mg/ml streptomycin 0.25 ⁇ of amphotericin B
  • HEPES 0.01M of HEPES (all from Invitrogen Corp., Carlsbad, CA)
  • 50 mg/L of proline 50 mg/L of glycine, 20 mg/L of alanine, 50 mg/L of ascorbic acid
  • CuSC-4 all from Sigma, St. Louis, MO
  • Endothelial cells Primary human aortic endothelial cells (HAEC) were maintained and expanded in Medium 200 supplemented with 2% FBS, 1 ⁇ / ml of hydrocortisone, 10 ng/ml of human epidermal growth factor, 3 ng/ml of basic fibroblast growth factor, 10 ⁇ i l of heparin, 100 U/ml Penicillin, 0.1 mg/ml streptomycin, and 0.25 ⁇ g/ml of amphotericin B (all from Invitrogen Corp., Carlsbad, CA). The cells were grown on gelatin (from porcine serum) coated tissue culture treated flasks at 37°C and 5% C0 2 . Confluent cultures of HAEC between passage 4 and 8 were used in all studies.
  • Fibroblasts Primary human dermal fibroblasts (HDF) were maintained and expanded in Medium 106 supplemented with 2% FBS, 1 ⁇ / ml of hydrocortisone, 10 ng/ml of human epidermal growth factor, 3 ng/ml of basic fibroblast growth factor, 10 ⁇ i l of heparin, 100 U/ml Penicillin, and 0.1 mg/ml streptomycin (all from Invitrogen Corp., Carlsbad, CA) at 37°C and 5% C0 2 . Confluent cultures of HDF between passage 4 and 8 were used in all studies.
  • Dulbecco's phosphate buffered saline DPBS
  • the DPBS and NovoGelTM were heated to 85°C on a hot plate with constant stirring until the NovoGelTM dissolves completely.
  • NovoGelTM solution was sterilized by steam sterilization at 125°C for 25 minutes.
  • the NovoGelTM solution remains in liquid phase as long as the temperature is maintained above 66.5°C. Below this temperature a phase transition occurs, the viscosity of the NovoGelTM solution increases and the NovoGelTM forms a solid gel.
  • NovoGelTM mold A NovoGelTM mold was fabricated for the incubation of cellular cylinders using a Teflon ® mold that fit a 10 cm Petri dish. Briefly, the Teflon ® mold was pre-sterilized using 70% ethanol solution and subjecting the mold to UV light for 45 minutes. The sterilized mold was placed on top of the 10 cm Petri dish and securely attached. This assembly (Teflon ® mold + Petri dish) was maintained vertically and 45 ml of pre -warmed, sterile 2% NovoGelTM solution was poured in the space between the Teflon ® mold and the Petri dish.
  • the assembly was then placed horizontally at room temperature for 1 hour to allow complete gelation of the NovoGelTM. After gelation, the Teflon ® print was removed and the NovoGelTM mold was washed twice using DPBS. Then, either 17.5 ml of HASMC culture medium was added to the NovoGelTM mold for incubating HASMC-HAEC mixed cell cylinders or 17.5ml of HDF culture medium is added to the NovoGelTM mold for incubating HDF cell cylinders.
  • HASMC-HAEC mixed cellular cylinders To prepare mixed cellular cylinders HASMC and HAEC were individually collected and then mixed at pre-determined ratios. Briefly, the culture medium was removed from confluent culture flasks and the cells were washed with DPBS (1 ml/5 cm 2 of growth area). Cells were detached from the surface of the culture flasks by incubation in the presence of trypsin (1 ml/15 cm 2 of growth area) for 10 minutes. HASMC were detached using 0.15% trypsin while HAEC were detached using 0.1% trypsin. Following the incubation appropriate culture medium was added to the flasks (2X volume with respect to trypsin volume).
  • the cell suspension was centrifuged at 200g for 6 minutes followed by complete removal of supernatant solution.
  • Cell pellets were resuspended in respective culture medium and counted using a hemacytometer. Appropriate volumes of HASMC and HAEC were combined to yield a mixed cell suspension containing 15% HAEC and remainder 85% HASMC (as a percentage of total cell population).
  • the mixed cell suspension was centrifuged at 200g for 5 minutes followed by complete removal of supernatant solution.
  • Mixed cell pellets were resuspended in 6 ml of HASMC culture medium and transferred to 20 ml glass vials, followed by incubation on an orbital shaker at 150 rpm for 60 minutes, and at 37°C and 5% C0 2 .
  • the cell suspension was transferred to a 15 ml centrifuge tube and centrifuged at 200g for 5mins. After removal of the supernatant medium, the cell pellet was resuspended in 400 ⁇ of HASMC culture medium and pipetted up and down several times to ensure all cell clusters were broken. The cell suspension was transferred into a 0.5 ml micro fuge tube placed inside a 15 ml centrifuge tube followed by centrifugation at 2000g for 4 minutes to form a highly dense and compact cell pellet.
  • the supernatant medium was aspirated and the cells were transferred into capillary tubes (OD 1.0 mm, ID 0.5 mm, L 75 mm) by aspiration so as to yield cell cylinders 50 mm in length.
  • the cell paste inside the capillaries was incubated in HASMC medium for 20 minutes at 37°C and 5% C0 2 .
  • the cellular cylinders were then deposited from the capillary tubes into the grooves of the NovoGelTM mold (covered with HASMC medium) using the plunger supplied with the capillaries. The cellular cylinders were incubated for 24 hours at 37°C and 5% C0 2 .
  • HDF cylinders were prepared using a method similar to preparing HASMC-HAEC mixed cellular cylinders. Briefly, the culture medium was removed from confluent HDF culture flasks and the cells were washed with DPBS (1 ml/5 cm 2 of growth area). Cells were detached from the surface of the culture flasks by incubation in the presence of trypsin (0.1%; 1 ml/15 cm 2 of growth area) for 10 minutes. Following the incubation HDF culture medium was added to the flasks (2X volume with respect to trypsin volume). The cell suspension was centrifuged at 200g for 6 minutes followed by complete removal of supernatant solution.
  • Cell pellets were resuspended in 6 ml of HDF culture medium and transferred to 20 ml glass vials, followed by incubation on an orbital shaker at 150 rpm for 75 minutes, and at 37°C and 5% C0 2 . Post-incubation, the cell suspension was transferred to a 15 ml centrifuge tube and centrifuged at 200g for 5 minutes. After removal of the supernatant medium, the cell pellet was resuspended in 400 ⁇ of HDF culture medium and pipetted up and down several times to ensure all cell clusters were broken.
  • the cell suspension was transferred into a 0.5 ml microfuge tube placed inside a 15 ml centrifuge tube followed by centrifugation at 2000g for 4 minutes to form a highly dense and compact cell pellet.
  • the supernatant medium was aspirated and the cells were transferred into capillary tubes (OD 1.0 mm, ID 0.5 mm, L 75 mm) by aspiration so as to yield cell cylinders 50 mm in length.
  • the cell paste inside the capillaries were incubated in HDF culture medium for 20 minutes at 37°C and 5% C0 2 .
  • the cellular cylinders were then deposited from the capillary tubes into the grooves of the NovoGelTM mold (covered with HDF medium). The cellular cylinders were incubated for 24 hours at 37°C and 5% C0 2 .
  • NovoGelTM base plate A NovoGelTM base plate was fabricated by dispensing 10 ml of pre-warmed (> 40°C) NovoGelTM (2% w/v) into a 10 cm Petri dish.
  • the NovoGelTM was evenly spread so as to cover the entire base of the dish and form a uniform layer.
  • the Petri dish was incubated at room temperature for 20 minutes to allow the NovoGelTM to gel completely.
  • Multi-layered vascular tube Vascular tubes consisting of an outer layer of HDF and an inner layer of HASMC-HAEC were fabricated utilizing HDF cylinders, and HASMC-HAEC mixed cell cylinders. A geometrical arrangement as shown in Fig. 4 was utilized. Briefly, at the end of the 24-hour incubation period mature HDF and HASMC-HAEC cylinders were aspirated back into the capillary tubes and placed in appropriate culture medium until further use.
  • the 5 cm long gelled NovoGelTM cylinder was deposited from the capillary (using the plunger) and laid down straight on the NovoGelTM base plate. A second NovoGelTM cylinder was adjoined to the first one and the process was repeated until 10 NovoGelTM cylinders were deposited to form the first layer. At this point 20 ⁇ of PBS was dispensed above the NovoGelTM cylinders to keep them wet. Further six NovoGelTM cylinders were deposited on top of layer 1 at positions as shown in Fig. 4 (layer 2). Three HDF cylinders were then deposited at positions 4, 5, and 6 to complete layer 2.
  • each HDF cylinder 40 ⁇ of HDF culture medium was dispensed on top of the deposited cylinder to assist the deposition of the subsequent cylinder as well as to prevent dehydration of the cellular cylinders.
  • Next NovoGelTM cylinders for layer 3 were deposited followed by HDF cylinders at positions 3 and 6.
  • HASMC-HAEC mixed cylinders were laid down in positions 4 and 5.
  • a bioprinter was assembled.
  • the bioprinter contained a printer head having a collet chuck grip for holding a cartridge, and a piston for dispensing the contents of the cartridge.
  • the cartridges used were glass microcapiUary tubes having a length of 75-85 mm. A new capillary tube was loaded each time bio-ink or support material was required.
  • the bioprinter In order to print structures, a dispense position repeatability of ⁇ 20 ⁇ was required for the duration of the printing process, i.e., when new capillaries were loaded into the printer head.
  • the bioprinter In order to maintain repeatability of all loaded capillary tubes relative to the same point in the x-, y- , and z-directions, the bioprinter contained a laser calibration system for calibrating the position of the microcapillary tube. The laser calibration system calibrated the position of all capillary tips to a common reference location. All printing moves were made relative to this reference position.
  • All three axes were calibrated through usage of a single laser distance measurement sensor.
  • the system consisted of a laser sensor and a laser beam.
  • the sensor threshold was the maximum sensing distance of the laser sensor.
  • the sensor was configured to ignore all signals further away than a pre-defined threshold.
  • the sensor used triangulation to determine distance to the object (the capillary tip).
  • the laser sensor was orientated with the beam aimed vertically up (+ z-axis).
  • the bio -ink or support material inside the capillary was primed so that the bio-ink or support material would begin printing at the very tip of the capillary.
  • the calibration laser was used to prime the capillary.
  • the capillary tip was moved just above the laser beam, with the beam centered in the y-axis. The tip was between 20-100 ⁇ above the laser beam.
  • the dispensing piston in the printer head was driven down until the bio -ink or support material started to dispense out of the capillary tip and interrupted the laser beam.
  • the dispensed bio-ink or support material was aspirated back into the capillary tube by driving the piston in the reverse direction (20-100 ⁇ ).
  • the capillary was then primed and ready to dispense.
  • NovoGelTM was used as a support material. In order to remove excess NovoGelTM sticking to the outside surface of the capillary tube and to avoid the excess NovoGelTM from affecting print quality, the excess NovoGelTM was removed. A wiping feature was integrated into a bulk NovoGelTM vessel. A bulk NovoGelTM vessel was fitted with a standard medical vial with an open cap for a septum to be attached. A septum was configured with a cross cut in the center of 1 -2 mm thick silicone. By dipping the capillary into the bulk NovoGelTM vessel through the septum and aspirating NovoGelTM, excess NovoGelTM was wiped from the capillary as it exited the vessel, and remained in the bulk vessel.
  • the bioprinter and cartridge was assembled as above.
  • the bioprinter had a stage having a Petri dish for receiving structures generated by the bioprinter.
  • the Petri dish was coated with NovoGelTM.
  • a two dimensional representation (see e.g., Fig. 4) of a vascular structure was inputted by a user into a software program into a computer which was connected to the bioprinter.
  • the two dimensional representation of the vascular structure consisted of rods of HASMC-HAEC mixed cellular cylinders, HDF cylinders, and NovoGelTM rods defining the voids of the vascular structure and surrounding the vascular structure.
  • HASMC-HAEC mixed cellular cylinders and HDF cellular cylinders were prepared as in Example 1, and aspirated into capillary tubes for insertion into the collet chuck of the printer head.
  • capillary tubes were loaded into the printer head and dipped into the bulk NovoGelTM vessel and NovoGelTM was aspirated into the capillary tube.
  • the capillary tubes were calibrated using the vertical laser calibration system.
  • the bioprinter would print the three-dimensional structure, alternating between HASMC-HAEC rods, HDF rods and NovoGelTM rods, onto the Petri dish, in predetermined locations. See Example 2. After each rod was laid down on the Petri dish, the rod was wetted with a small amount of culture medium. Once the entire construct was completed warm NovoGelTM was dispensed over each end of the construct and allowed to gel at room temperature, and cell culture medium was added to the Petri dish to submerge the entire construct. The construct was then incubated at 37°C and 5% C0 2 to allow for fusion between the cellular cylinders. At the end of the incubation time, the
  • the resultant solution is kept away from light in a vial chamber in a bioprinter.
  • This solution is then aspirated using a 300 ⁇ or 500 ⁇ sized glass capillary via extrusion method and exposed to UV light (wavelength 365 nm, intensity 15,000- 20,000 ⁇ W/cm 2 ) for at least 3 minutes to allow polymerization via cross-linking to occur.
  • the cross-linking converts the liquid hydrogel into semi-solid structure.
  • the semi-solid hydrogel is bioprintable with or without cells and be used to create geometrically complex structures such as sheets, sacs, tubes, conduits, cylinders, tissues, organs, etc.
  • PEG-DA is used to encapsulate cells, proteins, or other biological material prior to being extruded from the bioprinter.
  • a UV cross- linkable material e.g., PEG-DA, etc.
  • an attenuation filter is added to the UV module to achieve reduced UV light intensities.
  • the PEG-DA is exposed to UV light at an intensity and/or exposure time not optimal for full cross -linking.
  • PEG-DA including mammalian cells was exposed to UV light with an intensity of 800 mW/cm 2 and the UV source at a distance of 2 inches away from the PEG-DA material.
  • the degree of cross-linking is optionally controlled by altering the composition of UV cross-linkable material and photo initiator. See Table 2.
  • the bioprinter then prints successive layers of PEG-DA and cells in a structure where the cells are partially or completely encapsulated by the PEG-DA. Lastly, the entire structure is further exposed to UV to promote full cross-linking of the PEG-DA surrounding the cells. This procedure is optionally used to encapsulate other types of biological materials either in liquid or semi- so lid state.
  • PEG-DA is used as the basis of a scaffold onto which cells and other material is bioprinted.
  • a pre-formed PEG-DA structure is created via mechanical molding with exposure to UV light.
  • PEG-DA is dissolved in a 50mM Tris HCL buffer and cross-linked using 5% Irgacure 2959 at a 1 :250 dilution ratio.
  • Long-wave UV light i.e. 365 nm
  • the preformed PEG-DA structure is placed in the bioprinter and cells and other materials are printed onto the structure. Once the cells are printed, they are allowed to fuse and the PEG-DA scaffold is subsequently removed.
  • This technique is capable of producing cellular structures in the shape of organs such as a bladder and other complex shapes.
  • Cross-linked methacrylated hydrogel is bioprinted from a NovoGen MMXTM
  • Bioprinter including a UV module using the following parameters:
  • Dispense Height 0.5 mm (lxD using a 500 ⁇ capillary)
  • a longer exposure time is used in combination with a lower UV intensity.
  • a variable pump speed dispense command is configured to dispense a shorter length of material from the dispense pump at a slower speed than the actual robot axes movements.
  • bioprinter software script commands are configured as follows:

Landscapes

  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Sustainable Development (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Mechanical Engineering (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Described herein are bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio-ink, and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; a means for calibrating the position of at least one cartridge; and a means for dispensing the contents of at least one cartridge. Also described herein are methods of using and bioprinting cartridges for such bioprinters.

Description

DEVICES, SYSTEMS, AND METHODS FOR THE FABRICATION OF TISSUE
UTILIZING UV CROSS-LINKING
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Application Serial No. 61/636,442, filed April 20, 2012, and is a continuation of U.S. Application Serial No. 13/794,368, filed March 11, 2013, both of which are hereby incorporated by reference in their entirety.
BACKGROUND OF INVENTION
[0002] A number of pressing problems confront the healthcare industry. As of December 2009 there were 105,305 patients registered by United Network for Organ Sharing (UNOS) as needing an organ transplant. Between January and September 2009, only 21,423 transplants were performed. Each year more patients are added to the UNOS list than transplants are performed, resulting in a net increase in the number of patients waiting for a transplant. For example, at the beginning of 2008, 75,834 people were registered as needing a kidney; at the end of that year, the number had grown to 80,972. 16,546 kidney transplants were performed that year, but 33,005 new patients were added to the list. The 2008 transplant rate for a patient registered by UNOS as needing a kidney was 20%. The mortality rate of waitlist patients was 7%.
[0003] Additionally, the research and development cost of a new pharmaceutical compound is approximately $1.8 billion. See Paul, et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 9(3):203-214. Drug discovery is the process by which drugs are discovered and/or designed. The process of drug discovery generally involves at least the steps of: identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, expensive, and inefficient process with low rate of new therapeutic discovery.
SUMMARY OF THE INVENTION
[0004] There is a need for tools and techniques that facilitate application of regenerative medicine and tissue engineering technologies to relieving the urgent need for tissues and organs. There is also a need for tools and techniques that substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. Accordingly, the inventors describe herein devices, systems, and methods for fabricating tissues and organs.
[0005] In one aspect, disclosed herein are bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio-ink and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; and a means for dispensing the contents of at least one cartridge. In some embodiments, the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, hydraulics, or a combination thereof. In some
embodiments, the bio-ink or support material comprises one or more UV cross-linkable materials. In some embodiments, the UV light module exposes the contents of at least one cartridge to UV light prior to dispensing. In some embodiments, the UV light module is tunable with respect to wavelength, intensity, exposure time, or any combination thereof. In further embodiments, the UV light module comprises one or more optionally engaged attenuation filters, wherein the attenuation filters lower UV intensity when engaged. In some embodiments, the bioprinter further comprises a means for applying a wetting agent to one or more of: a printer stage; a receiving surface; a deposition orifice; the bio-ink; the support material; and a printed construct; wherein the wetting agent is applied at one or more time points selected from: before the bio -ink or support material is dispensed by the bioprinter, substantially concurrently with dispensing, and after the bio -ink or support material is dispensed by the bioprinter.
[0006] In another aspect, disclosed herein are methods of fabricating a tissue construct comprising the steps of: depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has been exposed to UV light to partially or completely cross-link the UV cross- linkable material to form a semi-solid or solid body; and incubating the bio-ink to allow it to cohere and to form a tissue, wherein said incubation has a duration of about 1 hour to about 10 days. In some embodiments, the method further comprises the step of preparing a liquid bio-ink solution comprising a UV cross-linkable material and cells. In further embodiments, the method further comprises the step of exposing a liquid bio-ink solution comprising a UV cross-linkable material and cells to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body. In some embodiments, the method further comprises the step of depositing bio-ink onto a support, wherein the bio -ink comprises a UV cross-linkable material and has not been exposed to UV light. In some embodiments, the UV cross-linkable material is a hydrogel. In some embodiments, the bio-ink comprises mammalian cells. In further embodiments, the bio-ink comprises differentiated, mammalian cells. In further embodiments, the bio -ink comprises non-differentiated, mammalian cells. In some embodiments, the bio -ink is deposited by extrusion from a bioprinter.
[0007] In another aspect, disclosed herein are bioprinter cartridges, wherein the contents of the cartridge comprises a UV cross-linkable material and optionally cells. In some embodiments, the UV cross-linkable material is partially or completely cross-linked. In some embodiments, the UV cross-linkable material is a hydrogel. In some embodiments, the cartridge comprises a glass-walled reservoir. In some embodiments, the cartridge is permeable to UV light.
[0008] In another aspect, disclosed herein are UV light modules for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light. In some embodiments, the UV light module is reversibly attachable to a bioprinter. In some embodiments, the UV light module is tunable with respect to wavelength, intensity, exposure time, or any combination thereof. In some embodiments, the UV light module further comprises one or more optionally engaged attenuation filters, wherein the attenuation filters lower UV intensity when engaged.
[0009] In another aspect, disclosed herein are tissue constructs comprising a multicellular body on a support substrate, wherein the multicellular body comprises a UV cross -linkable material and cells, wherein the multicellular body was deposited by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body. In some embodiments, the construct comprises a plurality of multicellular bodies. In some embodiments, the UV cross-linkable material is a hydrogel. In some embodiments, the multicellular body comprises differentiated, mammalian cells. In some embodiments, the multicellular body comprises non-differentiated, mammalian cells.
BRIEF DESCRIPTION OF FIGURES
[0010] Fig. 1 illustrates a non-limiting example of calibration of a cartridge using a horizontal laser.
[0011] Fig. 2 illustrates a non- limiting example of calibration of a cartridge using a vertical laser.
[0012] Fig. 3 illustrates a non-limiting example of a capillary priming process.
[0013] Fig. 4 illustrates a non-limiting example of a two-dimensional representation of a bio- printed tissue construct.
[0014] Fig. 5 illustrates a non-limiting example of a three-dimensional construct generated by continuous deposition of PF-127 using a NovoGen MMX™ bioprinter connected to a syringe with a 510 μιη needle; in this case, a pyramid-shaped construct.
[0015] Fig. 6 illustrates a non-limiting example of a three-dimensional construct generated by continuous deposition of PF-127 using a NovoGen MMX™ bioprinter connected to a syringe with a 510 μιη needle; in this case, cube-shaped (left) and hollow cube-shaped (right) constructs.
[0016] Fig. 7 illustrates a non-limiting schematic diagram depicting exemplary parameters for exposing a UV cross-linkable material to a UV light source in the context of a bioprinter. [0017] Fig. 8 illustrates a non-limiting example of a NovoGen MMX™ bioprinter including a UV module; in this case, a printer head is positioned such that a capillary tube is partially introduced to a UV module.
[0018] Fig. 9 illustrates a non-limiting example of a NovoGen MMX™ bioprinter including a UV module; in this case, a printer head is positioned such that a capillary tube is entirely introduced to a UV module.
DETAILED DESCRIPTION OF INVENTION
[0019] The invention relates to the fields of regenerative medicine, tissue/organ engineering, biologic and medical research, and drug discovery. More particularly, the invention relates to devices for fabricating tissues and organs, systems and methods for calibrating and using such devices, and tissues and organs fabricated by the devices, systems, and methods disclosed herein.
[0020] Disclosed herein, in certain embodiments, are bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; and a means for dispensing the contents of at least one cartridge.
[0021] Also disclosed herein, in certain embodiments, are methods of fabricating a tissue construct comprising the steps of: depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has been exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body; and incubating the bio-ink to allow it to cohere and to form a tissue, wherein said incubation has a duration of about 1 hour to about 10 days.
[0022] Also disclosed herein, in certain embodiments, are bioprinter cartridges, wherein the contents of the cartridge comprises a UV cross-linkable material and optionally cells.
[0023] Also disclosed herein, in certain embodiments, are UV light modules for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light.
[0024] Also disclosed herein, in certain embodiments, are tissue constructs comprising a multicellular body on a support substrate, wherein the multicellular body comprises a UV cross- linkable material and cells, wherein the multicellular body was deposited by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body. Certain Definitions
[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0026] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, references to "a nucleic acid" includes one or more nucleic acids, and/or compositions of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth. Any reference to "or" herein is intended to encompass "and/or" unless otherwise stated.
[0027] As used herein, "allograft" means an organ or tissue derived from a genetically non- identical member of the same species as the recipient.
[0028] As used herein, "bio-ink" means a liquid, semi-solid, or solid composition comprising a plurality of cells. In some embodiments, bio-ink comprises cell solutions, cell aggregates, cell- comprising gels, multicellular bodies, or tissues. In some embodiments, the bio -ink additionally comprises support material. In some embodiments, the bio -ink additionally comprises non-cellular materials that provide specific biomechanical properties that enable bioprinting.
[0029] As used herein, "bioprinting" means utilizing three-dimensional, precise deposition of cells (e.g., cell solutions, cell-containing gels, cell suspensions, cell concentrations, multicellular aggregates, multicellular bodies, etc.) via methodology that is compatible with an automated, computer-aided, three-dimensional prototyping device (e.g., a bioprinter).
[0030] As used herein, "cartridge" means any object that is capable of receiving (and holding) a bio-ink or a support material.
[0031] As used herein, a "computer module" means a software component (including a section of code) that interacts with a larger computer system. In some embodiments, a software module (or program module) comes in the form of a file and typically handles a specific task within a larger software system. In some embodiments, a module may be included in one or more software systems. In other embodiments, a module may be seamlessly integrated with one or more other modules into one or more software systems. A computer module is optionally a stand-alone section of code or, optionally, code that is not separately identifiable. A key feature of a computer module is that it allows an end user to use a computer to perform the identified functions.
[0032] As used herein, "implantable" means biocompatible and capable of being inserted or grafted into or affixed onto a living organism either temporarily or substantially permanently. [0033] As used herein, "organ" means a collection of tissues joined into structural unit to serve a common function. Examples of organs include, but are not limited to, skin, sweat glands, sebaceous glands, mammary glands, bone, brain, hypothalamus, pituitary gland, pineal body, heart, blood vessels, larynx, trachea, bronchus, lung, lymphatic vessel, salivary glands, mucous glands, esophagus, stomach, gallbladder, liver, pancreas, small intestine, large intestine, colon, urethra, kidney, adrenal gland, conduit, ureter, bladder, fallopian tube, uterus, ovaries, testes, prostate, thyroid, parathyroid, meibomian gland, parotid gland, tonsil, adenoid, thymus, and spleen.
[0034] As used herein, "patient" means any individual. The term is interchangeable with "subject," "recipient," and "donor." None of the terms should be construed as requiring the supervision (constant or otherwise) of a medical professional (e.g., physician, nurse, nurse practitioner, physician's assistant, orderly, hospice worker, social worker, clinical research associate, etc.) or a scientific researcher.
[0035] As used herein, "stem cell" means a cell that exhibits potency and self-renewal. Stem cells include, but are not limited to, totipotent cells, pluripotent cells, multipotent cells, oligopotent cells, unipotent cells, and progenitor cells. Stem cells may be embryonic stem cells, peri-natal stem cells, adult stem cells, amniotic stem cells, and induced pluripotent stem cells.
[0036] As used herein, "tissue" means an aggregate of cells. Examples of tissues include, but are not limited to, connective tissue (e.g., areolar connective tissue, dense connective tissue, elastic tissue, reticular connective tissue, and adipose tissue), muscle tissue (e.g., skeletal muscle, smooth muscle and cardiac muscle), genitourinary tissue, gastrointestinal tissue, pulmonary tissue, bone tissue, nervous tissue, and epithelial tissue (e.g., simple epithelium and stratified epithelium), endoderm-derived tissue, mesoderm-derived tissue, and ectoderm-derived tissue.
[0037] As used herein, "xenograft" means an organ or tissue derived from a different species as the recipient.
Current Methods of Organ Transplants
[0038] Currently, there is no reliable method for de novo organ synthesis. Organs are only derived from living donors (e.g., for kidney and liver donations), deceased donors (e.g., for lung and heart donations) and, in a few cases, animals (e.g., porcine heart valves). Thus, patients needing an organ transplant must wait for a donor organ to become available. This results in a shortage of available organs. Additionally, reliance on organs harvested from a living organism increases the chance of transplant rejection. Transplant Rejections
[0039] In certain instances, a patient receiving an organ transplant experience hyperacute rejection. As used herein, "hyperacute rejection" means a complement -mediated immune response resulting from the recipient's having pre-existing antibodies to the donor organ. Hyperacute rejection occurs within minutes and is characterized by blood agglutination. If the transplanted organ is not immediately removed, the patient may become septic. Xenografts will produce hyperacute rejection unless the recipient is first administered immunosuppressants. In some embodiments, a tissue or organ fabricated de novo will not comprise any antigens and thus cannot be recognized by any antibodies of the recipient.
[0040] In certain instances, a patient receiving an organ transplant experiences acute rejection. As used herein, "acute rejection" means an immune response that begins about one week after transplantation to about one year after transplantation. Acute rejection results from the presence of foreign HLA molecules on the donor organ. In certain instances, APCs recognize the foreign HLAs and activate helper T cells. In certain instances, helper T cells activate cytotoxic T cells and macrophages. In certain instances, the presence of cytotoxic T cells and macrophages results in the death of cells with the foreign HLAs and thus damage (or death) of the transplanted organ. Acute rejection occurs in about 60-75% of kidney transplants, and 50-60% of liver transplants. In some embodiments, a tissue or organ fabricated de novo will not comprise any HLAs and thus will not result in the activation of helper T cells.
[0041] In certain instances, a patient receiving an organ transplant experiences chronic rejection. As used herein, "chronic rejection" means transplant rejection resulting from chronic inflammatory and immune responses against the transplanted tissue. In some embodiments, a tissue or organ fabricated de novo will not comprise any antigens or foreign HLAs and thus will not induce inflammatory or immune responses.
[0042] In certain instances, a patient receiving an organ transplant experiences chronic allograft vasculopathy (CAV). As used herein, "chronic allograft vasculopathy" means loss of function in transplanted organs resulting from fibrosis of the internal blood vessels of the transplanted organ. In certain instances, CAV is the result of long-term immune responses to a transplanted organ. In some embodiments, a tissue or organ fabricated de novo will not comprise any antigens or foreign HLAs and thus will not result in an immune response.
[0043] In order to avoid transplant rejection, organ recipients are administered immunosuppressant drugs. Immunosuppressants include, but are not limited to, corticosteroids (e.g., prednisone and hydrocortisone), calcineurin inhibitors (e.g., cyclosporine and tacrolimus), anti-proliferative agents (e.g., azathioprine and mycophenolic acid), antibodies against specific components of the immune system (e.g., basiliximab, dacluzimab, anti-thymocyte globulin (ATG) and anti-lymphocyte globulin (ALG) and mTOR inhibitors (e.g., sirolimus and everolimus)). However,
immunosuppressants have several negative side-effects including, but not limited to, susceptibility to infection (e.g., infection by Pneumocystis carinii pneumonia (PCP), cytomegalovirus pneumonia (CMV), herpes simplex virus, and herpes zoster virus) and the spread of malignant cells, hypertension, dyslipidaemia, hyperglycemia, peptic ulcers, liver and kidney injury, and interactions with other medicines. In some embodiments, a tissue or organ fabricated de novo will not result in an immune response and thus will not require the administration of an immunosuppressant.
Infections
[0044] In certain instances, a donor organ may be infected with an infectious agent. Following the transplant of the infected organ, the infectious agent is able to spread throughout the donor (due in part to the use of immunosuppressant drugs). By way of non-limiting example, recipients have contracted HIV, West Nile Virus, rabies, hepatitis C, lymphocytic choriomeningitis virus (LCMV), tuberculosis, Chagas disease, and Creutzfeldt-Jakob disease from transplanted organs. While such infections are rare, they can nevertheless occur - social histories for deceased donors are often inaccurate as they are necessarily derived from next-of-kin, serological tests may produce false- negative results if seroconversion has not occurred, or serological tests may also produce false- negatives due to hemodilution following blood transfusion. Further, many uncommon infectious agents are not screened for due to the limited time a harvested organ is viable. In some
embodiments, a tissue or organ fabricated de novo will not comprise any infectious agents.
Donor Complications
[0045] A living donor may also experience complications as a result of donating an organ. These complications include nosocomial infections, allergic reactions to the anesthesia, and surgical errors. Further, an organ donor may one day find themselves in need of the organ they donated. For example, the remaining kidney of a kidney donor or the remaining lobe of a liver donor may become damaged. In some embodiments, a tissue or organ fabricated de novo obviates the need for donor organs and thus will avoid negative side-effects to the donor.
[0046] In light of the shortage of available organs and all the complications that can follow a donor organ transplant, there is a need for a method of de novo fabrication of tissues and organs.
Tissue Engineering
[0047] Tissue engineering is an interdisciplinary field that applies and combines the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function through augmentation, repair, or replacement of an organ or tissue. The basic approach to classical tissue engineering is to seed living cells into a biocompatible and eventually biodegradable environment (e.g., a scaffold), and then culture this construct in a bioreactor so that the initial cell population can expand further and mature to generate the target tissue upon implantation. With an appropriate scaffold that mimics the biological extracellular matrix (ECM), the developing tissue may adopt both the form and function of the desired organ after in vitro and in vivo maturation. However, achieving high enough cell density with a native tissue-like architecture is challenging due to the limited ability to control the distribution and spatial arrangement of the cells throughout the scaffold. These limitations may result in tissues or organs with poor mechanical properties and/or insufficient function. Additional challenges exist with regard to bio degradation of the scaffold, entrapment of residual polymer, and industrial scale -up of manufacturing processes. Scaffoldless approaches have been attempted. Current scaffoldless approaches are subject to several limitations:
• Complex geometries, such as multi-layered structures wherein each layer comprises a
different cell type, may require definitive, high-resolution placement of cell types within a specific architecture to reproducibly achieve a native tissue-like outcome.
• Scale and geometry are limited by diffusion and/or the requirement for functional vascular networks for nutrient supply.
• The viability of the tissues may be compromised by confinement material that limits
diffusion and restricts the cells' access to nutrients.
[0048] Disclosed herein, in certain embodiments, are devices, systems, and methods that generate a three-dimensional tissue construct. The devices, systems, and methods disclosed herein utilize a three-phase process: (i) pre-processing, or bio-ink preparation, (ii) processing, i.e. the actual automated delivery/printing of the bio-ink particles into the bio-paper by the bioprinter, and (iii) post-processing, i.e., the maturation/incubation of the printed construct in the bioreactor. Final structure formation takes place during post-processing via the fusion of the bio-ink particles. The devices, systems, and methods disclosed herein have the following advantages:
They are capable of producing cell-comprising tissues and/or organs.
They mimic the environmental conditions of the natural tissue -forming processes by
exploiting principles of developmental biology.
They can achieve a broad array of complex topologies (e.g., multilayered structures,
repeating geometrical patterns, segments, sheets, tubes, sacs, etc.).
They are compatible with automated means of manufacturing and are scalable. [0049] Bioprinting enables improved methods of generating cell-comprising implantable tissues that are useful in tissue repair, tissue augmentation, tissue replacement, and organ replacement. Additionally, bioprinting enables improved methods of generating micro -scale tissue analogs including those useful for in vitro assays.
Bioprinting
[0050] Disclosed herein, in certain embodiments, are devices, systems, and methods for fabricating tissues and organs. In some embodiments, the devices are bioprinters. In some embodiments, the methods comprise the use bioprinting techniques. In further embodiments, the tissues and organs fabricated by use of the devices, systems, and methods described herein are bioprinted.
[0051] In some embodiments, bioprinted cellular constructs, tissues, and organs are made with a method that utilizes a rapid prototyping technology based on three-dimensional, automated, computer-aided deposition of cells, including cell solutions, cell suspensions, cell-comprising gels or pastes, cell concentrations, multicellular bodies (e.g., cylinders, spheroids, ribbons, etc.), and support material onto a biocompatible surface (e.g., composed of hydrogel and/or a porous membrane) by a three-dimensional delivery device (e.g., a bioprinter). As used herein, in some embodiments, the term "engineered," when used to refer to tissues and/or organs means that cells, cell solutions, cell suspensions, cell-comprising gels or pastes, cell concentrates, multicellular aggregates, and layers thereof are positioned to form three-dimensional structures by a computer- aided device (e.g., a bioprinter) according to computer code. In further embodiments, the computer script is, for example, one or more computer programs, computer applications, or computer modules. In still further embodiments, three-dimensional tissue structures form through the post- printing fusion of cells or multicellular bodies similar to self-assembly phenomena in early morphogenesis.
[0052] While a number of methods are available to arrange cells, multicellular aggregates, and/or layers thereof on a biocompatible surface to produce a three-dimensional structure including manual placement, positioning by an automated, computer-aided machine such as a bioprinter is advantageous. Advantages of delivery of cells or multicellular bodies with this technology include rapid, accurate, and reproducible placement of cells or multicellular bodies to produce constructs exhibiting planned or pre-determined orientations or patterns of cells, multicellular aggregates and/or layers thereof with various compositions. Advantages also include assured high cell density, while minimizing cell damage.
[0053] In some embodiments, methods of bioprinting are continuous and/or substantially continuous. A non- limiting example of a continuous bioprinting method is to dispense bio -ink from a bioprinter via a dispense tip (e.g., a syringe, capillary tube, etc.) connected to a reservoir of bio- ink. In further non- limiting embodiments, a continuous bioprinting method is to dispense bio -ink in a repeating pattern of functional units. In various embodiments, a repeating functional unit has any suitable geometry, including, for example, circles, squares, rectangles, triangles, polygons, and irregular geometries. In further embodiments, a repeating pattern of bioprinted function units comprises a layer and a plurality of layers are bioprinted adjacently (e.g., stacked) to form an engineered tissue or organ. In various embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more layers are bioprinted adjacently (e.g., stacked) to form an engineered tissue or organ.
[0054] In some embodiments, a bioprinted functional unit repeats in a tessellated pattern. A
"tessellated pattern" is a plane of figures that fills the plane with no overlaps and no gaps. An advantage of continuous and/or tessellated bioprinting can include an increased production of bioprinted tissue. Increased production can include achieving increased scale, increased
complexity, or reduced time or cost of production. Another non- limiting potential advantage can be reducing the number of calibration events that are required to complete the bioprinting of a three- dimensional construct. Continuous bioprinting may also facilitate printing larger tissues from a large reservoir of bio-ink, optionally using a syringe mechanism.
[0055] Methods in continuous bioprinting may involve optimizing and/or balancing parameters such as print height, pump speed, robot speed, or combinations thereof independently or relative to each other. In one example, the bioprinter head speed for deposition was 3 mm/s, with a dispense height of 0.5 mm for the first layer and dispense height was increased 0.4 mm for each subsequent layer. In some embodiments, the dispense height is approximately equal to the diameter of the bioprinter dispense tip. Without limitation a suitable and/or optimal dispense distance does not result in material flattening or adhering to the dispensing needle. In various embodiments, the bioprinter dispense tip has an inner diameter of about, 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 μιη, or more, including increments therein. In various embodiments, the bio-ink reservoir of the bioprinter has a volume of about .5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 cubic centimeters, or more, including increments therein. The pump speed may be suitable and/or optimal when the residual pressure build-up in the system is low. Favorable pump speeds may depend on the ratio between the cross-sectional areas of the reservoir and dispense needle with larger ratios requiring lower pump speeds. In some embodiments, a suitable and/or optimal print speed enables the deposition of a uniform line without affecting the mechanical integrity of the material.
[0056] The inventions disclosed herein include business methods. In some embodiments, the speed and scalability of the devices and methods disclosed herein are utilized to design, build, and operate industrial and/or commercial facilities for production of engineered tissues and/or organs. In further embodiments, the engineered tissues and/or organs are produced, stored, distributed, marketed, advertised, and sold as, for example, materials, tools, and kits for medical treatment of tissue damage, tissue disease, and/or organ failure or materials, tools, and kits to conduct biological assays and/or drug screening as a service.
Bioprinter
[0057] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, a bioprinter is any instrument that automates a bioprinting process. In certain embodiments, a bioprinter disclosed herein comprises: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material; a means for calibrating the position of at least one cartridge; and a means for dispensing the contents of at least one cartridge.
[0058] In various embodiments, a bioprinter dispenses bio-ink and/or support material in predetermined geometries (e.g., positions, patterns, etc.) in two or three dimensions. In some embodiments, a bioprinter achieves a particular geometry by moving a printer head relative to a printer stage or receiving surface adapted to receive bioprinted materials. In other embodiments, a bioprinter achieves a particular geometry by moving a printer stage or receiving surface relative to a printer head. In certain embodiments, the bioprinter is maintained in a sterile environment.
[0059] In some embodiments, a bioprinter disclosed herein comprises one or more printer heads. In further embodiments, a printer head comprises a means for receiving and holding at least one cartridge. In some embodiments, a printer head comprises a means for receiving and holding more than one cartridge. In some embodiments, the means for receiving and holding at least one cartridge is selected from: magnetic attraction, a collet chuck grip, a ferrule, a nut, a barrel adapter, or a combination thereof. In some embodiments, the means for receiving and holding at least one cartridge is a collet chuck grip.
[0060] In some embodiments, a bioprinter disclosed herein comprises a means for calibrating the position of at least one cartridge. In some embodiments, the means for calibrating the position of at least one cartridge of is selected from: laser alignment, optical alignment, mechanical alignment, piezoelectric alignment, magnetic alignment, electrical field or capacitance alignment, ultrasound alignment, or a combination thereof. In some embodiments, the means for calibrating the position of at least one cartridge is laser alignment.
[0061] In some embodiments, a bioprinter disclosed herein comprises a means for dispensing the contents of at least one cartridge. In some embodiments, the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, application of hydraulics, or application of a combination thereof. In some embodiments, the means for dispensing the contents of at least one cartridge is application of a piston. In some
embodiments, the diameter of the piston is less than the diameter of a cartridge.
[0062] In some embodiments, a bioprinter disclosed herein further comprises a receiving surface. In further embodiments, a receiving surface is a non-cytotoxic surface onto which a bioprinter dispenses bio-ink and/or support material. In some embodiments, a bioprinter disclosed herein further comprises a printer stage. In further embodiments, a receiving surface is a surface of a printer stage. In other embodiments, a receiving surface is component separate from a printer stage, but is affixed to or supported by a stage. In some embodiments the receiving surface is flat or substantially flat. In some embodiments the surface is smooth or substantially smooth. In other embodiments, the surface is both substantially flat and substantially smooth. In still further embodiments the receiving surface is designed specifically to accommodate the shape, size, texture, or geometry of the bioprinted structure. In still further embodiments, the receiving surface controls or influences the size, shape, texture, or geometry of a bioprinted construct.
[0063] In some embodiments, a bioprinter disclosed herein further comprises a means for adjusting temperature. In some embodiments, the means for adjusting temperature adjusts and/or maintains the ambient temperature. In other various embodiments, the means for adjusting temperature adjusts and/or maintains the temperature of, by way of non-limiting example, the print head, cartridge, contents of the cartridge (e.g., bio-ink, support material, etc.), the printer stage, and the receiving surface.
[0064] In some embodiments, the means for adjusting temperature is a heating element. In some embodiments, the means for adjusting temperature is a heater. In some embodiments, the means for adjusting temperature is a radiant heater, a convection heater, a conductive heater, a fan heater, a heat exchanger, or a combination thereof. In some embodiments, the means for adjusting temperature is a cooling element. In some embodiments, the means for adjusting temperature is a container of coolant, a chilled liquid, ice, or a combination thereof. In some embodiments, the means for adjusting temperature is a radiant cooler, convection cooler, a conductive cooler, a fan cooler, or a combination thereof.
[0065] In various embodiments, the means for adjusting temperature adjusts a temperature to about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90°C including increments therein. In some embodiments, temperature is adjusted to between about 40°C and about 90°C. In other embodiments, temperature is adjusted to between about 0°C and about 10°C.
[0066] In some embodiments, a bioprinter disclosed herein, further comprises a means for applying a wetting agent to one or more of: the printer stage; the receiving surface, the deposition orifice, bio-ink, support material, or the printed construct. In some embodiments, the means for applying the wetting agent is any suitable method of applying a fluid (e.g., a sprayer, a pipette, an inkjet, etc.). In some embodiments, the wetting agent is water, tissue culture media, buffered salt solutions, serum, or a combination thereof. In further embodiments, a wetting agent is applied after the bio- ink or supporting material is dispensed by the bioprinter. In some embodiments, a wetting agent is applied simultaneously or substantially simultaneously with the bio -ink or supporting material being dispensed by the bioprinter. In some embodiments, a wetting agent is applied prior to the bio- ink or supporting material being dispensed by the bioprinter.
Printer Head
[0067] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, a bioprinter disclosed herein comprises one or more printer heads. In further embodiments, a printer head comprises a means for receiving and holding at least one cartridge. In still further embodiments, a printer head attaches at least one cartridge to a bioprinter.
[0068] Many means for receiving and holding at least one cartridge are suitable. Suitable means for receiving and holding at least one cartridge include those that reliably, precisely, and securely attach at least one cartridge to a bioprinter. In various embodiments, the means for receiving and holding at least one cartridge is, by way of non-limiting example, magnetic attraction, a collet chuck grip, a ferrule, a nut, a barrel adapter, or a combination thereof.
[0069] In some embodiments, a printer head disclosed herein receives and holds one cartridge. In various other embodiments, a printer head disclosed herein receives and holds 2, 3, 4, 5, 6, 7, 8, 9, 10, or more cartridges simultaneously. In further embodiments, a printer head disclosed herein further comprises a means to select a cartridge to be employed in bioprinting from among a plurality of cartridges received and held.
[0070] In some embodiments, a printer head disclosed herein further comprises (or is in fluid communication with) a reservoir to contain bio-ink and/or support materials beyond the capacity of the one or more cartridges. In further embodiments, a reservoir supplies bio -ink and/or support materials to one or more cartridges for dispensing via a dispensing orifice. Printer head
configurations including a reservoir are particularly useful in continuous or substantially continuous bioprinting applications. Many volumes are suitable for a reservoir disclosed herein. In various embodiments, a reservoir has an internal volume of, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 200, 250, 300, 350, 400, 450, 500 ml or more, including increments therein.
[0071] In some embodiments, bioprinting involves using a computer to configure parameters such as print height, pump speed, robot speed, or combinations thereof independently or relative to each other. In further embodiments, computer code specifies the positioning of a printer head to configure printer head height above a receiving surface. In further embodiments, computer code specifies the direction and speed of the motion of a printer head to configure dispensing
characteristics for bio-ink and/or support material.
Cartridges
[0072] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, a cartridge attached to the bioprinter comprises bio -ink or support material. In some embodiments, the bioprinter dispenses bio -ink or support material in a specific pattern and at specific positions in order to form a specific cellular construct, tissue, or organ. In order to fabricate complex tissue constructs, the bioprinter deposits the bio -ink or support material at precise speeds and in uniform amounts. Thus, there is a need for a cartridge with (a) a dispensing orifice that is smooth or substantially smooth, and (b) an internal surface that is smooth or substantially smooth. As used herein, "cartridge" means any object that is capable of receiving (and holding) a bio-ink and/or support material.
[0073] In some embodiments, a cartridge disclosed herein comprises bio -ink. In some
embodiments, a cartridge disclosed herein comprises support material. In some embodiments, a cartridge disclosed herein comprises a combination of bio -ink and support material.
[0074] Disclosed herein, in certain embodiments, are cartridges for use with a bioprinter disclosed herein, comprising at least one dispensing orifice. In some embodiments, a cartridge comprises one dispensing orifice. In various other embodiments, a cartridge comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more dispensing orifices. In further embodiment, the edges of a dispensing orifice are smooth or substantially smooth.
[0075] Many shapes are suitable for the dispensing orifices disclosed herein. In various
embodiments, suitable shapes for dispensing orifices include, by way of non-limiting examples, circular, ovoid, triangular, square, rectangular, polygonal, and irregular. In some embodiments, the orifice is circular. In other embodiments, the orifice is square. In yet other embodiments, the orifice is oval, oblong, or rectangular and dispenses solid or semi-solid bio-ink and/or support materials in a ribbon- like form.
[0076] In some embodiments, the internal surface of the cartridge is smooth or substantially smooth. In some embodiments, the cartridge is comprised of a rigid structure to facilitate calibration. In some embodiments, the walls of the cartridge are comprised of a material that resists attachment of cells. In some embodiments, the cartridges are comprised of a material that is biocompatible. [0077] Many types of cartridges are suitable for use with bioprinters disclosed herein and the methods of using the same. In some embodiments, a cartridge is compatible with bioprinting that involves extruding a semi-solid or solid bio-ink or a support material through one or more dispensing orifices. In some embodiments, a cartridge is compatible with bioprinting that involves dispensing a liquid or semi-solid cell solution, cell suspension, or cell concentration through one or more dispensing orifices. In some embodiments, a cartridge is compatible with non-continuous bioprinting. In some embodiments, a cartridge is compatible with continuous and/or substantially continuous bioprinting.
[0078] In some embodiments, a cartridge is a capillary tube or a micropipette. In some
embodiments, a cartridge is a syringe or a needle. Many internal diameters are suitable for substantially round or cylindrical cartridges. In various embodiments, suitable internal diameters include, by way of non- limiting examples, 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more μιη, including increments therein. In other various embodiments, suitable internal diameters include, by way of non-limiting examples, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more mm, including increments therein. In some embodiments, a cartridge has an internal diameter of about 1 μιη to about 1000 μιη. In a particular embodiment, a cartridge has an internal diameter of about 500 μιη. In another particular embodiment, a cartridge has an internal diameter of about 250 μιη. Many internal volumes are suitable for the cartridges disclosed herein. In various embodiments, suitable internal volumes include, by way of non- limiting examples, 1, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more μΐ, including increments therein. In other various embodiments, suitable internal volumes include, by way of non-limiting examples, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 or more ml, including increments therein. In some embodiments, a cartridge has a volume of about 1 μΐ to about 50 μΐ. In a particular embodiment, a cartridge has a volume of about 5 μΐ.
[0079] In some embodiments, a cartridge is compatible with ink -jet printing of bio-ink and/or support material onto a receiving surface such as that described in U.S. Patent Number 7,051,654. In further embodiments, a cartridge includes dispensing orifices in the form of voltage-gated nozzles or needles under the control of the computer code described herein.
[0080] In some embodiments, the cartridge is primed. In some embodiments, priming the cartridge increases the accuracy of the dispensing, deposition, or extrusion process. As used herein, "primed" means the contents of the cartridge are made ready for dispensing, deposition, or extrusion by compacting and advancing the contents of the cartridge until the material to be dispensed (bio -ink or supporting material) is located in a position in contact with the dispensing orifice. See, e.g., Fig. 3. In some embodiments, the cartridge is primed when the contents are compact or substantially compact, and the contents are in physical contact with the orifice of the cartridge.
[0081] In some embodiments, a cartridge is marked to indicate the composition of its contents. In further embodiments, a cartridge is marked to indicate the composition of a bio -ink and/or support material contained therein. In some embodiments, the surface of the cartridge is colored. In some embodiments, the outer surface of the cartridge is dyed, painted, marked with a pen, marked by a sticker, or a combination thereof.
[0082] In some embodiments, the outer surface of a cartridge is marked to increase the opacity of the surface of the cartridge (e.g., to increase the amount of a laser beam that is reflected off the surface of the cartridge). In some embodiments, the surface of a cartridge is colored. In some embodiments, the outer surface of a cartridge is scored. As used herein, "scored" means marking the surface of a cartridge to reduce the smoothness of the surface. Any suitable method is used to score the surface of a cartridge (e.g., application of an acidic substance, application of a caustic substance, application of an abrasive substance, etc.). In some embodiments, the outer surface of a cartridge is painted, polished (e.g., fire polished), etched (e.g., laser etched), marked with a pen, marked by a sticker, or a combination thereof.
Grip
[0083] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, a cartridge attached to a bioprinter comprises bio -ink and/or support material. In some embodiments, the bioprinter dispenses the bio -ink and/or support material in a specific pattern and at specific positions in order to form a specific cellular construct, tissue, or organ. In some embodiments, a cartridge comprising bio -ink is disposable. In some embodiments, the cartridge is ejected from the bioprinter following extrusion of the contents. In some
embodiments, a new cartridge is subsequently attached to the bioprinter.
[0084] In order to fabricate complex structures, the bioprinters disclosed herein dispense bio -ink and/or support material from a cartridge with a suitable repeatable accuracy. In various
embodiments, suitable repeatable accuracies include those of about ±5, 10, 20, 30, 40, or 50 μιη on any axis. In some embodiments, the bioprinters disclosed herein dispense bio -ink and/or support material from a cartridge with a repeatable accuracy of about ±20 μιη. However, uncontrolled removal and insertion of cartridges can result in alterations of the position of the printer head (and thus the cartridges) with respect to the tissue construct, such that precision of the placement of the first bio-ink particle deposited from a new cartridge may vary relative to the last bio -ink particle deposited from the previous cartridge. Thus, there is a need for a method of attaching and securing a cartridge to a printer head, wherein said attaching and securing produce minimal alterations in the position of the printer head.
[0085] Disclosed herein, in certain embodiments, are methods of attaching a cartridge to a bioprinter, comprising: (a) inserting the cartridge into a collet chuck, wherein the collet chuck is attached to a printer head of the bioprinter; and (b) adjusting the outer collar of the collet chuck; wherein the inserting and adjusting do not substantially alter the position of the printer head.
[0086] Disclosed herein, in certain embodiments, are systems for attaching a cartridge to a bioprinter, comprising: a means for receiving and securing a cartridge to a printer head of a bioprinter; wherein use of the means for receiving and securing the cartridge do not substantially alter the position of the printer head. In some embodiments, the means for receiving and securing the cartridge to a printer head is a chuck or ferrule. As used herein, "chuck" means a holding device consisting of adjustable jaws. In some embodiments, the means for receiving and securing the cartridge to a printer head is a collet. As used herein, "collet" means a subtype of chuck— that forms a collar around the object to be held and exerts a strong clamping. As used herein, "ferrule" means a band (e.g., a metal band) used to secure one object to another. In some embodiments, the means for receiving and securing the cartridge to a printer head is a barrel adaptor. As used herein, "barrel adaptor" means a threaded tube used to secure one object to another.
UV Module
[0087] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, a bioprinter comprises a ultraviolet (UV) light module. In further embodiments, a UV module enables a bioprinter disclosed herein to automatically cure and print UV cross-linkable materials. In some embodiments, a UV module comprises a light chamber for exposing the contents of a cartridge (e.g., a glass capillary tube) to UV light. In some embodiments, a UV module comprises a UV light line to expose the contents of a cartridge to UV light evenly along its length. In some embodiments, a UV module comprises a slot to accept an optional attenuation filter that reduces the intensity of UV light to which the contents of a cartridge is exposed. In some embodiments, a UV module is integrated with a bioprinter. In various further embodiments, a UV module is permanently, semi-permanently, or reversibly attached to a bioprinter. In other embodiments, a UV module is not attached to a bioprinter.
[0088] In some embodiments, a UV module described herein is used by first aspirating uncured material into a glass capillary tube. In further embodiments, the glass capillary then is lowered into the light chamber, where a high power fiber optic light line transmits UV light from a UV light source across the length of the capillary. In still further embodiments, once cured (e.g., cross- linked), the glass capillary is lifted out of the light chamber and the material is ready to print (e.g., be extruded or deposited, etc.). For applications where the contents of a cartridge include bio-ink and/or support material that comprises cells, an optional attenuation filter is placed between the capillary and the light guide to achieve lower UV intensities.
[0089] Many UV light sources are suitable for use with the UV module described herein. UV light is electromagnetic radiation with a wavelength in the range 10 nm to 400 nm and energies from 3 eV to 124 eV. UV light, in some cases, alters chemical bonds in molecules and can cause chemical reactions. UV light from various sources is characterized by having many suitable wavelengths and many suitable associated energies. See Table 1, infra.
[0090] Table 1
Figure imgf000020_0001
[0091] In some embodiments, suitable sources of UV light include, by way of non-limiting examples, UV lamps, UV fluorescent lamps, UV LEDs, UV lasers, and the like. A UV lamp (e.g., black light, black light blue or BLB lamps, etc.) emits long-wave UV radiation and very little visible light. Fluorescent black lights are typically made using a UV-emitting phosphor. The phosphor typically used for a near 368-371 nm emission peak is either europium-doped strontium fluoroborate (SrB40yF:Eu2+) or europium-doped strontium borate (SrB407:Eu2+), whereas the phosphor used to produce a peak around 350-353 nm is lead-doped barium silicate (BaSi205:Pb+). Fluorescent black lights are also typically made using Wood's glass, a nickel-oxide-doped glass, which blocks almost all visible light above 400 nm. A black light may also be formed, very inefficiently, by simply using Wood's glass instead of clear glass as the envelope for a common incandescent bulb. UV fluorescent lamps without a phosphorescent coating to convert UV to visible light, emit ultraviolet light with two peaks at 253.7 nm and 185 nm due to the peak emission of the mercury within the bulb. With the addition of a suitable phosphor (phosphorescent coating), they can be modified to produce UVA or UVB. Light-emitting diodes (LEDs) can be manufactured to emit light in the UV range, although practical LED arrays are limited below 365 nm. UV laser diodes and UV solid-state lasers can be manufactured to emit light in the UV range. Direct UV- emitting laser diodes are available at 375 nm. UV diode lasers have been demonstrated using crystals of cerium doped with lithium strontium aluminum fluoride (Ce:LiSAF). Wavelengths shorter than 375 nm are generated from diodes in solid-state modules that use frequency doubling or tripling diode-pumped solid state (DPSS) technology. Wavelengths available include 262, 266, 349, 351, 355, and 375 nm.
[0092] Referring to Fig. 7, in a particular embodiment, a UV module comprises a UV light source that is a UV lamp. Further in this embodiments, a cartridge includes a glass capillary tube into which a UV cross-linkable material is aspirated. The cartridge is positioned within the light chamber of the UV module such that it is about 3 inches from the UV lamp. The UV lamp in this embodiment emits UV light with a wavelength of about 365 nm.
[0093] Referring to Fig. 8, in a particular embodiment, a bioprinter includes a printer head 800, which holds a cartridge 810. In this embodiment, a cartridge 810 includes a glass capillary tube which is partially lowered into a UV light module 820 attached to the bioprinter. The UV module 820 in this case, comprises a housing, a cover, and an opening to allow introduction of the cartridge 810.
[0094] Referring to Fig. 9, in a further particular embodiment, a printer head 800, which holds a cartridge 810 is completely lowered into a UV light module 820.
[0095] In some embodiments, a UV module enables a bioprinter disclosed herein to automatically cure and print UV cross-linkable materials by exposing them to UV light for a pre-determined period of time. Many durations of exposure to a UV light source are suitable. In light of the disclosure provided herein, those of skill in the art will recognize that particular UV cross-linkable materials are suited to particular exposure times. In some embodiments, exposure time is selected to completely UV cross-link a material, resulting in a more solid structure. In other embodiments, exposure time is selected to partially UV cross-link a material, resulting in a more semi-solid structure. In various embodiments, suitable exposure times include, by way of non-limiting examples, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more seconds. In other various embodiments, suitable exposure times include, by way of non- limiting examples, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more minutes. [0096] In some embodiments, exposure time is about 5 seconds to about 15 minutes. In further embodiments, exposure time is about 10 seconds to about 10 minutes. In still further embodiments, exposure time is about 15 seconds to about 5 minutes. In some cases, exposure time is adjusted for the presence of cells in a UV cross-linkable material.
Receiving Surface
[0097] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, the bioprinter dispenses a plurality of elements, sections, and/or areas of bio-ink and/or support material onto a receiving surface. In further embodiments, dispensing occurs in a specific pattern and at specific positions. In still further embodiments, the locations at which the bioprinter deposits bio-ink and/or support material onto a receiving surface are defined by user input and translated into computer code.
[0098] In some embodiments, each of the elements, sections, and/or areas of bio -ink and/or support material has dimensions of less than 300 mm x 300 mm x 160 mm. By way of example only, the dimensions of a section of bio-ink or support material may be 75 mm x 5.0 mm x 5.0 mm; 0.3 mm x 2.5 mm x 2.5 mm; 1 mm x 1 mm x 50 mm; or 150 mm x 150 mm x 80 mm. Due to the generally small size of each section, and in some cases, the high degree of precision required, minute imperfections in the receiving surface may result in imperfections (and possibly, failure) of a cellular construct, tissue, or organ. Thus, there is a need for a substantially smooth and substantially flat receiving surface, or a defined or substantially defined receiving surface, that is able to receive sections of bio-ink and/or support material.
[0099] Disclosed herein, in certain embodiments, are receiving surfaces for receiving one or more structures generated by the bioprinter disclosed herein. In some embodiments, the receiving surface is flat or substantially flat. In some embodiments, the receiving surface is smooth or substantially smooth. In some embodiments, the receiving surface is flat or substantially flat. In some
embodiments, the receiving surface is defined or substantially defined. In other embodiments the receiving surface is designed specifically to accommodate the shape, size, texture, or geometry of a specific bioprinted structure. In further embodiments, the receiving surface controls or influences the size, shape, texture, or geometry of a bioprinted construct.
[00100] In some embodiments, the receiving surface comprises a solid material, a semi-solid material, or a combination thereof. In some embodiments, the receiving surface comprises glass, coated glass, plastic, coated plastic, metal, a metal alloy, or a combination thereof. In some embodiments, the receiving surface comprises a gel. In some embodiments, the receiving surface and any coatings thereon are biocompatible. In various embodiments, the receiving surface comprises any of the support materials and/or confinement materials disclosed herein. In specific embodiments, the receiving surface comprises polymerized NovoGel™ or polymerized agarose, polymerized gelatin, extracellular matrix (or components thereof), collagen, or a combination thereof.
Software
[00101] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, one or more cartridges attached to the bioprinter comprise bio -ink and/or support material. In some embodiments, the bioprinter dispenses bio-ink or support material in a specific pattern and at specific positions in order to form a specific cellular construct, tissue, or organ.
[00102] In order to fabricate complex tissue constructs, the bioprinter deposits the bio -ink or support material at precise locations (in two or three dimensions) on a receiving surface. In some embodiments, the locations at which the bioprinter deposits bio -ink and/or support material are defined by user input and translated into computer code. In further embodiments, the computer code includes a sequence of instructions, executable in the central processing unit (CPU) of a digital processing device, written to perform a specified task. In some embodiments, additional bioprinting parameters including, by way of non-limiting examples, print height, pump speed, robot speed, control of variable dispensing orifices, UV intensity, and UV exposure time are defined by user input and translated into computer code. In other embodiments, such bioprinting parameters are not directly defined by user input, but are derived from other parameters and conditions by the computer code described herein.
[00103] Disclosed herein, in certain embodiments, are methods for fabricating tissue constructs, tissues, and organs, comprising: a computer module receiving input of a visual representation of a desired tissue construct; a computer module generating a series of commands, wherein the commands are based on the visual representation and are readable by a bioprinter; a computer module providing the series of commands to a bioprinter; and the bioprinter depositing bio-ink and/or support material according to the commands to form a construct with a defined geometry.
Non-transitory Computer Readable Storage Medium
[00104] In some embodiments, the locations at which the bioprinter deposits the bio-ink and/or support material are defined by user input and translated into computer code. In some embodiments, the devices, systems, and methods disclosed herein further comprise non-transitory computer readable storage media or storage media encoded with computer readable program code. In further embodiments, a computer readable storage medium is a tangible component of a digital processing device such as a bioprinter (or a component thereof) or a computer connected to a bioprinter (or a component thereof). In still further embodiments, a computer readable storage medium is optionally removable from a digital processing device. In some embodiments, a computer readable storage medium includes, by way of non-limiting examples, CD-ROMs, DVDs, flash memory devices, solid state memory, magnetic disk drives, magnetic tape drives, optical disk drives, cloud computing systems and services, and the like. In some cases, the program and instructions are permanently, substantially permanently, semi-permanently, or non-transitorily encoded on the storage media.
Computer Modules
[00105] In some embodiments, the devices, systems, and methods described herein comprise software, server, and database modules. In some embodiments, a "computer module" is a software component (including a section of code) that interacts with a larger computer system. In further embodiments, a software module (or program module) comes in the form of one or more files and typically handles a specific task within a larger software system.
[00106] In some embodiments, a module is included in one or more software systems. In other embodiments, a module is integrated with one or more other modules into one or more software systems. A computer module is optionally a stand-alone section of code or, optionally, code that is not separately identifiable. In some embodiments, the modules are in a single application. In other embodiments, the modules are in a plurality of applications. In some embodiments, the modules are hosted on one machine. In other embodiments, the modules are hosted on a plurality of machines. In some embodiments, the modules are hosted on a plurality of machines in one location. In other embodiments, the modules are hosted a plurality of machines in more than one location. Further described herein is the formatting of location and positioning data. In some embodiments, the data files described herein are formatted in any suitable data serialization format including, by way of non-limiting examples, tab-separated values, comma-separated values, character-separated values, delimiter-separated values, XML, JSON, BSON, and YAML. A key feature of a computer module is that it allows an end user to use a computer to perform the identified functions.
Graphic User Interface
[00107] In some embodiments, a computer module comprises a graphic user interface (GUI).
As used herein, "graphic user interface" means a user environment that uses pictorial as well as textual representations of the input and output of applications and the hierarchical or other data structure in which information is stored. In some embodiments, a computer module comprises a display screen. In further embodiments, a computer module presents, via a display screen, a two- dimensional GUI. In other embodiments, a computer module presents, via a display screen, a three- dimensional GUI such as a virtual reality environment. In some embodiments, the display screen is a touchscreen or multitouchscreen and presents an interactive GUI.
[00108] In some embodiments, the display screen presents a GUI that consists essentially of a grid comprising regularly spaced objects of substantially the same shape and substantially equal size. The objects presented have any suitable shape. In some embodiments, suitable shapes for objects include, by way of non-limiting examples, circle, oval, square, rectangle, triangle, diamond, polygon, or a combination thereof.
[00109] In some embodiments, a user defines the content of one or more objects to form a two-dimensional or three-dimensional visual representation of a desired tissue construct. See, e.g., Fig. 4. In some embodiments, the user-defined content of an object is, by way of non-limiting examples, a bio-ink with various compositions or support material with various compositions. In some embodiments, the user defines the content of an object by modifying the color of the cell or the shape of the object.
Bio-ink
[00110] Disclosed herein, in certain embodiments, are devices, systems, and methods for fabricating tissues and organs. In some embodiments, the devices comprise one or more printer heads for receiving and holding at least one cartridge that optionally contains bio-ink. In some embodiments, the methods comprise the use of bio -ink. In further embodiments, the tissues and organs fabricated by use of the devices, systems, and methods described herein comprise bio -ink at the time of fabrication or thereafter.
[00111] In some embodiments, "bio-ink" includes liquid, semi-solid, or solid compositions comprising a plurality of cells. In some embodiments, bio-ink comprises liquid or semi-solid cell solutions, cell suspensions, or cell concentrations. In further embodiments, a cell solution, suspension, or concentration comprises a liquid or semi-solid (e.g., viscous) carrier and a plurality of cells. In still further embodiments, the carrier is a suitable cell nutrient media, such as those described herein. In some embodiments, bio-ink comprises semi-solid or solid multicellular aggregates or multicellular bodies. In further embodiments, the bio -ink is produced by 1) mixing a plurality of cells or cell aggregates and a biocompatible liquid or gel in a pre -determined ratio to result in bio-ink, and 2) compacting the bio-ink to produce the bio-ink with a desired cell density and viscosity. In some embodiments, the compacting of the bio -ink is achieved by centrifugation, tangential flow filtration ("TFF"), or a combination thereof. In some embodiments, the compacting of the bio-ink results in a composition that is extrudable, allowing formation of multicellular aggregates or multicellular bodies. In some embodiments, "extrudable" means able to be shaped by forcing (e.g., under pressure) through a nozzle or orifice (e.g., one or more holes or tubes). In some embodiments, the compacting of the bio-ink results from growing the cells to a suitable density. The cell density necessary for the bio -ink will vary with the cells being used and the tissue or organ being produced. In some embodiments, the cells of the bio -ink are cohered and/or adhered. In some embodiments, "cohere," "cohered," and "cohesion" refer to cell-cell adhesion properties that bind cells, multicellular aggregates, multicellular bodies, and/or layers thereof. In further embodiments, the terms are used interchangeably with "fuse," "fused," and "fusion." In some embodiments, the bio-ink additionally comprises support material, cell culture medium, extracellular matrix (or components thereof), cell adhesion agents, cell death inhibitors, anti-apoptotic agents, antioxidants, extrusion compounds, and combinations thereof.
Cells
[00112] Disclosed herein, in various embodiments, are bio-inks that include liquid, semisolid, or solid compositions comprising a plurality of cells. In some embodiments, bio -ink comprises liquid or semi-solid cell solutions, cell suspensions, or cell concentrations. In some embodiments, any mammalian cell is suitable for use in bio-ink and in the fabrication of tissues and organs using the devices, systems, and methods described herein. In various embodiments, the cells are any suitable cell. In further various embodiments, the cells are vertebrate cells, mammalian cells, human cells, or combinations thereof. In some embodiments, the type of cell used in a method disclosed herein depends on the type of cellular construct, tissue, or organ being produced. In some embodiments, the bio-ink comprises one type of cell (also referred to as a "homologous ink"). In some embodiments, the bio-ink comprises more than one type of cell (also referred to as a "heterologous ink").
[00113] In further embodiments, the cells are, by way of non-limiting examples, contractile or muscle cells (e.g., skeletal muscle cells, cardiomyocytes, smooth muscle cells, and myoblasts), connective tissue cells (e.g., bone cells, cartilage cells, fibroblasts, and cells differentiating into bone forming cells, chondrocytes, or lymph tissues), bone marrow cells, endothelial cells, skin cells, epithelial cells, breast cells, vascular cells, blood cells, lymph cells, neural cells, Schwann cells, gastrointestinal cells, liver cells, pancreatic cells, lung cells, tracheal cells, corneal cells, genitourinary cells, kidney cells, reproductive cells, adipose cells, parenchymal cells, pericytes, mesothelial cells, stromal cells, undifferentiated cells (e.g., embryonic cells, stem cells, and progenitor cells), endoderm-derived cells, mesoderm-derived cells, ectoderm-derived cells, and combinations thereof. [00114] In some embodiments, the cells are adult, differentiated cells. In further embodiments, "differentiated cells" are cells with a tissue-specific phenotype consistent with, for example, a smooth muscle cell, a fibroblast, or an endothelial cell at the time of isolation, wherein tissue-specific phenotype (or the potential to display the phenotype) is maintained from the time of isolation to the time of use. In other embodiments, the cells are adult, non-differentiated cells. In further embodiments, "non-differentiated cells" are cells that do not have, or have lost, the definitive tissue-specific traits of for example, smooth muscle cells, fibroblasts, or endothelial cells. In some embodiments, non-differentiated cells include stem cells. In further embodiments, "stem cells" are cells that exhibit potency and self-renewal. Stem cells include, but are not limited to, totipotent cells, pluripotent cells, multipotent cells, oligopotent cells, unipotent cells, and progenitor cells. Stem cells may be embryonic stem cells, adult stem cells, amniotic stem cells, and induced pluripotent stem cells. In yet other embodiments, the cells are a mixture of adult, differentiated cells and adult, non-differentiated cells.
Cell culture media
[00115] In some embodiments, the bio-ink comprises a cell culture medium. The cell culture medium is any suitable medium. In various embodiments, suitable cell culture media include, by way of non-limiting examples, Dulbecco's Phosphate Buffered Saline, Earle's Balanced Salts, Hanks' Balanced Salts, Tyrode's Salts, Alsever's Solution, Gey's Balanced Salt Solution, Kreb's- Henseleit Buffer Modified, Kreb's-Ringer Bicarbonate Buffer, Puck's Saline, Dulbecco's Modified Eagle's Medium, Dulbecco's Modified Eagle's Medium/Nutrient F-12 Ham, Nutrient Mixture F-10 Ham (Ham's F-10), Medium 199, Minimum Essential Medium Eagle, RPMI-1640 Medium, Ames' Media, BGJb Medium (Fitton- Jackson Modification), Click's Medium, CMRL-1066 Medium, Fischer's Medium, Glascow Minimum Essential Medium (GMEM), Iscove's Modified Dulbecco's Medium (IMDM), L-15 Medium (Leibovitz), McCoy's 5 A Modified Medium, NCTC Medium, Swim's S-77 Medium, Waymouth Medium, William's Medium E, or combinations thereof. In some embodiments, the cell culture medium is modified or supplemented. In some embodiments, the cell culture medium further comprises albumin, selenium, transferrins, fetuins, sugars, amino acids, vitamins, growth factors, cytokines, hormones, antibiotics, lipids, lipid carriers,
cyclodextrins, or a combination thereof.
Extracellular matrix
[00116] In some embodiments, the bio-ink further comprises one or more components of an extracellular matrix or derivatives thereof. In some embodiments, "extracellular matrix" includes proteins that are produced by cells and transported out of the cells into the extracellular space, where they may serve as a support to hold tissues together, to provide tensile strength, and/or to facilitate cell signaling. Examples, of extracellular matrix components include, but are not limited to, collagen, fibronectin, laminin, hyaluronates, elastin, and proteoglycans. For example, multicellular aggregates may contain various ECM proteins (e.g., gelatin, fibrinogen, fibrin, collagen, fibronectin, laminin, elastin, and/or proteoglycans). The ECM components or derivatives of ECM components can be added to the cell paste used to form the multicellular aggregate. The ECM components or derivatives of ECM components added to the cell paste can be purified from a human or animal source, or produced by recombinant methods known in the art. Alternatively, the ECM components or derivatives of ECM components can be naturally secreted by the cells in the elongate cellular body, or the cells used to make the elongate cellular body can be genetically manipulated by any suitable method known in the art to vary the expression level of one or more ECM components or derivatives of ECM components and/or one or more cell adhesion molecules or cell-substrate adhesion molecules (e.g., selectins, integrins, immunoglobulins, and adherins). The ECM components or derivatives of ECM components may promote cohesion of the cells in the multicellular aggregates. For example, gelatin and/or fibrinogen can suitably be added to the cell paste, which is used to form multicellular aggregates. The fibrinogen can then be converted to fibrin by the addition of thrombin.
[00117] In some embodiments, the bio-ink further comprises an agent that encourages cell adhesion.
[00118] In some embodiments, the bio-ink further comprises an agent that inhibits cell death
(e.g., necrosis, apoptosis, or autophagocytosis). In some embodiments, the bio-ink further comprises an anti-apoptotic agent. Agents that inhibit cell death include, but are not limited to, small molecules, antibodies, peptides, peptibodies, or combination thereof. In some embodiments, the agent that inhibits cell death is selected from: anti-TNF agents, agents that inhibit the activity of an interleukin, agents that inhibit the activity of an interferon, agents that inhibit the activity of an GCSF (granulocyte colony- stimulating factor), agents that inhibit the activity of a macrophage inflammatory protein, agents that inhibit the activity of TGF-B (transforming growth factor B), agents that inhibit the activity of an MMP (matrix metalloproteinase), agents that inhibit the activity of a caspase, agents that inhibit the activity of the MAPK/JNK signaling cascade, agents that inhibit the activity of a Src kinase, agents that inhibit the activity of a JAK (Janus kinase), or a
combination thereof. In some embodiments, the bio -ink comprises an anti-oxidant.
Extrusion compounds
[00119] In some embodiments, the bio-ink further comprises an extrusion compound (i.e., a compound that modifies the extrusion properties of the bio-ink). Examples of extrusion compounds include, but are not limited to gels, hydrogels (including UV cross-linkable and thermoreversible hydrogels described herein), surfactant polyols (e.g., Pluronic F-127 or PF-127), thermo -responsive polymers, hyaluronates, alginates, extracellular matrix components (and derivatives thereof), collagens, other biocompatible natural or synthetic polymers, nanofibers, and self-assembling nano fibers.
[00120] Gels, sometimes referred to as jellies, have been defined in various ways. For example, the United States Pharmacopoeia defines gels as semisolid systems consisting of either suspensions made up of small inorganic particles or large organic molecules interpenetrated by a liquid. Gels include a single-phase or a two-phase system. A single -phase gel consists of organic macro molecules distributed uniformly throughout a liquid in such a manner that no apparent boundaries exist between the dispersed macromolecules and the liquid. Some single -phase gels are prepared from synthetic macromolecules (e.g., carbomer) or from natural gums (e.g., tragacanth). In some embodiments, single-phase gels are generally aqueous, but will also be made using alcohols and oils. Two-phase gels consist of a network of small discrete particles.
[00121] Gels can also be classified as being hydrophobic or hydrophilic. In certain embodiments, the base of a hydrophobic gel consists of a liquid paraffin with polyethylene or fatty oils gelled with colloidal silica, or aluminum or zinc soaps. In contrast, the base of hydrophobic gels usually consists of water, glycerol, or propylene glycol gelled with a suitable gelling agent (e.g., tragacanth, starch, cellulose derivatives, carboxyvinylpolymers, and magnesium-aluminum silicates). In certain embodiments, the rheology of the compositions or devices disclosed herein is pseudo plastic, plastic, thixotropic, or dilatant.
[00122] Suitable hydrogels include those derived from collagen, hyaluronate, fibrin, alginate, agarose, chitosan, and combinations thereof. In other embodiments, suitable hydrogels are synthetic polymers. In further embodiments, suitable hydrogels include those derived from poly(acrylic acid) and derivatives thereof, poly(ethylene oxide) and copolymers thereof, poly( vinyl alcohol), polyphosphazene, and combinations thereof. In various specific embodiments, the support material is selected from: hydrogel, NovoGel™, agarose, alginate, gelatin, Matrigel™, hyaluronan, poloxamer, peptide hydrogel, poly(isopropyl n-polyacrylamide), polyethylene glycol diacrylate (PEG-DA), hydroxyethyl methacrylate, polydimethylsiloxane, polyacrylamide, poly(lactic acid), silicon, silk, or combinations thereof.
UV cross-linkable hydrogels
[00123] Suitable hydrogels include methacrylated hydrogels, such as Polyethylene (glycol) diacrylate-based (PEG-DA) hydrogels, which are used in cell biology due to their ability to crosslink in presence of UV light and due to their inertness to cells. PEG-DA is commonly used as scaffold in tissue engineering since polymerization occurs rapidly at room temperature and requires low energy input, has high water content, is elastic, and can be customized to include a variety of biological molecules.
Photoinitiators
[00124] In some embodiments, an extrusion compound comprises a photoinitiator, which is a molecule that upon absorption of light at a specific wavelength produces reactive species capable of catalyzing polymerization or poly condensation reactions. These reactions area also called photopolymerization or radiation curing. Photoinitiators are typically ketones which contain both aromatic and carbonyl groups.
[00125] There are two types of photoinitiators: cationic and radical photoinitiators. Radical photoinitiators are water-compatible and act on molecules containing an acrylate or styrene group. The range of wavelengths used is typically near UV (300 nm-400 nm) but recent progress in initiator chemistry is expanding the ranges of wavelengths that can be used. Photoinitiators used in biology such as Irgacure 2959, 184, and 651 fall into this class.
[00126] A suitable photoinitiator for use with the bio-inks and/or support materials described herein is Irgacure 2959 (4-(2-hydroxyethoxy) phenyl-(2 -propyl) ketone (Glycosan BioSystems, Inc.; Salt Lake City, Utah) due to its high solubility in water and its minimal toxicity compared to other Irgacure species. Upon absorption of UV light, Irgacure 2959 dissociates into 2 primary radicals which then react with the vinyl (C=C) groups of PEG-DA to initiate polymerization. There are three phases in photopolymerization: photoinitiation, propagation, and termination. Rate of reaction during the first step is dependent on the nature of the photoinitiator (quantum yield, photoinitiator efficiency) and intensity of light while the later steps (propagation and termination) are a function of vinyl bond concentration and the rate constants for propagation and termination.
Thermoreversible gels
[00127] In some embodiments, hydro gel-based extrusion compounds are thermoreversible gels (also known as thermo -responsive gels or thermogels). In some embodiments, a suitable thermoreversible hydrogel is not a liquid at room temperature. In specific embodiments, the gelation temperature (Tgel) of a suitable hydrogel is about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, and about 40°C, including increments therein. In certain
embodiments, the Tgel of a suitable hydrogel is about 10°C to about 25°C. In some embodiments, the bio-ink (e.g., comprising hydrogel, one or more cell types, and other additives, etc.) described herein is not a liquid at room temperature. In specific embodiments, the gelation temperature (Tgel) of a bio-ink described herein is about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, and about 40°C, including increments therein. In certain embodiments, the Tgel of a bio-ink described herein is about 10°C to about 25°C.
[00128] Polymers composed of polyoxypropylene and polyoxyethylene form
thermoreversible gels when incorporated into aqueous solutions. These polymers have the ability to change from the liquid state to the gel state at temperatures that can be maintained in a bioprinter apparatus. The liquid state-to-gel state phase transition is dependent on the polymer concentration and the ingredients in the solution.
[00129] Poloxamer 407 (Pluronic F-127 or PF-127) is a nonionic surfactant composed of polyoxyethylene-polyoxypropylene copolymers. Other polo xamers include 188 (F-68 grade), 237 (F-87 grade), 338 (F-108 grade). Aqueous solutions of poloxamers are stable in the presence of acids, alkalis, and metal ions. PF-127 is a commercially available po lyo xy ethylene - polyoxypropylene triblock copolymer of general formula El 06 P70 E 106, with an average molar mass of 13,000. The polymer can be further purified by suitable methods that will enhance gelation properties of the polymer. It contains approximately 70% ethylene oxide, which accounts for its hydrophilicity. It is one of the series of poloxamer ABA block copolymers. PF-127 has good solubilizing capacity, low toxicity and is, therefore, considered a suitable extrusion compound.
[00130] In some embodiments, the viscosity of the hydrogels and bio-inks presented herein is measured by any means described. For example, in some embodiments, an LVDV-II+CP Cone Plate Viscometer and a Cone Spindle CPE-40 is used to calculate the viscosity of the hydrogels and bio-inks. In other embodiments, a Brookfield (spindle and cup) viscometer is used to calculate the viscosity of the hydrogels and bio-inks. In some embodiments, the viscosity ranges referred to herein are measured at room temperature. In other embodiments, the viscosity ranges referred to herein are measured at body temperature (e.g., at the average body temperature of a healthy human).
[00131] In further embodiments, the hydrogels and/or bio-inks are characterized by having a viscosity of between about 500 and 1,000,000 centipoise, between about 750 and 1,000,000 centipoise; between about 1000 and 1,000,000 centipoise; between about 1000 and 400,000 centipoise; between about 2000 and 100,000 centipoise; between about 3000 and 50,000 centipoise; between about 4000 and 25,000 centipoise; between about 5000 and 20,000 centipoise; or between about 6000 and 15,000 centipoise.
[00132] In some embodiments, the bio-ink comprises cells and extrusion compounds suitable for continuous bioprinting. In specific embodiments, the bio-ink has a viscosity of about 1500 mPa»s. A mixture of Pluronic F-127 and cellular material may be suitable for continuous bioprinting. Such a bio-ink may be prepared by dissolving Pluronic F-127 powder by continuous mixing in cold (4 °C) phosphate buffered saline (PBS) over 48 hours to 30% (w/v). Pluronic F-127 may also be dissolved in water. Cells may be cultivated and expanded using standard sterile cell culture techniques. The cells may be pelleted at 200g for example, and re-suspended in the 30%> Pluronic F-127 and aspirated into a reservoir affixed to a bioprinter where it can be allowed to solidify at a gelation temperature from about 10 to about 25°C. Gelation of the bio -ink prior to bioprinting is optional. The bio-ink, including bio-ink comprising Pluronic F-127 can be dispensed as a liquid.
[00133] In various embodiments, the concentration of Pluronic F-127 can be any value with suitable viscosity and/or cytotoxicity properties. A suitable concentration of Pluronic F-127 may also be able to support weight while retaining its shape when bioprinted. In some embodiments, the concentration of Pluronic F-127 is about 10%>, about 15%, about 20%, about 25%, about 30%, about 35%), about 40%>, about 45%, or about 50%>. In some embodiments, the concentration of Pluronic F-127 is between about 30%> and about 40%>, or between about 30%> and about 35%.
[00134] Referring to Fig. 5, in a particular embodiment, a three-dimensional, pyramid- shaped construct is generated by continuous deposition of PF-127 using a NovoGen MMX™ bioprinter connected to a syringe with a 510 μιη needle.
[00135] Referring to Fig. 6, in a particular embodiment, a three-dimensional, cube-shaped
(left) and hollow cube-shaped (right) constructs generated by continuous deposition of PF-127 using a NovoGen MMX™ bioprinter connected to a syringe with a 510 μιη needle.
[00136] In some embodiments, the non-cellular components of the bio-ink (e.g., extrusion compounds, etc.) are removed prior to use. In further embodiments, the non-cellular components are, for example, hydrogels, surfactant polyols, thermo -responsive polymers, hyaluronates, alginates, collagens, or other biocompatible natural or synthetic polymers. In still further embodiments, the non-cellular components are removed by physical, chemical, or enzymatic means. In some embodiments, a proportion of the non-cellular components remain associated with the cellular components at the time of use.
[00137] In some embodiments, the cells are pre -treated to increase cellular interaction. For example, cells may be incubated inside a centrifuge tube after centrifugation in order to enhance cell-cell interactions prior to shaping the bio -ink.
Support Material
[00138] Disclosed herein, in certain embodiments, are devices, systems, and methods for fabricating tissues and organs. In some embodiments, the devices comprise one or more printer heads for receiving and holding at least one cartridge that optionally contains support material. In some embodiments, the methods comprise the use of support material. In further embodiments, the tissues and organs fabricated by use of the devices, systems, and methods described herein comprise support material at the time of fabrication or thereafter.
[00139] In some embodiments, the support material is capable of excluding cells growing or migrating into or adhering to it. In some embodiments, the support material is permeable for nutrient media.
[00140] In some embodiments, the viscosity of the support material is changeable. In some embodiments, the viscosity of the support material is changed by modifying the temperature of the support material. In some embodiments, the viscosity of the support material is changed by modifying the pressure of the support material. In some embodiments, the viscosity of the support material is changed by modifying the concentration of the support material. In some embodiments, the viscosity of the support material is changed by cross-linking (e.g., by use of a chemical cross- linker), or photo crossinking (e.g., using ultraviolet light exposure).
[00141] In some embodiments, the permeability of the support material is changeable. In some embodiments, the permeability of the support material is modified by varying the temperature of the support material or the temperature surrounding the support material. In some embodiments, the permeability of the support material is modified by contacting the support material with an agent that modifies permeability.
[00142] In some embodiments, the compliance (i.e., elasticity or hardness) of the support material is modified. In some embodiments, the compliance of the support material is modified by varying the temperature of the support material or the temperature surrounding the support material. In some embodiments, the compliance of the support material is modified by contacting the support material with an agent that modifies compliance.
[00143] Many support materials are suitable for use in the methods described herein. In some embodiments, hydrogels (including UV cross-linkable and thermoreversible hydrogels described herein) are exemplary support materials possessing one or more advantageous properties including: non-adherent, biocompatible, extrudable, bioprintable, non-cellular, and of suitable strength. In some embodiments, suitable hydrogels are natural polymers. In one embodiment, the confinement material is comprised of NovoGel™. In further embodiments, suitable hydrogels include those derived from surfactant polyols (e.g., Pluronic F-127), collagen, hyaluronate, fibrin, alginate, agarose, chitosan, derivatives or combinations thereof. In other embodiments, suitable hydrogels are synthetic polymers. In further embodiments, suitable hydrogels include those derived from poly(acrylic acid) and derivatives thereof, poly(ethylene oxide) and copolymers thereof, poly( vinyl alcohol), polyphosphazene, and combinations thereof. In various specific embodiments, the confinement material is selected from: hydrogel, NovoGel™, agarose, alginate, gelatin, Matrigel™, hyaluronan, poloxamer, peptide hydrogel, poly(isopropyl n-polyacrylamide), polyethylene glycol diacrylate (PEG-DA), hydroxyethyl methacrylate, polydimethylsiloxane, polyacrylamide, poly(lactic acid), silicon, silk, or combinations thereof.
[00144] In some embodiments, the support material contains cells prior to being present in the bioprinter. In some embodiments, the support material is a hydrogel containing a suspension of cells. In some embodiments, the support material is a hydrogel containing a mixture of more than one cell type.
Exemplary Uses of Support Materials
[00145] In some embodiments, the support material is used as building units for constructing a biological construct (e.g., cellular construct, tissue, organ, etc.). In further embodiments, the support material unit is used to define and maintain the domains void of cellular material (i.e., the intermediate cellular units) of a desired construct. In some embodiments, the support material is capable of assuming any shape or size.
[00146] For example, according to one embodiment, NovoGel™ solution (originally in powder phase mixed with buffer and water) may be heated to reduce its viscosity and taken up in a micropipette with a desired dimension (or in a chamber of a desired shape by negative displacement of a piston). The NovoGel™ solution in the pipette (or the chamber) may be cooled to room temperature, for example by forced air on the exterior of the pipette (or the chamber) or plunging the micropipette into a container with cold liquid, so that it can solidify into a gel with the desired shape, i.e., a support material. The resulting support material may be dispensed from the pipette or chamber during the construction of a particular cellular construct, tissue, or organ. See e.g., Fig. 4.
[00147] In some embodiments, the support material is used for increasing the viability of the engineered tissue or organ after bioprinting. In further embodiments, support material provides direct contact between the tissue or organ and a nutrient medium through a temporary or semipermanent lattice of confinement material (e.g., support material). In some embodiments, the tissue is constrained in a porous or gapped material. Direct access of at least some of the cells of the tissue or organ to nutrients increases the viability of the tissue or organ.
[00148] In further embodiments, the methods disclosed herein comprise additional and optional steps for increasing the viability of an engineered tissue or organ including: 1) optionally dispensing base layer of confinement material (e.g., support material) prior to placing cohered multicellular aggregates; 2) optionally dispensing a perimeter of confinement material; 3) bioprinting cells of the tissue within a defined geometry; and 4) dispensing elongate bodies (e.g., cylinders, ribbons, etc.) of confinement material overlaying the nascent tissue in a pattern that introduces gaps in the confinement material, such as a lattice, mesh, or grid.
[00149] In some embodiments, the gaps overlaying pattern are distributed uniformly or substantially uniformly around the surface of the tissue or organ. In other embodiments, the gaps are distributed non-uniformly, whereby the cells of the tissue or organ are exposed to nutrients non- uniformly. In non-uniform embodiments, the differential access to nutrients may be exploited to influence one or more properties of the tissue or organ. For instance, it may be desirable to have cells on one surface of a bioprinted, cellular construct, tissue, or organ proliferate faster than cells on another surface. In some embodiments, the exposure of various parts of the tissue or organ to nutrients can be changed at various times to influence the development of the tissue or organ toward a desired endpoint.
[00150] In some embodiments, the confinement material is removed at any suitable time, including but not limited to, immediately after bioprinting (e.g., within 10 minutes), after bioprinting (e.g., after 10 minutes), before the cells are substantially cohered to each other, after the cells are substantially cohered to each other, before the cells produce an extracellular matrix, after the cells produce an extracellular matrix, just prior to use, and the like. In various embodiments, confinement material is removed by any suitable method. For example, in some embodiments, the confinement material is excised, pulled off the cells, digested, or dissolved.
Methods and Systems for Calibrating the Position of a Bioprinter Cartridge
[00151] Disclosed herein, in certain embodiments, are bioprinters for fabricating tissues and organs. In some embodiments, a cartridge attached to the bioprinter comprises a bio -ink and/or a support material. In some embodiments, the bioprinter deposits the bio -ink or support material in a specific pattern and at specific positions in order to form a specific tissue construct. In some embodiments, a cartridge comprising bio-ink is disposable. In some embodiments, the cartridge is ejected from the bioprinter following extrusion, dispensing, or deposition of the contents. In some embodiments, a new cartridge is attached to the bioprinter.
[00152] In order to fabricate complex structures, the bioprinters disclosed herein dispense bio-ink and/or support material from a cartridge with a suitable repeatable accuracy. In various embodiments, suitable repeatable accuracies include those of about ±5, 10, 20, 30, 40, or 50 μιη on any axis. In some embodiments, the bioprinters disclosed herein dispense bio -ink and/or support material from a cartridge with a repeatable accuracy of about ±20 μιη. However, in some embodiments, due to the removal and insertion of cartridges, the position of the printer head (and thus the cartridges) with respect to the tissue construct varies. Thus, there is a need for a method of precisely calibrating the position of the printer head, cartridge, and dispensing orifice with respect to the printer stage, receiving surface, tissue, or organ.
[00153] In some embodiments, the method of calibrating the position of a printer head comprises use of at least one laser. In further embodiments, the method of calibrating the position of a printer head comprises use of a first and second laser.
[00154] In some embodiments, the method of calibrating the position of a printer head comprises manual (e.g., visual) calibration.
[00155] In some embodiments, the method of calibrating the position of a printer head comprises manual calibration and laser calibration.
[00156] In some embodiments, the position of the printer head is calibrated along one axis, wherein the axis is selected from the x-axis, the y-axis, and the z-axis. In some embodiments, the position of the printer head is calibrated along two axes, wherein the axes are selected from the x- axis, the y-axis, and the z-axis. In some embodiments, the position of the printer head is calibrated along three axes, wherein the axes are selected from the x-axis, the y-axis, and the z-axis.
[00157] In some embodiments, calibration is made by use of at least one laser. In further embodiments, calibration is made by use of a first and a second laser.
Method for Calibrating Using a Horizontal Laser
[00158] Disclosed herein, in certain embodiments, are methods of calibrating the position of a printer head comprising a dispensing orifice. In some embodiments, a method disclosed herein further comprises activating a laser and generating at least one substantially stable and/or substantially stationary laser beam, and where said laser beam is horizontal to the ground. See, e.g., Fig. 1.
[00159] In some embodiments, the methods comprise, calibrating the position of a printer head along at least one axis, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of the printer head along at least two axes, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of the printer head along at least three axes, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise (a) calibrating the position of the printer head along the y-axis; (b) calibrating the position of the printer head along the x-axis; and/or (c) calibrating the position of the printer head along the z-axis; wherein each axis corresponds to the axis of the same name in the Cartesian coordinate system. In some embodiments, calibration is made by use of at least one laser. In some embodiments, calibration is made by use of a first and a second laser. [00160] In some embodiments, calibrating the position of a printer head along the y-axis comprises: (a) positioning the printer head so that the printer head is (i) located in a first y octant and (ii) the dispensing orifice is below the upper threshold of the laser beam; (b) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted by the printer head is the first y position; (c) re -positioning the printer head so that the printer head is located in the second y octant and the dispensing orifice is below the upper threshold of the laser beam; (d) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted is the second y position; (e) and calculating the mid-point between the first y position and the second y position.
[00161] In some embodiments, calibrating the position of a printer head along the x-axis comprises: (a) positioning the printer head (i) at the mid-point between the first y position and the second y position, and (ii) outside the sensor threshold of the laser; and (b) moving the printer head towards the sensor threshold and stopping said movement as soon as the printer head contacts the sensor threshold; wherein the position at which the printer head contacts the sensor increased by half the printer head width is the x position.
[00162] In some embodiments, calibrating the position of a printer head along the y-axis comprises: (a) positioning the printer head so that the laser beam can measure the precise location of one side of the printer head; (b) positioning the printer head so that the laser beam can measure the precise location of the opposing side of the printer head; (c) and calculating the midpoint location of the printer head to be relative to the laser location during each measurement and the measured distances.
[00163] In some embodiments, calibrating the position of a printer head along the x-axis comprises: (a) positioning the printer head so that the laser beam can measure the precise location of one side of the printer head; (b) positioning the printer head so that the laser beam can measure the precise location of the opposing side of the printer head; (c) and calculating the midpoint location of the printer head to be relative to the laser location during each measurement and the measured distances.
[00164] In some embodiments, calibrating the position of a printer head along the z-axis comprises: (a) positioning the printer head so that the dispensing orifice is located above the laser beam; and (b) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted is the z position. Method for Calibrating Using a Vertical Laser
[00165] Disclosed herein, in certain embodiments, are methods of calibrating the position of a printer head comprising a dispensing orifice. In some embodiments, a method disclosed herein further comprises activating the laser and generating at least one substantially stable and/or substantially stationary laser beam, and where said laser beam is vertical to the ground. See, e.g., Fig. 2.
[00166] In some embodiments, the methods comprise, calibrating the position of a printer head along at least one axis, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of a printer head along at least two axes, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the methods comprise calibrating the position of a printer head along at least three axes, wherein the axis is selected from the x-axis, y-axis, and z-axis.
[00167] In some embodiments, the methods comprise (a) calibrating the position of the printer head along the y-axis; (b) calibrating the position of the printer head along the x-axis; and (c) calibrating the position of the printer head along the z-axis; wherein each axis corresponds to the axis of the same name in the Cartesian coordinate system.
[00168] In some embodiments, calibrating the position of a printer head along the y-axis comprises: (a) positioning the printer head so that the printer head is (i) located in a first y octant and (ii) the dispensing orifice is outside the sensor threshold of the laser; (b) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted by the printer head is the first y position; (c) re -positioning the printer head so that the printer head is located in the second y octant and the dispensing orifice is outside the sensor threshold of the laser; (d) moving the printer head towards the laser beam and stopping said movement as soon as the laser beam is interrupted by the printer head, wherein the position at which the laser beam is interrupted is the second y position; (e) and calculating the mid-point between the first y position and the second y position.
[00169] In some embodiments, calibrating the position of a printer head along the x-axis comprises: (a) positioning the printer head (i) at the mid-point between the first y position and the second y position, and (ii) outside the sensor threshold of the laser; and (b) moving the printer head towards the sensor threshold and stopping said movement as soon as the printer head contacts the sensor threshold; wherein the position at which the printer head contacts the sensor increased by half the printer head width is the x position. [00170] In some embodiments, calibrating the position of a printer head along the z-axis comprises: (a) positioning the printer head so that the dispensing orifice is located above the laser beam so that it is just outside of the laser sensor range threshold; and (b) lowering the printer head until the sensor threshold is reached, wherein the position at which the laser sensor threshold is reached is the z position. In some embodiments, steps (a) and (b) are repeated at multiple points of the printer head and measured heights are averaged to determine the z position.
[00171] In some embodiments, calibrating the position of a printer head along the z-axis comprises: (a) positioning the printer head so that the laser beam can measure the precise location of one or more points on the bottom of the printer head; (b) calculating the absolute or average location of the printer head based on the laser position and known measured distance.
Method for Calibrating Using a Vertical and Horizontal Laser
[00172] Disclosed herein, in certain embodiments, are methods of calibrating the position of a printer head comprising a dispensing orifice, wherein the printer head is attached to a bioprinter, comprising calibrating the position of the printer head along at least one axis, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the method comprises calibrating the position of a printer head along at least two axes, wherein the axis is selected from the x-axis, y-axis, and z-axis. In some embodiments, the method comprises calibrating the position of a printer head along at least three axes, wherein the axis is selected from the x-axis, y-axis, and z-axis.
[00173] In some embodiments, the methods comprise (a) calibrating the position of the printer head along the y-axis; (b) calibrating the position of the printer head along the x-axis; and (c) calibrating the position of the printer head along the z-axis; wherein each axis corresponds to the axis of the same name in the Cartesian coordinate system.
[00174] In some embodiments, calibration comprises use of a first laser and a second laser.
In some embodiments, the first laser is a vertical laser and the second laser is a horizontal laser.
System for Calibrating Using a Laser
[00175] Disclosed herein, in certain embodiments, are systems for calibrating the position of a cartridge comprising a deposition orifice, wherein the cartridge is attached to a bioprinter, said system comprising: a means for calibrating the position of the cartridge along at least one axis, wherein the axis is selected from the y-axis, x-axis, and z-axis.
[00176] Also disclosed herein, in certain embodiments, are systems for calibrating the position of a printer head comprising a dispensing orifice, wherein the printer head is attached to a bioprinter, said system comprising: a means for calibrating the position of the printer head along an x-axis; a means for calibrating the position of the printer head along a y-axis; and a means for calibrating the position of the printer head along a z-axis.
[00177] In some embodiments, a system for calibrating the position of a printer head comprises a means for calibrating the printer head along the x-axis, y-axis, and z-axis. In some embodiments, the means for calibrating a printer head along the x-axis, y-axis, and z-axis is laser alignment, optical alignment, mechanical alignment, piezoelectric alignment, magnetic alignment, electrical field or capacitance alignment, ultrasound alignment, or a combination thereof.
[00178] In some embodiments, a system for calibrating the position of a printer head comprises a means for calibrating the printer head along the x-axis, y-axis, and z-axis. In some embodiments, the means for calibrating a printer head along the x-axis, y-axis, and z-axis is laser alignment. In some embodiments, the laser alignment means comprises at least one laser. In some embodiments, the laser alignment means comprises a plurality of lasers.
[00179] In some embodiments, the laser alignment means it has any suitable accuracy. In various embodiments, suitable accuracies include those of about ±5, 10, 20, 30, 40, or 50 μιη on any axis. In some embodiments, the laser alignment means is accurate to ±40 μιη on the vertical axis and ±20 μιη on the horizontal axis.
[00180] In some embodiments, the laser path is uninterrupted between the laser source and the measurement point. In some embodiments, the laser path is altered by up to 179° by use of a reflective surface or optical lens. In some embodiments, the laser path is altered by 90°. In some embodiments, a horizontal laser beam is used to measure in a vertical path by deflection using a reflective surface. In some embodiments, a vertical laser beam is used to measure in a horizontal path by deflection using a reflective surface.
Various non-limiting embodiments
[00181] In some embodiments, disclosed herein are bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material; a UV light module for optionally exposing the contents of at least one cartridge to UV light; a means for calibrating the position of at least one cartridge; and a means for dispensing the contents of at least one cartridge. In some embodiments, the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, hydraulics, or a combination thereof. In some embodiments, the bio -ink and/or support material comprise one or more UV cross-linkable materials. In some embodiments, the UV light module exposes the contents of at least one cartridge to UV light prior to dispensing. In some embodiments, the UV light module exposes the contents of at least one cartridge to UV light with a wavelength of about 300 nm to about 400 nm. In further embodiments, the UV light module exposes the contents of at least one cartridge to UV light with a wavelength of about 365 nm. In some embodiments, the UV light module is configurable to expose the contents of at least one cartridge to UV light for about 5 seconds to about 20 minutes. In some embodiments, the UV light module transmits UV light across the length of the at least one cartridge. In some embodiments, the UV light module is tunable with respect to intensity, exposure time, or both intensity and exposure time. In further embodiments, the UV light module comprises one or more optionally engaged attenuation filters, where the attenuation filters lower UV intensity when engaged. In some embodiments, the bioprinters further comprise a means for adjusting temperature. In further embodiments, the bioprinters comprising a means for adjusting the ambient temperature, the temperature of a cartridge, the temperature of the contents of the cartridge, the temperature of the receiving surface, or a combination thereof. In still further embodiments, the means for adjusting temperature is a heating element. In still further embodiments, the means for adjusting temperature is a radiant heater, a convection heater, a conductive heater, a fan heater, a heat exchanger, or a combination thereof. In other embodiments, the means for adjusting temperature is a cooling element. In further embodiments, the means for adjusting temperature is a container of coolant, a chilled liquid, ice, a radiant cooler, a convection cooler, a conductive cooler, a fan cooler, or a combination thereof. In some embodiments, the bioprinters further comprise a means for applying a wetting agent to one or more of: the printer stage; the receiving surface; the deposition orifice; bio- ink; support material; and a printed construct; wherein the wetting agent is applied at one or more time points selected from: before the bio-ink or support material is dispensed by the bioprinter, substantially concurrently with dispensing, and after the bio -ink or support material is dispensed by the bioprinter.
[00182] In some embodiments, disclosed herein are methods of fabricating a tissue construct comprising the steps of: depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has been exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body; and incubating the bio-ink to allow it to cohere and to form a tissue, wherein said incubation has a duration of about 6 hours to about 10 days. In some embodiments, the method further comprises the step of preparing a liquid bio -ink solution comprising a UV cross-linkable material and mammalian cells. In further embodiments, the method further comprises the step of exposing a liquid bio-ink solution comprising a UV cross- linkable material and mammalian cells to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body. In some embodiments, the method further comprises the step of depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has not been exposed to UV light. In some embodiments, the UV cross- linkable material is a hydrogel. In further embodiments, the hydrogel is a methacrylated hydrogel. In still further embodiments, the methacrylated hydrogel is PEG-DA. In some embodiments, the UV light is characterized by having a wavelength of about 300 nm to about 400 nm. In further embodiments, the UV light is characterized by having a wavelength of about 365 nm. In some embodiments, the exposure to UV light has a duration of about 5 seconds to about 20 minutes. In some embodiments, the bio-ink comprises mammalian cells. In further embodiments, the bio -ink comprises adult, differentiated, mammalian cells. In further embodiments, the bio -ink comprises adult, non-differentiated, mammalian cells. In some embodiments, the bio -ink comprises human smooth muscle cells. In some embodiments, the bio -ink comprises human endothelial cells. In some embodiments, the bio-ink comprises human fibroblasts. In some embodiments, the mammalian cells are selected from the group consisting of: liver cells, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiac cells, skin cells, smooth muscle cells, connective tissue cells, corneal cells, genitourinary cells, breast cells, reproductive cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipose cells, bone cells, bone marrow cells, cartilage cells, pericytes, mesothelial cells, stromal cells, stem cells, progenitor cells, lymph cells, blood cells, endoderm-derived cells, ectoderm-derived cells, and mesoderm-derived cells. In some embodiments, the bio-ink is deposited onto a support by extrusion from a bioprinter.
[00183] In some embodiments, disclosed herein are bioprinter cartridges, wherein the contents of the cartridge comprise a UV cross-linkable material and optionally mammalian cells, wherein the UV cross-linkable material is partially or completely cross-linked. In some
embodiments, the UV cross-linkable material is a hydrogel. In further embodiments, the hydrogel is a methacrylated hydrogel. In still further embodiments, the methacrylated hydrogel is PEG-DA. In some embodiments, the cartridge comprises a glass-walled reservoir. In further embodiments, the cartridge comprises a glass capillary tube. In further embodiments, the cartridge comprises a glass syringe. In further embodiments, the cartridge is characterized by having an internal diameter of about 50 μι ΐο about 1000 μιη. In still further embodiments, the cartridge is characterized by having an internal diameter of about 500 μιη. In other embodiments, the cartridge is characterized by having an internal diameter of about 250 μιη.
[00184] In some embodiments, disclosed herein are UV light modules for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light. In some embodiments, the UV light source optionally exposes the contents of at least one bioprinter cartridge to UV light along the length of the cartridge. In further embodiments, the UV light source is a fiber optic light line. In some embodiments, the UV light module is reversibly attachable to a bioprinter. In some embodiments, the UV light source exposes the contents of at least one cartridge to UV light with a wavelength of about 300 nm to about 400 nm. In some embodiments, the UV light module is tunable with respect to intensity, exposure time, or both intensity and exposure time. In further embodiments, the UV light module further comprises one or more optionally engaged attenuation filters, where the attenuation filters lower UV intensity when engaged.
[00185] In some embodiments, disclosed herein are tissue constructs comprising a multicellular body on a support substrate, wherein the multicellular body comprises a UV cross- linkable material and mammalian cells, wherein the multicellular body was generated by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body prior to deposition. In some embodiments, the tissue construct comprises about 2 to about 100 multicellular bodies. In some embodiments, the UV cross-linkable material is a hydrogel. In further embodiments, the hydrogel is a methacrylated hydrogel. In still further embodiments, the methacrylated hydrogel is PEG-DA. In some embodiments, the UV light is characterized by having a wavelength of about 300 nm to about 400 nm. In further embodiments, the UV light is characterized by having a wavelength of about 365 nm. In some embodiments, the exposure to UV light has a duration of about 5 seconds to about 20 minutes. In some embodiments, the multicellular bodies comprise adult, differentiated, mammalian cells. In some embodiments, the multicellular bodies comprise adult, non-differentiated, mammalian cells. In some embodiments, at least one multicellular body comprises human smooth muscle cells. In some embodiments, at least one multicellular body comprises human endothelial cells. In some embodiments, at least one multicellular body comprises human fibroblasts. In some embodiments, the mammalian cells are selected from the group consisting of: liver cells, gastrointestinal cells, pancreatic cells, kidney cells, lung cells, tracheal cells, vascular cells, skeletal muscle cells, cardiac cells, skin cells, smooth muscle cells, connective tissue cells, corneal cells, genitourinary cells, breast cells, reproductive cells, endothelial cells, epithelial cells, fibroblasts, neural cells, Schwann cells, adipose cells, bone cells, bone marrow cells, cartilage cells, pericytes, mesothelial cells, stromal cells, stem cells, progenitor cells, lymph cells, blood cells, endoderm-derived cells, ectoderm-derived cells, mesoderm-derived cells, and combinations thereof. EXAMPLES
[00186] The following specific examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent.
Example 1: HASMC-HAEC mixed cellular cylinders Cell Culture
[00187] Smooth muscle cells: Primary human aortic smooth muscle cells (HASMC) were maintained and expanded in low glucose Dulbecco's modified eagle medium (DMEM; Invitrogen Corp., Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml Penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml of amphotericin B, 0.01M of HEPES (all from Invitrogen Corp., Carlsbad, CA), 50 mg/L of proline, 50 mg/L of glycine, 20 mg/L of alanine, 50 mg/L of ascorbic acid, and 3 μg/L of CuS04 (all from Sigma, St. Louis, MO) at 37°C and 5% C02. Confluent cultures of HASMCs between passage 4 and 8 were used in all studies.
[00188] Endothelial cells: Primary human aortic endothelial cells (HAEC) were maintained and expanded in Medium 200 supplemented with 2% FBS, 1 μ /ml of hydrocortisone, 10 ng/ml of human epidermal growth factor, 3 ng/ml of basic fibroblast growth factor, 10 μ i l of heparin, 100 U/ml Penicillin, 0.1 mg/ml streptomycin, and 0.25 μg/ml of amphotericin B (all from Invitrogen Corp., Carlsbad, CA). The cells were grown on gelatin (from porcine serum; Sigma, St. Louis, MO) coated tissue culture treated flasks at 37°C and 5% C02. Confluent cultures of HAEC's between passage 4 and 8 were used in all studies.
NovoGel™ Mold
[00189] Preparation of 2% w/v NovoGel™ solution: 1 g of low melting point NovoGel™ was dissolved in 50 ml of Dulbecco's phosphate buffered saline (DPBS). Briefly, the DPBS and NovoGel™ were heated to 85°C on a hot plate with constant stirring until the NovoGel™ dissolved completely. NovoGel™ solution was sterilized by steam sterilization at 125°C for 25 minutes. The NovoGel™ solution remained in liquid phase as long as the temperature is maintained above 66.5°C. Below this temperature a phase transition occurs, the viscosity of the NovoGel™ solution increases and the NovoGel™ forms a solid gel.
[00190] Preparation o NovoGel™ mold: A NovoGel™ mold was fabricated for the incubation of cellular cylinders using a Teflon® mold that fits a 10 cm Petri dish. Briefly, the Teflon® mold was pre-sterilized using 70% ethanol solution and subjecting the mold to UV light for 45 minutes. The sterilized mold was placed on top of the 10 cm Petri dish (VWR International LLC, West Chester, PA) and securely attached. This assembly (Teflon mold + Petri dish) was maintained vertically and 45 ml of pre-warmed, sterile 2% NovoGel™ solution was poured in the space between the Teflon® mold and the Petri dish. The assembly was then placed horizontally at room temperature for 1 hour to allow complete gelation of the NovoGel™. After gelation, the Teflon® print was removed and the NovoGel™ mold was washed twice using DPBS. 17.5 ml of HASMC culture medium was then added to the NovoGel™ mold.
HASMC-HAEC cylinders
[00191] Fabrication of HASMC-HAEC mixed cellular cylinders: To prepare mixed cellular cylinders HASMC and HAEC were individually collected and then mixed at pre-determined ratios. Briefly, the culture medium was removed from confluent culture flasks and the cells were washed with DPBS (1 ml/5 cm2 of growth area). Cells were detached from the surface of the culture flasks by incubation in the presence of trypsin (1 ml/15 cm2 of growth area) for 10 minutes. HASMC were detached using 0.15% trypsin while HAEC were detached using 0.1% trypsin. Following the incubation appropriate culture medium was added to the flasks (2X volume with respect to trypsin volume). The cell suspension was centrifuged at 200g for 6 minutes followed by complete removal of supernatant solution. Cell pellets were resuspended in respective culture medium and counted using a hemacytometer. Appropriate volumes of HASMC and HAEC were combined to yield mixed cell suspensions containing 5, 7.5, 10, 12.5, and 15% HAEC (as a % of total cell
population). The mixed cell suspensions were centrifuged at 200g for 5 minutes followed by complete removal of supernatant solution. Mixed cell pellets were resuspended in 6 ml of HASMC culture medium and transferred to 20 ml glass vials, followed by incubation on an orbital shaker at 150 rpm for 60 minutes, and at 37°C and 5% C02. This allows the cells to aggregate with one another and initiate cell-cell adhesions. Post-incubation, the cell suspension was transferred to a 15 ml centrifuge tube and centrifuged at 200g for 5 minutes. After removal of the supernatant medium, the cell pellet was resuspended in 400 μΐ of HASMC culture medium and pipetted up and down several times to ensure all cell clusters were broken. The cell suspension was transferred into a 0.5 ml micro fuge tube placed inside a 15 ml centrifuge tube followed by centrifugation at 2000g for 4 minutes to form a highly dense and compact cell pellet. The supernatant medium was aspirated and the cells were transferred into capillary tubes (OD 1.0 mm, ID 0.5 mm, L 75 mm; Drummond Scientific Co., Broomall, PA) by aspiration so as to yield cell cylinders 50 mm in length. The cell paste inside the capillaries was incubated in HASMC medium for 20 minutes at 37°C and 5% C02. The cellular cylinders were then deposited from the capillary tubes into the grooves of the
NovoGel™ mold (covered with HASMC medium) using the plunger supplied with the capillaries. The cellular cylinders were incubated for 24 and 48 hours at 37°C and 5% C02. Example 2: Multi-layered vascular tubes Cell Culture
[00192] Smooth muscle cells: Primary human aortic smooth muscle cells (HASMC; GIBCO) were maintained and expanded in low glucose dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml Penicillin, 0.1 mg/ml streptomycin, 0.25 μ^πιΐ of amphotericin B, 0.01M of HEPES (all from Invitrogen Corp., Carlsbad, CA), 50 mg/L of proline, 50 mg/L of glycine, 20 mg/L of alanine, 50 mg/L of ascorbic acid, and 3 μg/L of CuSC-4 (all from Sigma, St. Louis, MO) at 37°C and 5% C02. Confluent cultures of HASMC between passage 4 and 8 were used in all studies.
[00193] Endothelial cells: Primary human aortic endothelial cells (HAEC) were maintained and expanded in Medium 200 supplemented with 2% FBS, 1 μ /ml of hydrocortisone, 10 ng/ml of human epidermal growth factor, 3 ng/ml of basic fibroblast growth factor, 10 μ i l of heparin, 100 U/ml Penicillin, 0.1 mg/ml streptomycin, and 0.25 μg/ml of amphotericin B (all from Invitrogen Corp., Carlsbad, CA). The cells were grown on gelatin (from porcine serum) coated tissue culture treated flasks at 37°C and 5% C02. Confluent cultures of HAEC between passage 4 and 8 were used in all studies.
[00194] Fibroblasts: Primary human dermal fibroblasts (HDF) were maintained and expanded in Medium 106 supplemented with 2% FBS, 1 μ /ml of hydrocortisone, 10 ng/ml of human epidermal growth factor, 3 ng/ml of basic fibroblast growth factor, 10 μ i l of heparin, 100 U/ml Penicillin, and 0.1 mg/ml streptomycin (all from Invitrogen Corp., Carlsbad, CA) at 37°C and 5% C02. Confluent cultures of HDF between passage 4 and 8 were used in all studies.
NovoGel™ Solutions and Mold
[00195] Preparation of 2% and 4% (w/v) NovoGel™ solution : 1 g or 2 g (for 2% or 4% respectively) of low melting point NovoGel™ (Ultrapure LMP) was dissolved in 50 ml of
Dulbecco's phosphate buffered saline (DPBS). Briefly, the DPBS and NovoGel™ were heated to 85°C on a hot plate with constant stirring until the NovoGel™ dissolves completely. NovoGel™ solution was sterilized by steam sterilization at 125°C for 25 minutes. The NovoGel™ solution remains in liquid phase as long as the temperature is maintained above 66.5°C. Below this temperature a phase transition occurs, the viscosity of the NovoGel™ solution increases and the NovoGel™ forms a solid gel.
[00196] Preparation of NovoGel™ mold: A NovoGel™ mold was fabricated for the incubation of cellular cylinders using a Teflon® mold that fit a 10 cm Petri dish. Briefly, the Teflon® mold was pre-sterilized using 70% ethanol solution and subjecting the mold to UV light for 45 minutes. The sterilized mold was placed on top of the 10 cm Petri dish and securely attached. This assembly (Teflon® mold + Petri dish) was maintained vertically and 45 ml of pre -warmed, sterile 2% NovoGel™ solution was poured in the space between the Teflon® mold and the Petri dish. The assembly was then placed horizontally at room temperature for 1 hour to allow complete gelation of the NovoGel™. After gelation, the Teflon® print was removed and the NovoGel™ mold was washed twice using DPBS. Then, either 17.5 ml of HASMC culture medium was added to the NovoGel™ mold for incubating HASMC-HAEC mixed cell cylinders or 17.5ml of HDF culture medium is added to the NovoGel™ mold for incubating HDF cell cylinders.
Cellular Cylinders
[00197] Fabrication of HASMC-HAEC mixed cellular cylinders: To prepare mixed cellular cylinders HASMC and HAEC were individually collected and then mixed at pre-determined ratios. Briefly, the culture medium was removed from confluent culture flasks and the cells were washed with DPBS (1 ml/5 cm2 of growth area). Cells were detached from the surface of the culture flasks by incubation in the presence of trypsin (1 ml/15 cm2 of growth area) for 10 minutes. HASMC were detached using 0.15% trypsin while HAEC were detached using 0.1% trypsin. Following the incubation appropriate culture medium was added to the flasks (2X volume with respect to trypsin volume). The cell suspension was centrifuged at 200g for 6 minutes followed by complete removal of supernatant solution. Cell pellets were resuspended in respective culture medium and counted using a hemacytometer. Appropriate volumes of HASMC and HAEC were combined to yield a mixed cell suspension containing 15% HAEC and remainder 85% HASMC (as a percentage of total cell population). The mixed cell suspension was centrifuged at 200g for 5 minutes followed by complete removal of supernatant solution. Mixed cell pellets were resuspended in 6 ml of HASMC culture medium and transferred to 20 ml glass vials, followed by incubation on an orbital shaker at 150 rpm for 60 minutes, and at 37°C and 5% C02. This allows the cells to aggregate with one another and initiate cell-cell adhesions. Post-incubation, the cell suspension was transferred to a 15 ml centrifuge tube and centrifuged at 200g for 5mins. After removal of the supernatant medium, the cell pellet was resuspended in 400 μΐ of HASMC culture medium and pipetted up and down several times to ensure all cell clusters were broken. The cell suspension was transferred into a 0.5 ml micro fuge tube placed inside a 15 ml centrifuge tube followed by centrifugation at 2000g for 4 minutes to form a highly dense and compact cell pellet. The supernatant medium was aspirated and the cells were transferred into capillary tubes (OD 1.0 mm, ID 0.5 mm, L 75 mm) by aspiration so as to yield cell cylinders 50 mm in length. The cell paste inside the capillaries was incubated in HASMC medium for 20 minutes at 37°C and 5% C02. The cellular cylinders were then deposited from the capillary tubes into the grooves of the NovoGel™ mold (covered with HASMC medium) using the plunger supplied with the capillaries. The cellular cylinders were incubated for 24 hours at 37°C and 5% C02.
[00198] Fabrication of HDF cell cylinders: HDF cylinders were prepared using a method similar to preparing HASMC-HAEC mixed cellular cylinders. Briefly, the culture medium was removed from confluent HDF culture flasks and the cells were washed with DPBS (1 ml/5 cm2 of growth area). Cells were detached from the surface of the culture flasks by incubation in the presence of trypsin (0.1%; 1 ml/15 cm2 of growth area) for 10 minutes. Following the incubation HDF culture medium was added to the flasks (2X volume with respect to trypsin volume). The cell suspension was centrifuged at 200g for 6 minutes followed by complete removal of supernatant solution. Cell pellets were resuspended in 6 ml of HDF culture medium and transferred to 20 ml glass vials, followed by incubation on an orbital shaker at 150 rpm for 75 minutes, and at 37°C and 5% C02. Post-incubation, the cell suspension was transferred to a 15 ml centrifuge tube and centrifuged at 200g for 5 minutes. After removal of the supernatant medium, the cell pellet was resuspended in 400 μΐ of HDF culture medium and pipetted up and down several times to ensure all cell clusters were broken. The cell suspension was transferred into a 0.5 ml microfuge tube placed inside a 15 ml centrifuge tube followed by centrifugation at 2000g for 4 minutes to form a highly dense and compact cell pellet. The supernatant medium was aspirated and the cells were transferred into capillary tubes (OD 1.0 mm, ID 0.5 mm, L 75 mm) by aspiration so as to yield cell cylinders 50 mm in length. The cell paste inside the capillaries were incubated in HDF culture medium for 20 minutes at 37°C and 5% C02. The cellular cylinders were then deposited from the capillary tubes into the grooves of the NovoGel™ mold (covered with HDF medium). The cellular cylinders were incubated for 24 hours at 37°C and 5% C02.
Fabrication of Multi-layered Vascular Tubes
[00199] Preparation of NovoGel™ base plate: A NovoGel™ base plate was fabricated by dispensing 10 ml of pre-warmed (> 40°C) NovoGel™ (2% w/v) into a 10 cm Petri dish.
Immediately after dispensing, the NovoGel™ was evenly spread so as to cover the entire base of the dish and form a uniform layer. The Petri dish was incubated at room temperature for 20 minutes to allow the NovoGel™ to gel completely.
[00200] Multi-layered vascular tube: Vascular tubes consisting of an outer layer of HDF and an inner layer of HASMC-HAEC were fabricated utilizing HDF cylinders, and HASMC-HAEC mixed cell cylinders. A geometrical arrangement as shown in Fig. 4 was utilized. Briefly, at the end of the 24-hour incubation period mature HDF and HASMC-HAEC cylinders were aspirated back into the capillary tubes and placed in appropriate culture medium until further use. The support structure consisting of NovoGel™ rods was prepared as follows: Pre-warmed 2% NovoGel™ was aspirated into the capillary tubes (L=50 mm) and rapidly cooled in cold PBS solution (4°C). The 5 cm long gelled NovoGel™ cylinder was deposited from the capillary (using the plunger) and laid down straight on the NovoGel™ base plate. A second NovoGel™ cylinder was adjoined to the first one and the process was repeated until 10 NovoGel™ cylinders were deposited to form the first layer. At this point 20 μΐ of PBS was dispensed above the NovoGel™ cylinders to keep them wet. Further six NovoGel™ cylinders were deposited on top of layer 1 at positions as shown in Fig. 4 (layer 2). Three HDF cylinders were then deposited at positions 4, 5, and 6 to complete layer 2. After dispensing each HDF cylinder 40 μΐ of HDF culture medium was dispensed on top of the deposited cylinder to assist the deposition of the subsequent cylinder as well as to prevent dehydration of the cellular cylinders. Next NovoGel™ cylinders for layer 3 were deposited followed by HDF cylinders at positions 3 and 6. Following rewetting of the structure with HDF culture medium, HASMC-HAEC mixed cylinders were laid down in positions 4 and 5.
Subsequently, 40 μΐ of HASMC medium and 40 μΐ of HDF medium were dispensed on top of the cell cylinders. Layer 4 was completed by depositing NovoGel™ cylinders at positions 1 and 7, HDF cylinders at positions 2 and 6, HASMC-HAEC mixed cylinders at positions 3 and 5, and finally a 4% NovoGel™ cylinder at position 4. Layers 5, 6, and 7 were completed similarly by laying down NovoGel™ cylinders followed by HDF cylinders and finally HASMC-HAEC cylinders at positions shown in Fig. 4. Once the entire construct was completed 0.5 ml of warm NovoGel™ was dispensed over each end of the construct and allowed to gel at room temperature for 5 minutes. Following gelation of that NovoGel™, 30 ml of HASMC medium was added to the Petri dish (to ensure the entire construct was completely submerged). The construct was incubated for 24 hours at 37°C and 5% C02 to allow for fusion between the cellular cylinders.
[00201] At the end of 24 hours, the surrounding NovoGel™ support structure was removed from the fused multi-layered vascular tube.
Example 3: Bioprinter
[00202] A bioprinter was assembled. The bioprinter contained a printer head having a collet chuck grip for holding a cartridge, and a piston for dispensing the contents of the cartridge. The cartridges used were glass microcapiUary tubes having a length of 75-85 mm. A new capillary tube was loaded each time bio-ink or support material was required.
[00203] In order to print structures, a dispense position repeatability of ± 20 μιη was required for the duration of the printing process, i.e., when new capillaries were loaded into the printer head. In order to maintain repeatability of all loaded capillary tubes relative to the same point in the x-, y- , and z-directions, the bioprinter contained a laser calibration system for calibrating the position of the microcapillary tube. The laser calibration system calibrated the position of all capillary tips to a common reference location. All printing moves were made relative to this reference position.
[00204] All three axes (x-, y-, and z-axes) were calibrated through usage of a single laser distance measurement sensor. The system consisted of a laser sensor and a laser beam. The sensor threshold was the maximum sensing distance of the laser sensor. The sensor was configured to ignore all signals further away than a pre-defined threshold. The sensor used triangulation to determine distance to the object (the capillary tip). The laser sensor was orientated with the beam aimed vertically up (+ z-axis).
Vertical Laser Calibration
[00205] For calibration in the x-axis: The capillary tip was moved in the range of the laser sensor, with the tip to the left (-x) of the laser beam. The capillary was moved to in the +x direction until the sensor detected the capillary edge, and this position was recorded. The above steps were repeated from the opposite side (i.e., the tip was positioned at the right (+x) of the laser beam and moved in the -x direction until the sensor detected the capillary edge). The positions from both steps were averaged to calculate the mid-point of the capillary. Optionally, the above process was repeated for different y-positions and the calculated mid-points were averaged.
[00206] For calibration in the y-axis: The above procedure (for the x-axis) was repeated for the y-axis.
[00207] For calibration in the z-axis The capillary tip was moved to above the sensor beam so that the bean hit the bottom surface of the capillary, and the tip was just outside of the sensor range threshold. The capillary was lowered until the sensor threshold was reached, and that position was recorded as the z-position. Optionally, the above steps were repeated at multiple points on the capillary tip surface and measured heights were averaged.
Horizontal Laser Calibration
[00208] For calibration in the y-axis The capillary was moved so that the tip was just below the laser beam height, and the capillary was off to one side (in the y-direction). The capillary was moved in the y-direction towards the laser. The capillary was stopped when the laser sensor detected the beam reflected off the capillary, and this position was recorded. The above steps were repeated with the capillary off to the other side of the laser, and moved in the -y direction). The mid-point from the above steps was recorded as the y-position.
[00209] For calibration in the x-axis: Using the results of the calibration in the y-axis, the y- axis was moved so that the laser was centered on the capillary. The capillary was moved past the sensor threshold and moved towards the sensor. The capillary was stopped as soon as the capillary crossed the sensor threshold and the sensor output changed. This position, plus ½ the capillary width (from the y-calibration) was recorded as the x-position.
[00210] For calibration in the z-axis: The capillary was moved up from the x-position until it was clear of the laser beam. The capillary tip was moved down towards the laser beam, and stopped as soon as the laser beam was interrupted (using the same process as for the y-axis). This position was recorded as the z-positioa
Capillary Priming
[00211] Before printing from a capillary, the bio -ink or support material inside the capillary was primed so that the bio-ink or support material would begin printing at the very tip of the capillary. The calibration laser was used to prime the capillary. The capillary tip was moved just above the laser beam, with the beam centered in the y-axis. The tip was between 20-100 μιη above the laser beam. The dispensing piston in the printer head was driven down until the bio -ink or support material started to dispense out of the capillary tip and interrupted the laser beam. The dispensed bio-ink or support material was aspirated back into the capillary tube by driving the piston in the reverse direction (20-100 μιη). The capillary was then primed and ready to dispense.
NovoGel™ Capillary Cleaning
[00212] NovoGel™ was used as a support material. In order to remove excess NovoGel™ sticking to the outside surface of the capillary tube and to avoid the excess NovoGel™ from affecting print quality, the excess NovoGel™ was removed. A wiping feature was integrated into a bulk NovoGel™ vessel. A bulk NovoGel™ vessel was fitted with a standard medical vial with an open cap for a septum to be attached. A septum was configured with a cross cut in the center of 1 -2 mm thick silicone. By dipping the capillary into the bulk NovoGel™ vessel through the septum and aspirating NovoGel™, excess NovoGel™ was wiped from the capillary as it exited the vessel, and remained in the bulk vessel.
Printing of a Vascular Structure
[00213] The bioprinter and cartridge was assembled as above. The bioprinter had a stage having a Petri dish for receiving structures generated by the bioprinter. The Petri dish was coated with NovoGel™.
[00214] A two dimensional representation (see e.g., Fig. 4) of a vascular structure was inputted by a user into a software program into a computer which was connected to the bioprinter. The two dimensional representation of the vascular structure consisted of rods of HASMC-HAEC mixed cellular cylinders, HDF cylinders, and NovoGel™ rods defining the voids of the vascular structure and surrounding the vascular structure. HASMC-HAEC mixed cellular cylinders and HDF cellular cylinders were prepared as in Example 1, and aspirated into capillary tubes for insertion into the collet chuck of the printer head. Alternatively, capillary tubes were loaded into the printer head and dipped into the bulk NovoGel™ vessel and NovoGel™ was aspirated into the capillary tube. The capillary tubes were calibrated using the vertical laser calibration system.
[00215] When the commands from the software program were provided to the bioprinter, the bioprinter would print the three-dimensional structure, alternating between HASMC-HAEC rods, HDF rods and NovoGel™ rods, onto the Petri dish, in predetermined locations. See Example 2. After each rod was laid down on the Petri dish, the rod was wetted with a small amount of culture medium. Once the entire construct was completed warm NovoGel™ was dispensed over each end of the construct and allowed to gel at room temperature, and cell culture medium was added to the Petri dish to submerge the entire construct. The construct was then incubated at 37°C and 5% C02 to allow for fusion between the cellular cylinders. At the end of the incubation time, the
surrounding NovoGel™ support structure was removed from the fused multi-layered vascular tube.
Example 4: Bioprinting of UV Cross-Linked PEG-DA
[00216] A solution of 10% (w/v) PEG-DA (Glycosan BioSystems, Inc.; Salt Lake City,
Utah) in water is mixed with a curing agent (0.1% w/v PEGcure Photo initiator) (Glycosan
BioSystems, Inc.; Salt Lake City, Utah). The resultant solution is kept away from light in a vial chamber in a bioprinter. This solution is then aspirated using a 300 μιη or 500 μιη sized glass capillary via extrusion method and exposed to UV light (wavelength 365 nm, intensity 15,000- 20,000 μW/cm2) for at least 3 minutes to allow polymerization via cross-linking to occur. The cross-linking converts the liquid hydrogel into semi-solid structure. The semi-solid hydrogel is bioprintable with or without cells and be used to create geometrically complex structures such as sheets, sacs, tubes, conduits, cylinders, tissues, organs, etc.
Cross-Linked PEG-DA with cells
[00217] In various applications, PEG-DA is used to encapsulate cells, proteins, or other biological material prior to being extruded from the bioprinter. For applications where a UV cross- linkable material (e.g., PEG-DA, etc.) including cells is bioprinted, an attenuation filter is added to the UV module to achieve reduced UV light intensities. In one application, the PEG-DA is exposed to UV light at an intensity and/or exposure time not optimal for full cross -linking. In a particular case, PEG-DA including mammalian cells was exposed to UV light with an intensity of 800 mW/cm2 and the UV source at a distance of 2 inches away from the PEG-DA material. The degree of cross-linking is optionally controlled by altering the composition of UV cross-linkable material and photo initiator. See Table 2.
[00218] Table 2
Figure imgf000053_0001
[00219] The bioprinter then prints successive layers of PEG-DA and cells in a structure where the cells are partially or completely encapsulated by the PEG-DA. Lastly, the entire structure is further exposed to UV to promote full cross-linking of the PEG-DA surrounding the cells. This procedure is optionally used to encapsulate other types of biological materials either in liquid or semi- so lid state.
Cross-Linked PEG-DA without cells
[00220] In another application, PEG-DA is used as the basis of a scaffold onto which cells and other material is bioprinted. A pre-formed PEG-DA structure is created via mechanical molding with exposure to UV light. For example, PEG-DA is dissolved in a 50mM Tris HCL buffer and cross-linked using 5% Irgacure 2959 at a 1 :250 dilution ratio. Long-wave UV light (i.e. 365 nm) with an intensity of 800 mW/cm2 is utilized to achieve complete cross-linking in 5 minutes of exposure. The preformed PEG-DA structure is placed in the bioprinter and cells and other materials are printed onto the structure. Once the cells are printed, they are allowed to fuse and the PEG-DA scaffold is subsequently removed. This technique is capable of producing cellular structures in the shape of organs such as a bladder and other complex shapes.
Example 5: Bioprinting of UV Cross-Linked Methacrylated Hydrogel
[00221] Cross-linked methacrylated hydrogel is bioprinted from a NovoGen MMX™
Bioprinter including a UV module using the following parameters:
• Hydrogel Concentration: 5%
• Irgacure 2959 Concentration: 0.5%
• UV Intensity: 1.50 W/cm2
• UV Exposure Time: 15 sec
• Dispense Height: 0.5 mm (lxD using a 500 μιη capillary) [00222] Optionally, a longer exposure time is used in combination with a lower UV intensity. Because some methacrylated hydrogels expand to a bioprintable length approximately 40% longer than the aspiration amount, a variable pump speed dispense command is configured to dispense a shorter length of material from the dispense pump at a slower speed than the actual robot axes movements. To print a 50 mm long piece of methacrylated hydrogel in the +Y axis at 2 mm/sec. The following calculations are made to determine the correct amount of material to aspirate and the corresponding pump speed to result in a 50 mm line:
• Calculate the amount of methacrylated hydrogel to aspirate: 50 mm / 1.4 = 35.71 mm
• Calculate pump speed: 2 mm/sec / 1.4 = 1.43 mm/sec
[00223] The bioprinter software script commands are configured as follows:
• Aspirates 35.71 mm of fluid and then moves to the UV exposure chamber for 15 seconds.
• Moves the gel capillary to the zero point at a dispense height of 0.5 mm.
• Moves the robot 50 mm in the Y-axis at a speed of 2 mm/sec and moves the gel dispense pump 35.71 mm at a speed of 1.43 mm/sec. The gel pump and Y-axis should stop at the same time, resulting in a 50 mm line.
[00224] While the invention has been described in connection with specific embodiments thereof, it will be understood that the inventive methodology is capable of further modifications. This patent application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features herein before set forth and as follows in scope of the appended claims.

Claims

CLAIMS WHAT IS CLAIMED IS:
1. A bioprinter comprising:
a. one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio -ink and support material;
b. a UV light module for optionally exposing the contents of at least one cartridge to UV light; and
c. a means for dispensing the contents of at least one cartridge.
2. The bioprinter of claim 1, wherein the means for dispensing the contents of at least one cartridge is application of a piston, application of pressure, application of compressed gas, hydraulics, or a combination thereof.
3. The bioprinter of claim 1, wherein the bio -ink or support material comprises one or more UV cross-linkable materials.
4. The bioprinter of claim 1, wherein the UV light module exposes the contents of at least one cartridge to UV light prior to dispensing.
5. The bioprinter of claim 1, wherein the UV light module is tunable with respect to
wavelength, intensity, exposure time, or any combination thereof.
6. The bioprinter of claim 5, wherein the UV light module comprises one or more optionally engaged attenuation filters, wherein the attenuation filters lower UV intensity when engaged.
7. The bioprinter of claim 1, further comprising a means for applying a wetting agent to one or more of:
a. a printer stage;
b. a receiving surface;
c. a deposition orifice;
d. the bio-ink;
e. the support material; and
f. a printed construct;
wherein the wetting agent is applied at one or more time points selected from: before the bio-ink or support material is dispensed by the bioprinter, substantially concurrently with dispensing, and after the bio-ink or support material is dispensed by the bioprinter.
8. A method of fabricating a tissue construct comprising the steps of: a. depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross- linkable material and has been exposed to UV light to partially or completely crosslink the UV cross-linkable material to form a semi-solid or solid body; and b. incubating the bio-ink to allow it to cohere and to form a tissue, wherein said
incubation has a duration of about 1 hour to about 10 days.
9. The method of claim 8, further comprising the step of preparing a liquid bio -ink solution comprising a UV cross-linkable material and cells.
10. The method of claim 9, further comprising the step of exposing a liquid bio -ink solution comprising a UV cross-linkable material and cells to UV light to partially or completely cross-link the UV cross-linkable material to form a semi-solid or solid body.
11. The method of claim 8, further comprising the step of depositing bio-ink onto a support, wherein the bio-ink comprises a UV cross-linkable material and has not been exposed to UV light.
12. The method of claim 8, wherein the UV cross-linkable material is a hydrogel.
13. The method of claim 8, wherein the bio-ink comprises mammalian cells.
14. The method of claim 13, wherein the bio-ink comprises differentiated, mammalian cells.
15. The method of claim 13, wherein the bio -ink comprises non-differentiated, mammalian cells.
16. The method of claim 8, wherein the bio-ink is deposited by extrusion from a bioprinter.
17. A bioprinter cartridge, wherein the contents of the cartridge comprises a UV cross-linkable material and optionally cells.
18. The bioprinter cartridge of claim 17, wherein the UV cross-linkable material is partially or completely cross-linked.
19. The bioprinter cartridge of claim 17, wherein the UV cross-linkable material is a hydrogel.
20. The bioprinter cartridge of claim 17, wherein the cartridge comprises a glass-walled
reservoir.
21. The bioprinter cartridge of claim 17, wherein the cartridge is permeable to UV light.
22. A UV light module for a bioprinter comprising a UV light source that optionally exposes the contents of at least one bioprinter cartridge to UV light.
23. The UV light module of claim 22, wherein the UV light module is reversibly attachable to a bioprinter.
24. The UV light module of claim 22, wherein the UV light module is tunable with respect to wavelength, intensity, exposure time, or any combination thereof.
25. The UV light module of claim 24, further comprising one or more optionally engaged attenuation filters, wherein the attenuation filters lower UV intensity when engaged.
26. A tissue construct comprising a multicellular body on a support substrate, wherein the
multicellular body comprises a UV cross-linkable material and cells, wherein the multicellular body was deposited by a bioprinter, provided that the multicellular body was exposed to UV light to partially or completely cross-link the UV cross-linkable material to form a semi- so lid or solid body.
27. The tissue construct of claim 26, wherein the construct comprises a plurality of multicellular bodies.
28. The tissue construct of claim 26, wherein the UV cross-linkable material is a hydrogel.
29. The tissue construct of claim 26, wherein the multicellular body comprises differentiated, mammalian cells.
30. The tissue construct of claim 26, wherein the multicellular body comprises non- differentiated, mammalian cells.
PCT/US2013/036479 2012-04-20 2013-04-12 Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking WO2013158508A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2868530A CA2868530A1 (en) 2012-04-20 2013-04-12 Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking
EP13778583.8A EP2838985B1 (en) 2012-04-20 2013-04-12 Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking
AU2013249569A AU2013249569B2 (en) 2012-04-20 2013-04-12 Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking
HK15108255.6A HK1207660A1 (en) 2012-04-20 2015-08-25 Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261636442P 2012-04-20 2012-04-20
US61/636,442 2012-04-20
US13/794,368 US9499779B2 (en) 2012-04-20 2013-03-11 Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking
US13/794,368 2013-03-11

Publications (1)

Publication Number Publication Date
WO2013158508A1 true WO2013158508A1 (en) 2013-10-24

Family

ID=49383973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/036479 WO2013158508A1 (en) 2012-04-20 2013-04-12 Devices, systems, and methods for the fabrication of tissue utilizing uv cross-linking

Country Status (6)

Country Link
US (2) US9499779B2 (en)
EP (1) EP2838985B1 (en)
AU (1) AU2013249569B2 (en)
CA (1) CA2868530A1 (en)
HK (1) HK1207660A1 (en)
WO (1) WO2013158508A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015111366A1 (en) 2014-01-23 2015-07-30 Ricoh Company, Ltd. Three-dimensional object and method for forming same
WO2015148646A3 (en) * 2014-03-25 2016-01-14 Biobots, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
EP3018531A1 (en) * 2014-11-10 2016-05-11 Technische Universität Berlin Method and device for creating a three-dimensional multi-cell object
USD760825S1 (en) 2015-03-25 2016-07-05 Biobots, Inc. Bioprinter
WO2017029495A1 (en) * 2015-08-17 2017-02-23 Imperial Innovations Limited Ink composition comprising thermo-responsive polymer
WO2017132464A1 (en) * 2016-01-28 2017-08-03 3D Systems, Inc. Methods and apparatus for 3d printed hydrogel materials
RU2643138C2 (en) * 2013-06-13 2018-01-30 Аспект Биосистемс Лтд. System and method of three-dimensional structures additive manufacturing
EP3326661A4 (en) * 2015-07-21 2018-08-01 Bioink Solutions Inc. Bio-ink composition having improved physical and biological properties
WO2018167401A1 (en) * 2017-03-15 2018-09-20 Poietis Bioprinting process
US10555808B2 (en) 2015-05-14 2020-02-11 Cephea Valve Technologies, Inc. Replacement mitral valves
US10782217B2 (en) 2016-07-12 2020-09-22 Deka Products Limited Partnership System and method for applying force to a device
US10808218B2 (en) 2015-10-09 2020-10-20 Deka Products Limited Partnership Fluid pumping and bioreactor system
US11254901B2 (en) 2016-07-12 2022-02-22 Deka Products Limited Partnership System and method for printing tissue
US11299705B2 (en) 2016-11-07 2022-04-12 Deka Products Limited Partnership System and method for creating tissue
US11530380B2 (en) 2017-07-12 2022-12-20 Deka Products Limited Partnership System and method for transferring tissue
EP4144883A1 (en) 2021-09-03 2023-03-08 PhosPrint P.C. Laser printing and photopolymerization of cell-laden hydrogels
US11655456B2 (en) 2016-11-10 2023-05-23 Organovo, Inc. Engineered intestinal tissue and uses thereof
US11724450B2 (en) 2017-03-15 2023-08-15 Aspect Biosystems Ltd. Systems and methods for printing a fiber structure
US11850330B2 (en) 2016-11-10 2023-12-26 Organovo, Inc. Bioprinted hair follicles and uses thereof

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241905B2 (en) 2004-02-24 2012-08-14 The Curators Of The University Of Missouri Self-assembling cell aggregates and methods of making engineered tissue using the same
KR101611936B1 (en) 2008-06-24 2016-04-12 더 큐레이터스 오브 더 유니버시티 오브 미주리 Self-assembling multicellular bodies and methods of producing a three-dimensional biological structure using the same
WO2012054195A2 (en) 2010-10-21 2012-04-26 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue
EP2640403A4 (en) 2010-11-15 2014-04-23 Jua-Nan Lee Generation of neural stem cells from human trophoblast stem cells
US9034589B2 (en) * 2012-03-22 2015-05-19 Board Of Regents, The University Of Texas System Magnetic separation of cells
US9499779B2 (en) 2012-04-20 2016-11-22 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking
CA2891542C (en) 2012-11-30 2021-12-14 Accelerated Biosciences Corp. Pancreatic progenitor cells expressing betatrophin and insulin
US9442105B2 (en) 2013-03-15 2016-09-13 Organovo, Inc. Engineered liver tissues, arrays thereof, and methods of making the same
JP6842918B2 (en) 2013-07-31 2021-03-17 オルガノボ,インク. Automated devices, systems, and methods for tissue fabrication
US9910935B2 (en) * 2013-10-11 2018-03-06 Advanced Solutions Life Sciences, Llc System and workstation for the design, fabrication and assembly of bio-material constructs
US20170023550A1 (en) * 2014-04-04 2017-01-26 Organovo, Inc. Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model
US9650537B2 (en) * 2014-04-14 2017-05-16 Ut-Battelle, Llc Reactive polymer fused deposition manufacturing
US9764515B2 (en) * 2014-05-01 2017-09-19 Musc Foundation For Research Development Multidispensor cartesian robotic printer
EA028039B1 (en) * 2014-09-05 2017-09-29 Частное Учреждение Лаборатория Биотехнологических Исследований "3Д Биопринтинг Солюшенс" Device and methods for printing biological tissues and organs
SG11201702795QA (en) 2014-10-06 2017-05-30 Organovo Inc Engineered renal tissues, arrays thereof, and methods of making the same
US11529436B2 (en) 2014-11-05 2022-12-20 Organovo, Inc. Engineered three-dimensional skin tissues, arrays thereof, and methods of making the same
US10538725B1 (en) 2014-11-14 2020-01-21 Autodesk, Inc. Multi-dimensional bioprinting system
AU2015353521B2 (en) 2014-11-26 2021-11-04 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
US10363731B2 (en) 2014-12-18 2019-07-30 Palo Alto Research Center Incorporated Ejector device
US20180117219A1 (en) 2015-04-29 2018-05-03 Northwestern University 3d printing of biomedical implants
EP3304201A4 (en) * 2015-04-30 2019-06-26 Castanon, Diego Improved stereolithography system
EP3344387B1 (en) 2015-08-31 2021-04-07 Cellink AB Clean chamber technology for 3d printers and bioprinters
US10201964B2 (en) 2015-11-02 2019-02-12 The Regents Of The University Of California Treatment for reducing the toxicity of 3D-printed parts
AU2016352873B2 (en) 2015-11-09 2023-01-05 Organovo, Inc. Improved methods for tissue fabrication
US12103173B2 (en) * 2016-04-20 2024-10-01 The Brigham And Women's Hospital, Inc. Systems and methods for in vivo multi-material bioprinting
JP2019530435A (en) 2016-08-15 2019-10-24 オルガノボ インコーポレイテッド Three-dimensional bioprinted tumor model for drug testing
EP3427949B1 (en) 2017-07-12 2024-10-09 MAPTECH Holdings UG Mechanically tunable bioinks for bioprinting
US20240200011A1 (en) * 2017-07-12 2024-06-20 Deka Products Limited Partnership System and method for transferring tissue
WO2019079424A1 (en) * 2017-10-20 2019-04-25 Indiana University Research And Technology Corporation Scaffold-free 3d bioprinting of porcine cells
SG11202008774YA (en) * 2018-03-13 2020-10-29 Frontier Bio Corp Electrohydrodynamic bioprinter system and method
US11426818B2 (en) 2018-08-10 2022-08-30 The Research Foundation for the State University Additive manufacturing processes and additively manufactured products
WO2020251591A1 (en) * 2019-06-14 2020-12-17 Hewlett-Packard Development Company, L.P. Print head marking
US12019040B2 (en) 2019-09-30 2024-06-25 Cornell University System and devices for monitoring cell-containing materials and methods of their use
US12030256B2 (en) 2021-02-19 2024-07-09 The Board Of Trustees Of The University Of Illinois Coated tubular construct for biological and industrial applications and method of making a tubular construct
WO2022182636A1 (en) 2021-02-26 2022-09-01 University Of Rochester Skeletal stem cell isolation and uses thereof
CN113459241B (en) * 2021-08-02 2022-12-02 山东大学 Hollow ceramic 3D printing method and control system of XZA rotating shaft 3D printer
WO2023159107A1 (en) 2022-02-18 2023-08-24 The Forsyth Institute Markers for skeletal stem cell and uses thereof
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020171178A1 (en) * 2001-04-19 2002-11-21 David Dean Fabrication of a polymeric prosthetic implant
US6986739B2 (en) * 2001-08-23 2006-01-17 Sciperio, Inc. Architecture tool and methods of use
US7051654B2 (en) 2003-05-30 2006-05-30 Clemson University Ink-jet printing of viable cells
US20060237880A1 (en) * 2005-04-22 2006-10-26 Board Of Regents, The University Of Texas System Hydrogel constructs using stereolithography
WO2009102484A2 (en) * 2008-02-14 2009-08-20 Wake Forest University Health Sciences Inkjet printing of tissues and cells
WO2011107599A1 (en) * 2010-03-04 2011-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Bioprinting station, assembly comprising such bioprinting station and bioprinting method
WO2011119059A1 (en) * 2010-03-26 2011-09-29 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof
WO2012054195A2 (en) 2010-10-21 2012-04-26 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4759764A (en) 1985-05-24 1988-07-26 Clayton Foundation For Research Peripheral nerve regeneration
US4808435A (en) 1987-04-06 1989-02-28 International Business Machines Corporation Screen printing method for producing lines of uniform width and height
US5099090A (en) 1988-05-11 1992-03-24 Ariel Electronics, Inc. Circuit writer
CA2306346C (en) 1997-07-03 2010-09-14 Massachusetts Institute Of Technology Tissue-engineered tubular construct having circumferentially oriented smooth muscle cells
US6401795B1 (en) 1997-10-28 2002-06-11 Sandia Corporation Method for freeforming objects with low-binder slurry
EP1084454B1 (en) 1998-04-21 2016-03-09 University of Connecticut Free-form nanofabrication using multi-photon excitation
US6697694B2 (en) 1998-08-26 2004-02-24 Electronic Materials, L.L.C. Apparatus and method for creating flexible circuits
US7338798B2 (en) 1998-09-15 2008-03-04 The Regents Of The University Of Michigan System and method for forming a cardiac muscle construct
DE69907397T2 (en) 1999-02-17 2004-01-22 Hewlett-Packard Co. (N.D.Ges.D.Staates Delaware), Palo Alto printing device
US6979670B1 (en) 1999-03-10 2005-12-27 Biora Bioex Ab Matrix protein compositions for grafting
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same
JP2001145956A (en) 1999-11-19 2001-05-29 Meiko:Kk Apparatus and method for laminate shaping of photosetting resin three-dimensional shaped article
US6503273B1 (en) 1999-11-22 2003-01-07 Cyograft Tissue Engineering, Inc. Tissue engineered blood vessels and methods and apparatus for their manufacture
US6454972B1 (en) 1999-11-24 2002-09-24 Sandia Corporation Solid freeform fabrication using chemically reactive suspensions
US6520997B1 (en) 1999-12-08 2003-02-18 Baxter International Inc. Porous three dimensional structure
US6315469B1 (en) 2000-01-19 2001-11-13 Hewlett-Packard Company Tool and method for adjustment of printhead to platen spacing in a printer
DE10013223C2 (en) 2000-03-13 2002-07-18 Co Don Ag Process for the in vitro production of three-dimensional, vital cartilage or bone tissue and its use as a transplant material
US20050091576A1 (en) 2003-10-24 2005-04-28 Microsoft Corporation Programming interface for a computer platform
DE10018987A1 (en) 2000-04-17 2001-10-31 Envision Technologies Gmbh Device and method for producing three-dimensional objects
AU2001283492A1 (en) 2000-07-11 2002-01-21 The Johns Hopkins University School Of Medicine Methods of patterning protein and cell adhesivity
US7998735B2 (en) 2000-08-21 2011-08-16 Victorian Tissue Engineering Centre Pty. Ltd. Vascularized tissue graft
US6561607B1 (en) 2000-10-05 2003-05-13 Eastman Kodak Company Apparatus and method for maintaining a substantially constant closely spaced working distance between an inkjet printhead and a printing receiver
US6939489B2 (en) 2001-03-23 2005-09-06 Ivoclar Vivadent Ag Desktop process for producing dental products by means of 3-dimensional plotting
DE10127225A1 (en) * 2001-05-22 2002-11-28 Zeiss Carl Ultraviolet light cut filter
US20030049839A1 (en) 2001-08-01 2003-03-13 The University Of Texas System Transparent multi-channel cell scaffold that creates a cellular and/or molecular gradient
US6934600B2 (en) 2002-03-14 2005-08-23 Auburn University Nanotube fiber reinforced composite materials and method of producing fiber reinforced composites
US20100254900A1 (en) 2002-03-18 2010-10-07 Campbell Phil G Biocompatible polymers and Methods of use
US20030175410A1 (en) * 2002-03-18 2003-09-18 Campbell Phil G. Method and apparatus for preparing biomimetic scaffold
US6907307B2 (en) 2002-07-02 2005-06-14 3D Systems, Inc. Support volume calculation for a CAD model
AU2003251874A1 (en) 2002-07-12 2004-02-02 Dirk R. Albrecht Three dimensional cell patterned bioploymer scaffolds and method of making the same
US7641898B2 (en) 2003-03-21 2010-01-05 Materials Evolution And Development Usa, Inc. Keratinocyte-fibrocyte concomitant grafting for wound healing
US20040197375A1 (en) 2003-04-02 2004-10-07 Alireza Rezania Composite scaffolds seeded with mammalian cells
CA2528134C (en) 2003-06-04 2015-05-12 University Of South Carolina Tissue scaffold having aligned fibrils, apparatus and method for producing the same, and artificial tissue and methods of use thereof
JP4474858B2 (en) 2003-07-07 2010-06-09 セイコーエプソン株式会社 GAP ADJUSTMENT DEVICE, CALIBRATION JIG USED FOR THE SAME, DROPLET DISCHARGE DEVICE EQUIPPED WITH GAP ADJUSTMENT DEVICE, AND ELECTRO-OPTICAL DEVICE MANUFACTURING METHOD
US20050074877A1 (en) 2003-07-28 2005-04-07 Mao Jeremy Jian Biological engineering of articular structures containing both cartilage and bone
FR2859128B1 (en) 2003-08-29 2006-03-10 Centre Nat Rech Scient METHOD AND DEVICE FOR MANUFACTURING A THREE DIMENSIONAL MULTIMATERIAL COMPONENT BY INKJET TYPE PRINTING
US8043614B2 (en) 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
DE10353281A1 (en) 2003-11-14 2005-06-16 Bayer Cropscience Ag Combination of active ingredients with insecticidal and acaricidal properties
US20050276791A1 (en) 2004-02-20 2005-12-15 The Ohio State University Multi-layer polymer scaffolds
US8241905B2 (en) 2004-02-24 2012-08-14 The Curators Of The University Of Missouri Self-assembling cell aggregates and methods of making engineered tissue using the same
US20090142307A1 (en) 2004-07-09 2009-06-04 Athanasiou Kyriacos A Shape-Based Approach for Scaffoldless Tissue Engineering
WO2006020685A2 (en) 2004-08-11 2006-02-23 Cornell Research Foundation, Inc. Modular fabrication systems and methods
US7651665B2 (en) 2004-09-07 2010-01-26 Hewlett-Packard Development Company, L.P. Microtray for handling biosubstances
US7767446B2 (en) 2004-09-16 2010-08-03 Becton, Dickinson And Company Perfusion bioreactors for culturing cells
KR100606457B1 (en) * 2004-11-11 2006-11-23 한국기계연구원 Three-dimensional printing prototyping system
JP4539316B2 (en) 2004-12-08 2010-09-08 セイコーエプソン株式会社 Head position correction method, head position correction apparatus, droplet discharge apparatus, and electro-optical device manufacturing method
US7568904B2 (en) 2005-03-03 2009-08-04 Laser Solutions Co., Ltd. Stereolithography apparatus
JP4729948B2 (en) 2005-03-09 2011-07-20 ブラザー工業株式会社 Liquid supply apparatus and ink jet recording apparatus provided with the liquid supply apparatus
EP2495310A3 (en) 2005-05-24 2013-03-27 The Regents Of the University of California Microscale micropatterned engineered in vitro tissue
WO2007126411A2 (en) 2005-07-28 2007-11-08 Carnegie Mellon University Biocompatible polymers and methods of use
US8690957B2 (en) 2005-12-21 2014-04-08 Warsaw Orthopedic, Inc. Bone graft composition, method and implant
US20070200276A1 (en) 2006-02-24 2007-08-30 Micron Technology, Inc. Method for rapid printing of near-field and imprint lithographic features
US7680555B2 (en) 2006-04-03 2010-03-16 Stratasys, Inc. Auto tip calibration in an extrusion apparatus
US20070231787A1 (en) 2006-04-04 2007-10-04 Voelker Mark A Methods and devices for imaging and manipulating biological samples
EP2007312A4 (en) 2006-04-05 2012-08-22 Univ Rice William M A shape-based approach for scaffoldless tissue engineering
WO2007124023A2 (en) 2006-04-21 2007-11-01 Wake Forest University Health Sciences Ink-jet printing of tissues
WO2007124481A2 (en) 2006-04-21 2007-11-01 Drexel University Bioprinting three-dimensional structures onto microscale tissue analog devices for pharmacokinetic study and other uses
JP4051077B2 (en) 2006-04-28 2008-02-20 シャープ株式会社 Droplet applicator, gap measurement method for droplet discharge unit, and gap adjustment method for droplet discharge unit
FR2901143B1 (en) 2006-05-16 2008-10-03 Centre Nat Rech Scient "METHOD OF CONSTRUCTING FUNCTIONAL LIVING MATERIALS, MATERIALS OBTAINED AND APPLICATIONS"
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
DE102006053121B3 (en) 2006-11-10 2007-12-27 Eos Gmbh Electro Optical Systems Coating device for applying powdered layers to a device for producing a three-dimensional object comprises longitudinal walls joined together, a unit for fluidizing powdered material and a controlling and/or regulating unit
US8097455B2 (en) 2007-02-02 2012-01-17 The Regents Of The University Of Michigan System and method for forming skeletal muscle constructs having functional tissue interfaces
US8343740B2 (en) 2007-03-29 2013-01-01 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Micro-organ device
US20090117087A1 (en) 2007-04-13 2009-05-07 Wake Forest University Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
US9045757B2 (en) 2007-06-07 2015-06-02 Wake Forest University Health Sciences Inkjet gene printing
EP2188114B1 (en) 2007-07-25 2018-09-12 Stratasys Ltd. Solid freeform fabrication using a plurality of modeling materials
ATE530274T1 (en) 2007-08-29 2011-11-15 Vito Nv METHOD FOR PRODUCING A THREE-DIMENSIONAL MACROPOROUS FILAMENT CONSTRUCTION BASED ON PHASE INVERSION AND THE CONSTRUCTION OBTAINED THEREFROM
US20090076531A1 (en) 2007-09-18 2009-03-19 Richardson Charles L Method and apparatus for bypass graft
US7923846B2 (en) 2007-11-16 2011-04-12 Stats Chippac Ltd. Integrated circuit package-in-package system with wire-in-film encapsulant
EP2090584A1 (en) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
US20090248145A1 (en) 2008-03-28 2009-10-01 Nanyang Technological University Method of forming a three-dimensional structure of unidirectionally aligned cells
US8876513B2 (en) 2008-04-25 2014-11-04 3D Systems, Inc. Selective deposition modeling using CW UV LED curing
ES2672525T3 (en) 2008-06-20 2018-06-14 Universiteit Maastricht Self-assembling tissue modules
KR101611936B1 (en) 2008-06-24 2016-04-12 더 큐레이터스 오브 더 유니버시티 오브 미주리 Self-assembling multicellular bodies and methods of producing a three-dimensional biological structure using the same
US9097702B2 (en) 2008-07-29 2015-08-04 Cornell University Pathologically relevant tumor microenvironments for high-throughput drug screening
WO2010030964A2 (en) 2008-09-12 2010-03-18 The Brigham And Women's Hospital, Inc. 3-dimensional multi-layered hydrogels and methods of making the same
WO2010060080A1 (en) 2008-11-24 2010-05-27 Immunotrex Corporation Three dimensional tissue generation
EP2450707B1 (en) 2010-11-04 2016-04-27 University of Pécs Lung tissue model
WO2011038373A2 (en) 2009-09-28 2011-03-31 Virginia Tech Intellectual Properties, Inc. Three-dimensional bioprinting of biosynthetic cellulose (bc) implants and scaffolds for tissue engineering
US8409603B2 (en) 2009-10-01 2013-04-02 University Of South Carolina Compositions and methods for tissue engineering, tissue regeneration and wound healing
EP2521587B1 (en) 2010-01-08 2020-04-08 Wake Forest University Health Sciences Delivery system
WO2011088213A1 (en) * 2010-01-15 2011-07-21 University Of Utah Research Foundation Crosslinked hydrogels and methods of making and using thereof
KR20120125331A (en) 2010-02-02 2012-11-14 더 큐레이터스 오브 더 유니버시티 오브 미주리 Engineered biological nerve graft fabrication and application thereof
GB2489081B (en) 2010-03-16 2013-03-27 Organovo Inc Multilayered vascular tubes
US9592255B2 (en) 2010-07-01 2017-03-14 The Regents Of The University Of Michigan Scaffold-free three dimensional nerve fibroblast constructs
US20120089238A1 (en) 2010-10-06 2012-04-12 Hyun-Wook Kang Integrated organ and tissue printing methods, system and apparatus
DE202011003443U1 (en) 2011-03-02 2011-12-23 Bego Medical Gmbh Device for the generative production of three-dimensional components
AU2012225644B2 (en) 2011-03-07 2017-05-04 Wake Forest University Health Sciences Delivery system
GB201105226D0 (en) 2011-03-29 2011-05-11 Univ Leiden Methods
JP5599356B2 (en) 2011-03-31 2014-10-01 富士フイルム株式会社 A simulation method, a program, a recording medium on which the program is recorded, a method of creating a droplet arrangement pattern using the program, a nanoimprint method, a method of manufacturing a patterned substrate, and an inkjet apparatus.
BR112014005746A2 (en) 2011-09-12 2017-03-28 Organovo Inc engineered fabrics for in vitro research use, arrangement thereof, and methods of manufacturing the same
US20130164339A1 (en) 2011-09-12 2013-06-27 Organovo, Inc. Platform for engineered implantable tissues and organs and methods of making the same
US10059056B2 (en) 2012-02-01 2018-08-28 Nscrypt, Inc. Micro-dispensing multi-layered 3D objects with curing steps
WO2013130823A1 (en) 2012-02-29 2013-09-06 Massachusetts Institute Of Technology Inverse patterning process for three-dimensional multi-compartmental micro-organization of multiple cell types
KR20140142278A (en) 2012-03-06 2014-12-11 더 유에이비 리서치 파운데이션 Three-dimensional, prevascularized, engineered tissue constructs, methods of making and methods of using the tissue constructs
US9499779B2 (en) 2012-04-20 2016-11-22 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking
US20140099709A1 (en) 2012-06-19 2014-04-10 Organovo, Inc. Engineered three-dimensional connective tissue constructs and methods of making the same
US20140042657A1 (en) 2012-08-08 2014-02-13 Makerbot Industries, Llc Printed circuit board with integrated temperature sensing
US9442105B2 (en) 2013-03-15 2016-09-13 Organovo, Inc. Engineered liver tissues, arrays thereof, and methods of making the same
US20140265049A1 (en) 2013-03-15 2014-09-18 Matterfab Corp. Cartridge for an additive manufacturing apparatus and method
US9802360B2 (en) 2013-06-04 2017-10-31 Stratsys, Inc. Platen planarizing process for additive manufacturing system
JP6842918B2 (en) 2013-07-31 2021-03-17 オルガノボ,インク. Automated devices, systems, and methods for tissue fabrication

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020171178A1 (en) * 2001-04-19 2002-11-21 David Dean Fabrication of a polymeric prosthetic implant
US6986739B2 (en) * 2001-08-23 2006-01-17 Sciperio, Inc. Architecture tool and methods of use
US7051654B2 (en) 2003-05-30 2006-05-30 Clemson University Ink-jet printing of viable cells
US20060237880A1 (en) * 2005-04-22 2006-10-26 Board Of Regents, The University Of Texas System Hydrogel constructs using stereolithography
WO2009102484A2 (en) * 2008-02-14 2009-08-20 Wake Forest University Health Sciences Inkjet printing of tissues and cells
WO2011107599A1 (en) * 2010-03-04 2011-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Bioprinting station, assembly comprising such bioprinting station and bioprinting method
WO2011119059A1 (en) * 2010-03-26 2011-09-29 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof
WO2012054195A2 (en) 2010-10-21 2012-04-26 Organovo, Inc. Devices, systems, and methods for the fabrication of tissue

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUI, X. ET AL., TISSUE ENGINEERING, vol. 18, 2012, pages 1304 - 1312
FRISMAN, ILYA ET AL.: "Nanostructuring of PEG-fibrinogen polymeric scaffolds", ACTA BIOMATERIALIA, vol. 6, no. 7, 15 July 2009 (2009-07-15), pages 2518 - 2524, XP027052681 *
HOCKADAY, L. A. ET AL.: "Rapid 3D printing of anatomically accurate and mechanically heterogeneous aortic valve hydrogel scaffolds", BIOFABRICATION, vol. 4, no. 3, 23 August 2012 (2012-08-23), pages 1 - 12, XP055169335 *
PAUL ET AL.: "How to improve R&D productivity: the pharmaceutical industry's grand challenge", NATURE REVIEWS DRUG DISCOVERY, vol. 9, no. 3, 2010, pages 203 - 214

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046930B2 (en) 2013-06-13 2021-06-29 Aspect Biosystems Ltd. System for additive manufacturing of three-dimensional structures and method for same
US11738501B2 (en) 2013-06-13 2023-08-29 Aspect Biosystems Ltd. System for additive manufacturing of three-dimensional structures and method for same
RU2643138C2 (en) * 2013-06-13 2018-01-30 Аспект Биосистемс Лтд. System and method of three-dimensional structures additive manufacturing
EP3096936A4 (en) * 2014-01-23 2017-05-17 Ricoh Company, Ltd. Three-dimensional object and method for forming same
CN106414039B (en) * 2014-01-23 2022-01-18 株式会社理光 Three-dimensional object and method of forming the same
WO2015111366A1 (en) 2014-01-23 2015-07-30 Ricoh Company, Ltd. Three-dimensional object and method for forming same
CN106414039A (en) * 2014-01-23 2017-02-15 株式会社理光 Three-dimensional object and method for forming same
US11779472B2 (en) 2014-03-25 2023-10-10 3D Systems, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
US10512552B2 (en) 2014-03-25 2019-12-24 Biobots, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
WO2015148646A3 (en) * 2014-03-25 2016-01-14 Biobots, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
EP3122559A4 (en) * 2014-03-25 2017-11-29 Biobots, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
US10893956B2 (en) 2014-03-25 2021-01-19 Allevi, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
US11033407B2 (en) 2014-03-25 2021-06-15 Allevi, Inc. Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation
KR20170082567A (en) * 2014-11-10 2017-07-14 테크니쉐 유니베르시타트 베를린 Method and device for producing a three-dimensional, multi-cell object
KR102375312B1 (en) 2014-11-10 2022-03-17 테크니쉐 유니베르시타트 베를린 Method and device for producing a three-dimensional, multi-cell object
EP3018531A1 (en) * 2014-11-10 2016-05-11 Technische Universität Berlin Method and device for creating a three-dimensional multi-cell object
US10299940B2 (en) 2014-11-10 2019-05-28 Technische Universität Berlin Method and device for producing a three-dimensional, multi-cell object
IL252069B2 (en) * 2014-11-10 2023-03-01 Univ Berlin Tech Method and device for producing a three-dimensional, multi-cell object
IL252069B (en) * 2014-11-10 2022-11-01 Univ Berlin Tech Method and device for producing a three-dimensional, multi-cell object
WO2016075103A1 (en) * 2014-11-10 2016-05-19 Technische Universität Berlin Method and device for producing a three-dimensional, multi-cell object
RU2718719C2 (en) * 2014-11-10 2020-04-14 Технише Универзитет Берлин Method and apparatus for producing a three-dimensional multicellular object
JP2017536113A (en) * 2014-11-10 2017-12-07 テヒーニィシエ ウニヴェルジテート ベルリン Method and apparatus for creating a three-dimensional multicellular object
USD760825S1 (en) 2015-03-25 2016-07-05 Biobots, Inc. Bioprinter
US10555808B2 (en) 2015-05-14 2020-02-11 Cephea Valve Technologies, Inc. Replacement mitral valves
EP3326661A4 (en) * 2015-07-21 2018-08-01 Bioink Solutions Inc. Bio-ink composition having improved physical and biological properties
WO2017029495A1 (en) * 2015-08-17 2017-02-23 Imperial Innovations Limited Ink composition comprising thermo-responsive polymer
US10808218B2 (en) 2015-10-09 2020-10-20 Deka Products Limited Partnership Fluid pumping and bioreactor system
US11305480B2 (en) 2016-01-28 2022-04-19 3D Systems, Inc. Methods and apparatus for 3D printed hydrogel materials
CN108883572A (en) * 2016-01-28 2018-11-23 3D系统公司 The method and apparatus of hydrogel material for 3D printing
CN108883572B (en) * 2016-01-28 2021-06-25 3D系统公司 Method and apparatus for hydrogel materials for 3D printing
WO2017132464A1 (en) * 2016-01-28 2017-08-03 3D Systems, Inc. Methods and apparatus for 3d printed hydrogel materials
US10782217B2 (en) 2016-07-12 2020-09-22 Deka Products Limited Partnership System and method for applying force to a device
US11254901B2 (en) 2016-07-12 2022-02-22 Deka Products Limited Partnership System and method for printing tissue
US11543336B2 (en) 2016-07-12 2023-01-03 Deka Products Limited Partnership System and method for applying force to a device
US11299705B2 (en) 2016-11-07 2022-04-12 Deka Products Limited Partnership System and method for creating tissue
US12024701B2 (en) 2016-11-07 2024-07-02 Deka Products Limited Partnership System and method for creating tissue
US11939566B2 (en) 2016-11-07 2024-03-26 Deka Products Limited Partnership System and method for creating tissue
US11655456B2 (en) 2016-11-10 2023-05-23 Organovo, Inc. Engineered intestinal tissue and uses thereof
US11850330B2 (en) 2016-11-10 2023-12-26 Organovo, Inc. Bioprinted hair follicles and uses thereof
FR3063930A1 (en) * 2017-03-15 2018-09-21 Poietis BIOIMPRESSION PROCESS
CN110402283A (en) * 2017-03-15 2019-11-01 波艾蒂斯公司 Biometric print method
US11724450B2 (en) 2017-03-15 2023-08-15 Aspect Biosystems Ltd. Systems and methods for printing a fiber structure
WO2018167401A1 (en) * 2017-03-15 2018-09-20 Poietis Bioprinting process
KR102615057B1 (en) * 2017-03-15 2023-12-19 포이에티스 Bio-printing process
US11517453B2 (en) 2017-03-15 2022-12-06 Poietis Bioprinting process
KR20190130605A (en) * 2017-03-15 2019-11-22 포이에티스 Bio-printing process
JP2020512013A (en) * 2017-03-15 2020-04-23 ポワティス Methods for bioprinting
US11530380B2 (en) 2017-07-12 2022-12-20 Deka Products Limited Partnership System and method for transferring tissue
US11939564B2 (en) 2017-07-12 2024-03-26 Deka Products Limited Partnership System and method for transferring tissue
EP4144883A1 (en) 2021-09-03 2023-03-08 PhosPrint P.C. Laser printing and photopolymerization of cell-laden hydrogels
WO2023031278A1 (en) 2021-09-03 2023-03-09 PhosPrint P.C. Laser printing and photopolymerization of cell-laden hydrogels

Also Published As

Publication number Publication date
EP2838985B1 (en) 2019-08-07
CA2868530A1 (en) 2013-10-24
EP2838985A1 (en) 2015-02-25
HK1207660A1 (en) 2016-02-05
US10174276B2 (en) 2019-01-08
EP2838985A4 (en) 2015-12-09
US20140093932A1 (en) 2014-04-03
AU2013249569A1 (en) 2014-10-30
US9499779B2 (en) 2016-11-22
AU2013249569B2 (en) 2017-04-20
US20170037349A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US10174276B2 (en) Devices, systems, and methods for the fabrication of tissue utilizing UV cross-linking
US11577451B2 (en) Bioprinter for the fabrication of tissue
US20210008788A1 (en) Automated devices, systems, and methods for the fabrication of tissue
AU2015202836B2 (en) Devices, systems, and methods for the fabrication of tissue
AU2016253591B2 (en) Devices, systems, and methods for the fabrication of tissue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13778583

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2868530

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013778583

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013249569

Country of ref document: AU

Date of ref document: 20130412

Kind code of ref document: A